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ABSTRACT 
Modulation of host innate immunity by health-promoting bacteria and 
dietary compounds  
In its widest meaning, the probiotic approach consists in exogenous administration of microbial 
cells (or cell components) aimed at benefiting the host‟s health, both in terms of maintenance of 
homeostasis and also as alternative strategy for the prevention and/or treatment of infectious 
diseases. More recently, it has been demonstrated that an important way through which 
probiotics can exert their beneficial effects is the ability to interact with host‟s immune system, 
both at local and systemic level, thus having efficacy also in body niches different from the gut. 
Starting from these observations, in the first part of the PhD research activity we screened 
several bacterial strains for their potential use as probiotics for the pharyngeal mucosa. We 
tested the ability of bacteria employed in food industry and newly isolated from the pharynx of 
healthy volunteers to adhere to the human pharyngeal epithelium, and to antagonize the oro-
pharyngeal pathogen S. pyogenes on FaDu cells and HaCat keratinocytes. Two bacterial strains, 
Streptococcus salivarius ST3, and the dairy starter Lactobacillus helveticus MIMLh5 were 
selected and compared with the oral commercial probiotic S. salivarius strain K12. These 
strains resulted sensitive to a variety of antibiotics routinely used for the control of upper 
respiratory tract infections. The in vitro immunological characterization performed on FaDu 
cells revealed that ST3 and MIMLh5 were both able to significantly reduce the activation of the 
nuclear-factor (NF)-κB in presence of the pro-inflammatory stimulus interleukin (IL)-1β, 
whereas presenting different modulatory abilities at baseline. Moreover these strain showed 
different cytokine profile under the above mentioned conditions. We subsequently decided to 
characterize the effects of the combined use of strain ST3 and MIMLh5. We found that strains 
MIMLh5 and ST3 activated innate immunity by inducing in U937 human macrophages the 
expression of cyclooxygenase (COX)-2, a balanced IL10/Tumor-Necrosis Factor (TNF)-α ratio, 
and we demonstrated that Toll-like receptor 2 (TLR-2) participates in the recognition of both 
strains. We also observed that these microorganisms grow efficiently when co-coltured in milk, 
suggesting that the preparation of a milk-based fermented product containing both strains can 
be a practical solution for the administration of these bacteria. 
Considered the ability of L. helveticus MIMLh5 to trigger immune responses also on murine 
bone marrow-derived dendritic cells, in the second part of the research we focused our attention 
on the possible molecular determinants involved in the immunostimulating activity of this 
strain. We studied MIMLh5 surface layer protein (SlpA) and we found that the bacterium and 
its SlpA exerted anti-inflammatory effects on the intestinal epithelial Caco-2 cell line by 
reducing the activation of NF-κB. On the contrary, MIMLh5 and SlpA acted as stimulators of 
the innate immune system by triggering the expression of the pro-inflammatory factors TNF-α 
and COX-2 in the human macrophage cell line U937 via recognition through TLR-2, whereas 
having slighter effect on the anti-inflammatory IL10, particularly for SlpA. When we tested 
MIMLh5 bacterial cells depleted from the protein, we observed a reduced pro-inflammatory 
activity, suggesting that SlpA plays a major role in mediating the immunostimulatory attitude of 
the bacterium, which could help to induce host‟s defenses against and responses towards 
infections. Most of these results were confirmed when we tested the bacterium and the protein 
on murine macrophages isolated from bone marrow and from peritoneal cavity. 
In the third part of the research we analyzed the effects on immune system of food compounds 
from vegetal origin. To this aim, we evaluated the immunomodulatory potential of different 
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fractions extracted from wild blueberries (WB) powder. We observed that only the anthocyanin 
(ACN) fraction was effective in reducing the activation of NF-κB on Caco-2 cells, whereas both 
the soluble and the phenolic fractions had no significant effects. Consequently, we used only the 
anthocyanin fraction for the subsequent characterization on U937 macrophages. We found that 
the presence of ACNs decreased the induction of TNF-α triggered by lipopolysaccharide (LPS) 
from Escherichia coli on U937, particularly when the cells were pretretated with ACNs and 
afterwards treated with LPS. These data suggest that ACNs from WB might have a protective 
role towards inflammation and that, probably, the described anti-oxidant features of these 
compound might be partially mediated by direct effects on immune system. 
In conclusion, this PhD work evidenced the noticeable abilities of bacteria and dietary 
compounds to modulate host immune system responses. Particularly, this study suggests that 
the use of selected food-grade bacteria, bacterial components or dietary compounds has a 
promising potential for the maintenance of host health and the prevention of diseases. 
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RIASSUNTO 
Modulazione dell’immunità innata dell’ospite da parte di batteri probiotici 
e di componenti della dieta. 
Nel suo più ampio significato, l‟approccio probiotico consiste nella somministrazione di batteri 
(o di componenti batteriche) finalizzate a un beneficio per la salute dell‟ospite, sia in termini di 
mantenimento dell‟omeostasi sia come strategia alternativa per la prevenzione di malattie 
infettive. Recentemente, è stato dimostrato che un‟importante via di azione dei probiotici è la 
capacità di interagire con il sistema immunitario dell‟ospite, sia a livello locale sia sistemico, 
agendo così anche in distretti corporei diversi dall‟intestino. Partendo da queste considerazioni, 
nella prima parte del progetto di dottorato sono stati selezionati ceppi batterici come potenziali 
probiotici per la mucosa faringea. Sono stati utilizzati ceppi batterici alimentari e ceppi isolati 
dalla faringe di soggetti sani per valutare sulle linee cellulari FaDu e su cheratinociti HaCat la 
loro capacità di aderire all‟epitelio della mucosa faringea umana, e di inibire Streptococcus 
pyogenes, il principale patogeno batterico della cavità oro-faringea. Un batterio di origine orale, 
Sterptocossus salivarius ST3, e lo starter caseario Lactobacillus helveticus MIMLh5 sono stati 
selezionati e confrontati con il probiotico orale commerciale S. salivarius K12. Tali ceppi sono 
risultati sensibili a diversi antibiotici usati comunemente per il controllo delle infezioni delle 
alte vie respiratorie. La caratterizzazione immunologica in vitro effettuata su cellule FaDu ha 
dimostrato che ST3 e MIMLh5 erano in grado di ridurre l‟attivazione del nuclear-factor (NF)-
κB in modo significativo in presenza dello stimolo pro-infiammatorio interleuchina (IL)-1β; 
presentando un‟attività modulatoria diversa a livello basale. Inoltre, tali ceppi hanno mostrato 
un profilo di espressione di citochine diverso nelle medesime condizioni sopra indicate. 
Conseguentemente, abbiamo caratterizzato gli effetti dell‟uso combinato dei 2 ceppi. È stato 
dimostrato che ST3 e MIMLh5 attivavano l‟immunità innata inducendo nella linea cellulare 
U937 di macrofagi di origine umana l‟espressione di ciclooxigenase (COX)-2 e un rapporto 
bilanciato IL10/Tumor-Necrosis Factor (TNF)-α. È stato inoltre dimostrato che il recettore 
Toll-like 2 (TLR-2) partecipa al riconoscimento di entrambi i ceppi. Abbiamo infine osservato 
che tali microorganismi crescono efficientemente in co-coltura in latte, suggerendo come 
possibile via di somministrazione per questi batteri un prodotto a base di latte fermentato. 
Considerata la capacità di L. helveticus MIMLh5 di indurre risposte immunitarie anche in 
cellule dendritiche di origine murina estratte da midollo osseo, nella seconda parte della  ricerca 
abbiamo focalizzato l‟attenzione sui possibili determinanti molecolari coinvolti nell‟attività 
immunostimolatoria di questo ceppo. È stata studiata la proteina di superficie S-layer (SlpA) di 
MIMLh5 ed è stato evidenziato che il batterio e la sua SlpA esercitavano effetti anti-
infiammatori sulla linea cellulare epiteliale intestinale Caco-2 mediante la riduzione 
dell‟attivazione del NF-κB. Al contrario, MIMLh5 e SlpA agivano da stimolatori del sistema 
immunitario innato attivando l‟espressione dei fattori pro-infiammatori TNF-α e COX-2 in 
macrofagi U937, attraverso il riconoscimento da parte del TLR-2, e, particolarmente per SlpA, 
una più bassa espressione della citochina anti-infiammatoria IL-10,. Quando le cellule 
batteriche di MIMLh5 sono state private della proteina, è stata osservata una ridotta attività pro-
infiammatoria.. Questo dato suggerisce come SlpA abbia un ruolo importante nel mediare 
l‟attitudine immunostimolatoria del batterio, che può risultare positiva nell‟aiutare l‟ospite ad 
attivare meccanismi di difesa e di risposta contro le infezioni. Molti di questi dati si sono 
riconfermati su macrofagi di origine murina estratti da midollo osseo e da cavità peritoneale. 
Riassunto 
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Nella terza parte del progetto di ricerca sono stati valutati gli effetti di componenti alimentari di 
origine vegetale sul sistema immunitario. A tale scopo, abbiamo valutato il potenziale 
immunomodulatorio di diverse frazioni estratte da polvere di mirtillo selvatico (WB). La sola 
frazione contenente antociani (ACN) è risultata efficace nel ridurre l‟attivazione del NF-κB 
nelle cellule Caco-2, mentre la frazione solubile e quella fenolica non hanno dato variazioni 
significative. Di conseguenza, abbiamo utilizzato unicamente la frazione antocianica per la 
caratterizzazione immunologica sui macrofagi U937. Tali esperimenti hanno evidenziato come 
l‟induzione di TNF-α indotta dal lipopolisaccaride (LPS) di Escherichia coli nelle cellule U937 
diminuisse in presenza degli ACN. Questo effetto è stato particolarmente evidente quando le 
cellule sono state pretrattate con ACN e in seguito con LPS. Questi dati indicano come gli ACN 
derivati da WB possano avere un ruolo protettivo contro i processi infiammatori. Pertanto le 
proprietà anti-ossidanti descritte in letteratura per questi composti possono probabilmente in 
parte derivare da effetti diretti sul sistema immunitario. 
Concludendo, il presente lavoro di dottorato di ricerca ha evidenziato le notevoli capacità dei 
batteri e di componenti bioattivi della dieta di modulare le risposte del sistema immunitario 
dell‟ospite. In particolare, questo studio suggerisce l‟impiego di batteri “food-grade”, di 
componenti batteriche e di componenti alimentari come potenziale e promettente strategia per il 
mantenimento della salute dell‟ospite e per la prevenzione di malattie. 
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PREFACE 
There are increasing evidences of the importance that a proper and well-balanced functioning of 
the immune system plays in host‟s health maintenance (Wichers, 2009). Different endogenous 
and exogenous factors can take part in the modulation of the type and the magnitude of immune 
responses. Diet and nutrition have been demonstrated to affect diverse immune parameters 
(López-Varela et al., 2002; Veldhoen & Brucklacher-Waldert, 2012), and several studies 
revealed the pivotal role that microbiota has in shaping host‟s immune system (Macpherson & 
Harris, 2004; Round & Mazmanian, 2009). Moreover, the strong interrelationship between 
these factors has been shown both in terms of influence that diet can have on gut microbiota 
composition (Turnbaugh et al., 2009; Maslowski & Mackay, 2011) and impact that commensal 
and/or ingested bacteria have on host‟s nutritional status, depending on their metabolic 
activities (Sekirov et al., 2010; Tremaroli & Bäckhed, 2012). All these observations opened the 
way to an expanding field of studies targeted to the evaluation of the immunomodulatory 
potential of food-derived compounds, and food-associated and commensal/probiotic 
microorganisms. According to FAO/WHO, probiotics are defined as „live microorganisms 
which when administered in adequate amounts confer a health benefit on the host‟ (FAO/WHO 
2002). Increasing evidences support the idea that one of the main mechanisms through which 
beneficial microbes can positively affect the host‟s health involves their ability to interact with 
the host‟s immune system by eliciting responses at both local and systemic level (Borchers et 
al., 2009; Lebeer et al., 2010; Taverniti & Guglielmetti, 2011). Thus far probiotics have been 
most predominantly investigated for and applied to the intestinal tract; however, more recently 
it has been demonstrated that commensals and probiotic bacteria can act on immune functions 
beyond the gut (Noverr & Huffnagle, 2004; Smith et al., 2007), and that they can influence both 
innate and adaptive immunity (Chervonsky, 2010). But, even though commensal/beneficial 
microorganisms are important components of host‟s defence in many body sites, only a few 
applications beyond the gut suggested the potential positive role of probiotics, for instance for 
the stomach (Johnson-Henry et al., 2004), vaginal mucosa (Reid et al., 2009; Rose et al., 2012), 
urinary tract (Borchert et al., 2008), skin (Krutmann, 2009) and oral cavity (Tagg & Dierksen, 
2003; Guglielmetti et al., 2010a,b). Moreover, elucidations of the mechanisms involved in the 
cross-talk between microorganisms and host‟s cells, in terms of identification of bacterial 
molecules involved and immune signaling pathways activated, are still needed. Several studies 
demonstrate that even non-viable bacterial cells or single cell components are able to drive 
immune responses, supporting the potentiality of a “paraprobiotic” approach (Taverniti & 
Guglielmetti, 2011). Identifying and characterizing unique bacterial components that act as 
effectors of the immune system is crucial for the elucidation of host-microbial interplay. In 
addition, a deeper understanding of the molecular mechanisms underlying the dialogue between 
bacteria and the host organism‟s system is of great importance for several reasons: to better 
define both the benefits and the potential risks associated with the administration of probiotic 
therapies (Besselink et al., 2008), and to open to new perspectives and alternative uses and 
applications of probiotics. 
Considered all the previous observations concerning diet and microbes beneficial potential, the 
subsequent topics have been investigated during the PhD research activity:  
1. Identification and characterization of bacterial strains isolated from the oro-pharyngeal 
cavity; evaluation of the probiotic abilities of food-derived bacteria and oral isolates 
for a potential application in the prevention and/or treatment of upper-respiratory tract 
infections; characterization of the immumodulatory properties derived from the 
combined use of a dairy strain of Lactobacillus helveticus with a selected strain of the 
Preface 
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oral commensal Streptococcus salivarius, targeted to the improvement of host‟s 
surveillance at level of innate immunity. 
2. Immunological evaluation of the previous characterized L. helveticus strain and study 
of its surface layer protein involvement in mediating the bacterial immunostimulating 
activity. Comparison with the immunological behavior of a commercial probiotic 
strain of L. acidophilus, and evaluation of the kind of immune responses and signaling 
pathways activated by our selected bacterium and its purified protein. 
3. Evaluation of the immunomodulatory potential of food-associated compounds by 
characterizing the anthocyanin (ACN) fraction isolated from wild blueberries 
(Vaccinium angustifolium) powder, by analyzing the potential anti-inflammatory 
activities of ACNs in presence of pro-inflammatory stimuli. 
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1.1 STATE OF THE ART 
1.1.1 History of probiotics 
The term “probiotic” (derived from the ancient Greek meaning “for life”) dates back to 1956, 
when it was probably used for the first time by the food scientist Werner Kollath to indicate 
microbial cells or molecules able to promote or improve the survival of live organisms (in 
contrast to the terms “antibiotics”). Although a relatively new word, the beneficial effects of 
certain fermented foods containing live bacteria have been recognized for centuries. The 
Russian physiologist Elie Metchnikoff (1845-1916) proposed, in fact, that shortening of life is a 
consequence of chronic poisoning due to intestinal putrefactions, and that the modification of 
microbiota composition through the consumption of viable microbes might help to improve 
health and longevity. Following Metchnikoff, in the early 20
th
 century other investigators 
started to suggest that gut flora could be altered with beneficial bacteria replacing harmful 
microbes, leading to the concept of probiotics (Williams, 2010). Interestingly, the use of this 
word in scientific literature was negligible until the 1990s, but it reached 100 papers/y at the 
turn of the millennium, and is present today in about 900 papers/y. In 2001, the year of the Food 
and Agriculture Organization and World Health Oganization (FAO/WHO) Expert Consultation 
on “Health and Nutritional Properties on Probiotics in Food”, there were 274 papers listed in 
PubMed under the keyword “probiotics,” whereas in 2011 this number was as high as 975 (data 
from http://www.gopubmed.org; Morelli & Capurso, 2012).  
For what it concerns the market of probiotics, the first probiotic product, including a bacterium 
belonging to the species Lactobacillus paracasei, has been isolated in 1930 by Prof. Shirota 
from human intestine, and later sold in yogurt drink “Yakult” in Japan in the 50‟s. In Europe, 
the first probiotic has been introduced in 1980, and nowadays the continuously growing interest 
in the field of probiotic microorganisms and products supports a global market expected to be 
worth $19.6 billion in 2013 (BCC Research 2008). 
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Table 1.1.1 Commercial Strains Sold As Probiotics. Selected probiotic strains and products 
available in the US and Europe. This table does not constitute an endorsement of any of these 
products, nor does it include all strains/mixtures currently available (California Dairy 
Research Foundation, 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
Parenthetic entries indicate alternative strain designations; B. lactis is a shorthand 
designation for Bifidobacterium animalis subsp lactis. 
2
Strains sold as ingredients are available in numerous consumer products; contact responsible 
company for product list. Products listed are examples and do not reflect a comprehensive list 
of available products containing the indicated strain. 
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1.1.2 Probiotic definition and regulation  
According to the definition proposed by the FAO/WHO workshop of 2002, probiotics are „live 
microorganisms which when administered in adequate amounts confer a health benefit on the 
host‟ (“Guidelines for the Evaluation of Probiotics in Food”, FAO/WHO, 2002). The 
FAO/WHO consultation had as major outcomes the providing of an official definition for 
probiotics, together with guidelines regarding safety evaluation of the microorganisms possibly 
employed as probiotics, indications about the strategies for the assessment of nutritional and 
beneficial properties, and an overview of the rules needed for the elaboration of the health 
claims. An aspect of particular importance stated in these recommendations is that the probiotic 
properties must be strictly correlated to a single bacterial strain, meaning that benefits obtained 
from the ingestion of a specific bacterial strain cannot be extended to other strains, even 
belonging to the same species.  
Nowadays, the situation of probiotics products regulation, especially in European Union (EU), 
is still a controversial issue. Probiotic products which have been introduced on market after 
1997 must follow the indications regarding the Novel Foods reported in the Regulation (EC) of 
the European Parliament and of the Council No 258/1997, as well as the general guidelines 
reported in the Regulation (EC) No 1924/2006 on nutrition and health claims made on food, 
which thus encompass also the health claims allowed for probiotic products. Moreover, 
subsequent regulations on labeling, presentation and advertising of foodstuffs were introduced 
starting from 2007, aimed to provide a common regulation in all members states of EU, and to 
guarantee consumers safety and protection against misleading labels. To these specific aims, in 
2002 the European Food Safety Authority (EFSA) was established by EU politicians in order to 
ensure an high level of consumer protection and to restore confidence in food, in particular after 
several food scares. According to current rules, food industry before introduce a new probiotic 
product on market must receive an EU authorization based on EFSA‟s assessment of safety.  
In 2007 EFSA introduced the concept of “Qualified Presumption of Safety” (QPS), an 
evaluation tool to assess the safety of a microorganism for a deliberate introduction into food 
and feed. These guidelines establish that, to obtain the QPS status (akin to the concept of 
“Generally recognized as safe”, the American Food and Drug Administration designation that a 
chemical or substance added to food must be considered safe by experts) for a microorganism it 
is required the deposition of the strain and its characterization to molecular level, together with 
data on antibiotic resistances, genetic stability, toxins and virulence factors, and a body of 
knowledge regarding history of safe use and established uses of the bacterium, accompanied by 
scientific literature on absence of clinical cases and evidences of beneficial effects from in vitro 
and in vivo studies. Thus, industry must submit to EFSA each health claim for scientific 
evaluation prior to its approval and use in EU. In particular, the European Commission in 2008 
produced guidance that indicated that the Authority would have rejected any health claim not 
including human clinical data (Vogel, 2010). Thus far EFSA has rejected every submitted 
dossiers regarding health claims for probiotics.  
Currently, in Italy the only label allowed from the Health Ministry for a probiotic product is “it 
supports gut flora balance”, even though in the Opinion reported in “EFSA Journal 2009; 
7(9):1232”, the NDA (nutrition, dietetic and allergy) panel of EFSA states: “Increasing the 
number of any group of bacteria is not considered in itself as beneficial”.  
Even in the United States market, which is showing a growing interest for these products, 
probiotics regulation is very complex. Probiotics sold as dietary supplements do not require 
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Food and Drug Administration (FDA) approval before introduction on market. Labels allowed 
for probiotics sold as dietary supplements without FDA consent may refer only to effects on 
structure/function of the body (like claims for the strengthening of body‟s defense, caring for 
the digestive system..), but they cannot refer to reduction of risk of diseases without FDA 
approval. Thus far, FDA has not approved any health claims for probiotics (Saldanha, 2008). 
Similarly, in Australia probiotics sold for specific health benefits require premarket review by 
the Therapeutic Goods Administration and are regulated as complementary medicines, and in 
Japan a premarket review by Health Ministry is required (Boyle et al., 2006). Nonetheless, 
research on probiotics is moving on, both towards laboratory studies and clinical trials (Table 
1.1.2), in order to evaluate the effects on several medical conditions. 
Table 1.1.2 The beneficial effects of probiotic bacteria documented in human intervention 
studies (adapted from Saxelin et al., 2005). The strains used are indicated, as are specific 
comments on the trials. META, indicates meta-analyses and LGG, 299v and BB12 refer to L. 
rhamnosus GG, L. plantarum 299v and B. lactis BB1,  respectively. 
 
 
 
1.1.3 Safety of probiotics 
The scientific evaluation of probiotic beneficial properties is becoming increasingly rigorous 
since the last years. When performing a literature search, combining the key words “probiotics”, 
“clinical trials” and “humans”, more than 750 are listed, the major of which in top ranking 
nutritional and clinical journal. But, even though there exists a lot of strong evidences of 
probiotics administration efficacy in the treatment and prevention of several disorders, from 
acute gastroenteritis to intestinal neoplasia (Marteau, 2002), actually there are several risks due 
to a misuse of probiotics. In some conditions, in fact, these products might turn into detrimental 
factors, since their administration is often wider than the recommended and specific indications 
(Boyle et al., 2006), and the beneficial use of specific strains in healthy subjects might lead to 
detrimental consequences in patients (Besselink et al., 2008; Capurso & Morelli, 2010). 
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Safety evaluation of probiotics is controversial. Probiotics have been used for years in food 
industry, and there are also several studies confirming that the wider use of probiotic products 
has not caused any increase of bacteremia cases (Saxelin et al., 1996; Salminen et al., 2002). 
Moreover, some studies reported the safe use of probiotics even in high risk populations 
(Stansbridge et al., 1993; Wolf et al., 1998; Salminen et al., 2004). However, cases of sepsis are 
reported in literature (Ha et al., 1999; Kunz et al., 2004; Land et al., 2005). Along with 
translocation potential, other possible risks which can derive from the introduction of 
microorganisms include antibiotic resistance-transfers, gastrointestinal toxicity (caused by 
deleterious metabolic activities and production of dangerous metabolites), excessive immune 
stimulation (Snydman, 2008). The major obstacle in a safe definition of the possible 
applications of probiotic therapy is the deficiency in the knowledge of probiotic mechanism of 
action, in particular at immunological level. In general, the main aspect that still creates concern 
and confusion about probiotics use is the target consumer. FAO/WHO guidelines are in fact 
only related to food and the use of beneficial bacteria in healthy subject, thus excluding the use 
in pathologic conditions, which is properly a “therapeutic matter”. Probiotics can be considered 
safe for the use in healthy people, but the observed beneficial properties cannot be extended to 
other populations, and administration should be evaluated with caution in medical conditions 
and in specific categories of person, like immunocompromised subjects, preterm infants or with 
underlying diseases, elderly patients”. So each probiotic strain characterization activity should 
have a study-by-study and population-based approach (Snydman, 2008). 
 
1.1.4 The probiotic approach 
The probiotic approach could be an alternative and mild strategy for the prevention and 
treatment of either inflammatory or allergic diseases. It is estimated that the human microbiota 
contains as many as 1014 bacterial cells, a number that is 10 times greater than the number of 
human cells present in our bodies, starting from the skin surface to the genitourinary tract, oral 
cavity, respiratory tract, ear, and the gastrointestinal tract (Ley et al., 2006). Metagenomics and 
functional molecular immunology substantiate the interpretation of humans as holobionts, in the 
sense of functional superorganisms, combining self and microbes acting in concert to produce 
phenomena governed by the collective (Kelly, 1994; Zilber-Rosenberg & Rosenberg, 2008). 
The association between host and symbionts affects the fitness of the holobiont within its 
environment and it often governs the physiological homeostasis on the narrow balance between 
host wellbeing and dysfunction (Eberl & Lochner, 2009; Proal et al., 2009). The mechanisms 
underlying the cross-talk between a human host and microbes are only marginally understood. 
However, several studies have shown that different bacterial strains can exert their probiotic 
abilities by influencing the host‟s immune system, thereby modulating immune responses, at 
both the local level and the systemic level (Borchers et al., 2009; Lebeer et al., 2010; Taverniti 
& Guglielmetti, 2011). Thus, the elucidation of probiotic effects at molecular level could supply 
the theoretical bases to develop strategies for preventing or treating several human 
dysfunctions, through the reconstitution of a proper human-microbe mutualism. The probiotic 
approach, in its widest sense, falls into this context, since it consists of the modification of a 
human microbiota by exogenous administration of microbial cells or cell components, aimed at 
benefiting the host's health. The majority of probiotic bacteria belong to the genera 
Lactobacillus and Bifidobacterium (Table 1.1.1), which are Gram-positive bacteria that 
constitute a major part of the normal intestinal microflora in animals and humans (Kotzampassi 
& Giamarellos-Bourboulis, 2012). However, there are also evidences of probiotic roles of 
other microbes such as yeasts (Saccharomyces boulardii and Saccharomyces cerevisiae) and 
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some non-pathogenic strains of Escherichia coli and Bacillus spp. not normally found in the 
gastrointestinal tract (de Vrese & Schrezenmeir, 2008). 
 
1.1.5 Probiotics in infectious diseases 
Infectious diseases represent a perpetual issue to deal with. According to the World Health 
Organization (WHO)‟s 2004 World Health Report, infectious diseases are the second cause of 
death (following cardiovascular diseases) responsible for about the 26 % of the deaths occurred 
worldwide in 2002. One of the major concerns is represented by the acquiring of antimicrobial 
resistance by pathogens, and thus to the spread of resistant microorganisms. This event is 
mainly caused by the misuse of antibiotics that often are prescribed unnecessarily (Wise et al., 
1998). In this context, the use of probiotic microorganisms able to exert an antagonistic activity 
towards pathogens can represent an alternative intervention to prevent infections, and might 
also reduce excessive antibiotics administration. Regarding their role for the prevention and 
treatment of infectious diseases, there is an increasing evidence coming from randomized 
clinical trials (RCTs) for what it concerns antibiotic-associated diarrhea (AAD), Clostridium 
difficile infection (CDI), acute gastroenteritis and infectious complications following admission 
to the Intensive Care Unit (ICU).  
Traditionally, probiotics have been associated with gastrointestinal tract (GIT) and used for the 
prevention and treatment of gastrointestinal disorders. However, more recently, probiotics 
effectiveness has been proposed also for a broader use. In fact, several probiotics have been 
designed for the vaginal mucosa (Reid et al., 2009), the urinary tract (Borchert et al., 2008), the 
skin (Krutmann, 2009), and the oro-pharyngeal cavity (Tagg & Dierksen, 2003). Particularly for 
the latter, related studies report that the mechanisms of action of probiotics at oro-pharyngeal 
level is analogous of that described for the gut (Rao et al., 2012). 
 
1.1.6 Upper respiratory tract infections and probiotics for the oro-pharyngeal mucosa 
The use of probiotics for the oro-pharyngeal tract (OPT) is particularly promising. OPT 
dysfunctions are often related to the presence of microbial pathogens (for instance, 
Streptococcus mutans, group A streptococci, or Porphyromonas gingivalis) or to microbial 
dysbiosis. Furthermore, compared with the distal GIT, the OPT is a more accessible site for 
microorganisms of exogenous origin. For these reasons, the OPT is a potential target for new, 
specifically designed probiotic products. Upper respiratory tract infections (URTIs) represent 
the most common acute illness in the patient outsetting, and they account for 9% of all 
consultations in general practice (Bourke, 2007). URTIs include rhinitis, rhinosinusitis, 
rhinopharyngitis, also called the common cold, pharyngitis, epiglottitis and laryngitis (Popova 
et al., 2012). There are reported different studies demonstrating probiotics beneficial effects in 
several pediatric infectious diseases (Weichert et al, 2012). In studies performed thus far on 
probiotic effects for URTIs, half of the species employed belong to Lactobacillus genus (L. 
rhamnosus, L. acidophilus, L. debrueckii, L. paracasei, L. plantarum) and Bifidobacterium 
genus (B. animalis, B. bifidum, B. longum); the rest are represented by Streptococcus genus (S. 
salivarius, S. mitis, S. oralis, S. sanguinis). Among these studies, an interesting example 
demonstrating the potential of the probiotic approach for the OPT and URTIs is represented by 
the research activity of Prof. J. R. Tagg and coworkers, who isolated the Streptococcus 
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salivarius strain K12 (Wescombe et al., 2006). Strain K12 has a marked ability to inhibit 
pathogenic bacteria, mainly due to the production of three different bacteriocins, salivaricin A2, 
B and 9 (Power et al., 2008). Strain K12 was also demonstrated to be able to colonize the upper 
respiratory tract (Horz et al., 2007) and to down-regulate the innate immune responses of 
human epithelial cells (Cosseau et al., 2008). The scientific results from the Tagg lab studies 
supported the creation of a set of probiotic pharmaceutical products (lozenges, powders and 
chewing gum), commercialized under the name of BLIS, that were specifically designed for the 
prevention or treatment of dysfunctions such as cavities, periodontitis, halitosis and pharyngitis 
(http://blis.co.nz/international/). In July 2011, the oral probiotic products BLIS K12 were 
granted GRAS status by FDA, enabling this probiotic to be included as an ingredient in food 
products within the United States. 
 
1.1.7 The oro-pharyngeal environment 
In any potential probiotic application it is important consider the peculiarity of the target body 
site. In the oro-pharyngeal cavity is present an organized secondary lymphoid tissue, namely the 
naso-pharynx associated lymphoid tissue (NALT), a specialized component of the family of 
mucosa-associated lymphoid tissue (MALTs), that all together constitute the mucosal immune 
system (Fukuyama et al., 2009). In humans NALT is mainly represented by the Waldeyer's 
ring, that comprise palatine tonsils, nasopharyngeal tonsil (adenoid) and lingual tonsil as major 
constituents (Hellings et al., 2000). Defense responses at level of mucous membranes are very 
critical, since these sites are continuously exposed to a large amount of different antigens, 
meaning that their role is not only to provide an efficient barrier to potentially harmful agents, 
but also to induce protective immune reactions (Debertin et al., 2003). In particular, the oro-
pharyngeal tract is a way of entrance of both airborne and alimentary antigens. Characteristics 
and functions of the immune system at this level are organized in order to act either with local 
mucosal response or systemic immunological effects (Brandtzaeg, 2011). Considering the 
enormous number of microorganisms with which the mucosal immune system has constantly to 
interface, the ability to discriminate between “friends and foe”, and thus to recognize and 
eliminate pathogens while tolerating harmless commensals, represents the basis for the 
maintenance of homeostasis (Cutler & Jotwani, 2006).  
 
1.1.8 Probiotics mechanisms of action: the modulation of the immune response 
The modes of action by which probiotics are suggested to affect human health fall include three 
main categories (Lebeer et al., 2008). First, some probiotics can inhibit pathogens though 
various antagonism mechanisms. This is the most studied probiotic mechanism and has been 
exhaustively reviewed (Servin, 2004). A second way is the enhancement of the functions of 
mucosal barriers, particularly at intestinal level, and the modulation of various signalling 
pathways that lead to, for instance, the induction of mucus, and defensin production, 
enhancement of tight junction functioning, and prevention of apoptosis (Lebeer et al., 2010). 
The third mechanism is the modulation of host‟s immune responses, both at local and systemic 
level (Smits et al., 2005). Increasing evidence supports this hypothesis (Borchers et al., 2009; 
Lebeer et al., 2010; Adams, 2010; Taverniti & Guglielmetti, 2011). Clinical applications of the 
immunomodulatory properties of bacteria have been performed particularly for lactobacilli and 
bifidobacteria. These studies refer to prevention and treatment of allergic diseases, in particular 
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atopic dermatitis in children, inflammatory bowel diseases, and prevention of virus infection 
and use as an adjuvant in vaccination (Borchers et al., 2009). In spite of this, the mechanisms 
determining the microbial ability to interact with the immune system of mammals are largely 
unexplored. Thus, studies targeted to elucidate the mechanisms involved in bacteria-host‟s cells 
cross-talk are required.  
 
1.1.9 The first line of defense of the immune system: the innate immunity 
The role of the immune system is to defend against diseases and to maintain homeostasis. 
Host‟s cells are continuously exposed to both endogenous and exogenous bacteria, which 
encompass harmless and potential detrimental microorganisms. Thus, one of the most important 
function of a balanced immune system is a proper recognition of self and non-self, that results 
in the mounting of non-inflammatory or sub-inflammatory responses against commensals, and 
activation of immune responses against pathogens. The immune system consists of two 
components, innate and acquired immunity, that induce both the systemic and the mucosal 
immune responses. The innate immunity is the first line of defense and is preposed to provide 
an early and non-specific response to antigens, targeted to a rapid elimination of the harmful 
agents. Innate immune responses can be initiated at level of epithelial cells and, more 
specifically, by phagocytes like neutrophils, dendritic cells, monocytes and macrophages, that 
play a crucial role in host defense (Galdeano & Perdigón, 2006).  
Macrophages, once activated by microbial products, acquire microbicidal competence 
(Mackaness, 1964). Polarized macrophages have been classified into two main groups, M1 and 
M2, differing for their phenotype and effector functions: M1 subset, activated by bacterial 
products and inflammatory cytokines, produces cytokines like IL6, IL12, COX-2, IL1β and 
TNFα, and possesses microbicidal and inflammatory properties, while M2 are poorly 
microbicidal and with immunomodulating characteristics (Benoit et al., 2008). Macrophages are 
able to produce cytokines recruiting other inflammatory cells such as neutrophils. Phagocytic 
cells are attracted to the infection site by chemotaxis.  
Natural Killer (NK) cells also participate in the innate immune response. NK cells rapidly react 
to the presence of virus infected cells in the early stages of infection by killing the infected 
target cells (Delcenserie et al., 2008).  
Lymphocytes (B and T) are the main actors in the adaptive immune response. The adaptive 
immune system can provide a more effective protection against pathogens through the ability to 
recognize and remember an impressive number of antigens. (Delcenserie et al., 2008). Helper T 
cells are mainly found in two distinct cell types, Th1 and Th2, distinguished by the cytokines 
they produce and respond to, and the immune responses they are involved in. Th1 cells produce 
pro-inflammatory cytokines which stimulate the phagocytosis and destruction of microbial 
pathogens, while Th2 cytokines such as IL-4 generally stimulate the production of antibodies 
directed toward large extracellular parasites. Even though a true balance between Th1 and Th2 
profiles is difficult to maintain, there are categories of immune cells, i. e. regulatory T cells 
(Treg), which are preposed to this crucial function. The balance between Th1 and Th2 
responses determines, in fact, the direction and outcome of an immune response; moreover, 
prolonged or exaggerated responses in each direction can lead to the development of Th1-
driven (chronic-inflammatory diseases) or Th2-driven (allergic diseases) pathologies 
(Delcenserie et al., 2008). 
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Dendritic cells (DCs), as well as macrophages and monocytes, are the link between the innate 
and adaptive immune systems, since they act as professional “antigen-presenting cells” (APCs). 
This function is crucial in initiating the adaptive immune response, as T cells do not respond to 
free-antigen but only to antigen that is presented by APCs. Cells of the innate immune system 
also influence the adaptive immune response through the production of chemical mediators 
called “cytokines”: these are proteins which are involved in the communication among cells, 
and are essential in regulating cell priming, acquiring of a specific phenotype, and thus 
determining the outcomes of an immune response at both innate and adaptive levels (Fig. 1.1.1). 
Epithelial cells and phagocytes interact with and respond to microorganisms by means of their 
pattern recognition receptors (PRRs). PRRs detect microorganism-associated molecular patterns 
(MAMPs), which are widespread and conserved among microorganisms (Lebeer et al., 2010). 
The best studied PRRs are Toll-like receptors (TLRs), which are transmembrane proteins 
present at the cell surface or on the membrane of endocytic vesicles or other intracellular 
organelles (Medzhitov, 2007). TLRs play a central role in alerting antigen-presenting cells to 
the presence of pathogenic material (Dunzendorfer et al., 2004).  
 
Figure 1.1.1 Cells and selected cytokines taking part in innate and adaptive immunity (adapted 
from Trinchieri, 2003). 
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The modality through which bacteria can elicit a specific immune response, both in terms of 
cells signaling pathways activated and mechanisms involved in the host-microbes interplays, is 
still poorly understood. Thus, in order to identify the ways of action of health-promoting 
bacteria, and to find new applications in the prevention and treatment of several disorders, as 
well as for the evaluation of potential risks, studies at mechanistic level are required. Moreover, 
it is important to stress that bacteria interact with host cells in a strain-specific way. That leads 
to the need to identify which component in each bacterial strain is responsible for an 
immunomodulatory activity. 
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1.2 AIMS OF THE STUDY 
Starting from the above-mentioned promising studies regarding the beneficial properties of 
food-grade bacteria in infectious diseases and on host innate immunity, we screened bacterial 
strains both from oral and food origin for their potential use as probiotics for the oro-pharyngeal 
mucosa. We tested the ability of bacteria, newly isolated from the pharynges of healthy 
volunteers or from dairy origin, to adhere to a human pharyngeal cell layer and to antagonize S. 
pyogenes on two different epithelial cell lines. As a result of these studies, we selected the oral 
isolate Streptococcus salivarius ST3 and the dairy strain Lactobacillus helveticus MIMLh5 as 
new probiotic candidates for the pharyngeal mucosa. These strains were further investigated for 
their in vitro probiotic properties when employed in combination, and also analyzed from an 
immunological point of view. Specifically, we examined their ability to adhere to FaDu human 
pharyngeal cells, to antagonize Streptococcus pyogenes and to modulate the immune response 
on U937 macrophages. Moreover, to explore the potential of combining strains ST3 and 
MIMLh5 in a fermented food product, we also studied the growth of S. salivarius ST3 in the 
presence of different sugars and in milk in co-culture with strain MIMLh5. 
Our results support the possibility of producing a novel milk-based fermented food product to 
be used as probiotic for the oro-pharyngeal mucosa. 
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1.3 MATERIALS AND METHODS 
1.3.1 Isolation of bacteria from pharyngeal mucosa and culture conditions 
To isolate bacteria from pharynx, specimens were collected using polyester fiber-tipped 
applicator swabs (VWR, Milano, Italy) from 4 healthy donors (3 females, 58, 32 and 29 years 
old, and a 32 years old male). After serial dilutions in 0.1 % peptonated saline, speciments were 
plated on MRS agar (Fluka Feinchemikalien GmbH, Neu-Ulm, Germany) supplemented with 
0,05 % cysteine-HCl (cMRS), M17 (Fluka Feinchemikalien GmbH) containing 2 % lactose (L-
M17) and 2 % glucose TSA (Difco, Detroit, MI, USA). Around 50 colonies were randomly 
picked up and spread on plate with a loop. This procedure was repeated at least four time, in 
order to obtain pure cultures. Tables 1.3.1 and 1.3.2  list the bacterial strains used in this study. 
If not differently specified, oral streptococci, Streptococcus thermophilus and lactococci were 
routinely grown overnight at 37°C in L-M17. Lactobacilli were cultivated overnight in cMRS at 
37°C. Bifidobacterium animalis subsp. lactis Bb12 was grown anaerobically at 37°C in pre-
reduced cMRS, while Streptococcus pyogenes was grown overnight at 37°C in BHI (Difco) 
supplemented with 0.3 % yeast extract. 
 
1.3.2 Identification and molecular characterization of bacterial isolates 
The isolates from each subject have been clustered by means of BOX-PCR assay (Table 1.3.1), 
which was performed with primer BoxA1 (5′-CTACGGCAAGGCGACGCTGACG- 3′) in a 
PCR reaction mix consisting of of 20 mM Tris–HCl, 50 mM KCl, 200 μM of each 
deoxynucleoside triphosphate, 1 μM of the primer, 1.5 mM MgCl2 and 1.5 U of Taq 
polymerase (Fermentas, Vilnius, Lithuania). The 16S rRNA gene was amplified from at least 
one representative isolate from each BOX-genotypic group (Table 1.3.1) by PCR using the 
primers P0 (5′-GAAGAGTTTGATCCTGGCTCAG-3′) and P6 (5′-
CTACGGCTACCTTGTTACGA-3′). Each PCR mixture (50 μl) was as for BOX-PCR analysis. 
Each PCR cycling profile consisted of an initial denaturation time of 2 min at 95°C followed by 
an amplification for 35 cycles of denaturation (30 s at 95°C), annealing (45 s at 55°C) and 
extension steps (2 min at 72°C). The PCR was completed with an elongation period (7 min at 
72°C). The resulting amplicons were then sequenced by using an ABI Prism BigDye™ 
terminator technology in an ABI Prism™ 310 DNA sequencer (Applied Biosystems, Foster 
City, CA, USA). Streptococcus salivarius isolates were further characterized by RAPD 
analysis, performed with primers OPI17 (5‟-CGAGGGTGGTGATC -3‟), OPI02-mod (5‟-
GCTCGGAGGAGAGG-3‟), M13 (5‟-GTAAAACGACGGCCAGT-3‟) and PedAF (5‟-
ATACTACGGTAATGGGGT-3‟). Reaction mix was as for BOX analysis, and the temperature 
profile was as follows: primary DNA denaturation step at 94°C for 2 min followed by 5 cycles 
of 45 s at 94°C, 45 s at 31°C and 2 min at 72°C; 35 additional cycles were carried out 
increasing the annealing temperature to 40°C. For all the amplification cycles the final 
extension was continued for 7 min at 72°C. 
Similarity dendrogram was built using NTSYSpc v. 2.01 (Applied Biostatistic Inc., New York, 
NY). 
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Table 1.3.1 Bacteria isolated from pharyngeal mucosa. 
Human 
source‟s 
designation 
BOX-PCR 
genotype1 
Denomination of 
the isolates2 
Isolation 
medium 
Taxonomic identification3 
Additional 
identification 
method4 
IS 
IS-A1 
IS1 cMRS 
S. salivarius  
IS8, IS10, IS12 L-M17 
IS-A2 
IS5, IS6,  L-M17 
S. salivarius  
IS7 gTSA 
IS-B IS3, IS4 cMRS S. sanguinis  
IS-C 
IS9 L-M17 
Staphylococcus aureus  
IS15 gTSA 
IS-D 
IS11, IS13 L-M17 
Rothia mucillaginosa  
IS14 gTSA 
RS 
RS-A1 
RS1, RS8, RS10 L-M17 
S. salivarius  RS3, RS6 cMRS 
RS13, RS14 gTSA 
RS-A2 RS9 L-M17 S. salivarius  
RS-B RS4 cMRS Alloscardovia omnicolens  
RS-C RS5 cMRS Lactococcus lactis subsp. Lactis his 
RS-D RS11 L-M17 Micrococcus sp. (luteus)  
RS-E RS12 gTSA Rothia mucillaginosa  
RS-F RS15 gTSA Bacillus subtilis  
SM 
SM-A1 
SM1, SM2, 
SM4, SM5 
cMRS S. salivarius  
SM6, SM8, SM9 L-M17 S. salivarius  
SM11, SM14, 
SM15 
gTSA S. salivarius  
SM-A2 SM12 gTSA S. salivarius  
SM-B SM3 cMRS S. oralis gdh 
SM-C SM7 L-M17 Rothia mucillaginosa  
SM-D SM13 gTSA Neisseria sp. (subflava)  
ST 
ST-A1 ST3 cMRS S. salivarius  
ST-A2 ST12 L-M17 S. salivarius  
ST-B ST2, ST5p cMRS S. oralis gdh 
ST-C ST5g cMRS S. sanguinis  
ST-D 
ST4 cMRS 
S. oralis gdh 
ST15 gTSA 
ST-E ST7, ST11 L-M17 S. infantis gdh 
ST-F ST1, ST8 L-M17 Bacillus sp. (cereus)  
ST-G ST9 L-M17 S. oralis gdh 
ST-H ST6 cMRS Staphylococcus epidermidis  
ST-I ST13, ST14 gTSA Rothia mucillaginosa  
1 Similar (but not identical) BOX-PCR electrophoretic patters are indicated with the same letter and a 
different number. 
2 Representative strains chosen for 16S rDNA sequence analyses are in bold. 
3 S. salivarius stands for Streptococcus salivarius. Species designation between brackets refers to 16S 
rDNA sequence similarity below 95%. 
4 gdh: taxonomic identification based on the sequence of an approximately 500-bp internal fragment of the 
glucose-6-phosphate dehydrogenase gene (gdh) (Bek-Thomsen et al., 2008); his: taxonomic identification 
based on the length polymorphism of a PCR amplified fragment from histidine biosynthesis operon 
(Beimfohor et al., 1997). 
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Table 1.3.2 Streptococcus salivarius K12 and non-oral bacteria included in the study. 
Species Strain Source Reference 
Bifidobacterium animalis subsp. lactis Bb12 Probiotic commercial strain Juntunen et al., 2001 
Lactobacillus acidophilus LA5 Probiotic commercial strain Juntunen et al., 2001 
Lactobacillus paracasei Shirota Probiotic commercial strain Juntunen et al., 2001 
Lactobacillus helveticus MIMLh5 Dairy natural starter Guglielmetti et al., 2008 
Lactobacillus rhamnosus GG Probiotic commercial strain Juntunen et al., 2001 
Lactococcus lactis subsp. cremoris Viili Finnish fermented milk Kahala et al., 2008 
Streptococcus salivarius K12 BLIS throat guard Burton et al., 2006 
Streptococcus thermophilus DSM20617T DSMZ type strain, yogurt / 
 
 
1.3.3 Antibacterial activity against Streptococcus pyogenes and PCR detection of 
bacteriocin encoding genes of pharyngeal isolates 
In a first set of experiments, tester bacterial strains were spread with a loop on agar plate 
containing LM17 medium and incubated overnight at 37°C. Then, 15 ml of soft yeBHI agar 
containing about 10
6
 cells of the indicator strain (S. pyogenes C11) were poured over the plates. 
The plates were checked for inhibition zones after incubation at 37°C for 24 and 48 h. The 
production of antimicrobial substances was also tested through disk-diffusion. Briefly, tester 
strains were grown until stationary growth phase in LM17 medium. Culture supernatants were 
neutralized to pH 7, filter-sterilized and spotted (0.1 ml) on a filter paper disk, which was 
previously placed on yeBHI softagar plates inoculated with about 10
5
 S. pyogenes cells. The 
presence of an inhibition halo was checked after 24 and 48 h.The PCR reactions to detect 
previously characterized bacteriocin structural genes (salivaricin A, salivaricin B, streptin, and 
peptide SA-FF22) were performed as described by Wescombe et al. (2006). 
 
1.3.4 Preparation of bioluminescent Streptococcus pyogenes 
Reporter vector pCSS810, carrying a phage T5 promoter–lac operator upstream of the insect 
luciferase gene lucFF (Lampinen et al., 1992), was used to obtain the luminescent phenotype in 
Streptococcus pyogenes C11. In brief, electrocompetent S. pyogenes cells were prepared as 
follows. Fresh BHI broth (25 ml) supplemented with 0.3% yeast extract (yeBHI) was inoculated 
with 0.25 ml of an overnight culture of the bacterium and incubated at 37°C until an optical 
density (at 600 nm) of about 0.2 was reached. The cells were chilled on ice and concentrated in 
further washing steps of 25 and 10 ml (washing buffer EB: 0.3 M sucrose and 1 mM MgCl2 in 5 
mM phosphate buffer, pH 6.9). After washing, the pellet was resuspended in 2 ml of the same 
buffer, dispensed in 80 μl-aliquotes and maintained at -80°C until used for electroporation with 
an Eppendorf Multiporator 2510 (Eppendorf, Milano, Italy), at 12.5 kV/cm, in 2-mm cuvettes. 
The yeBHI supplemented with sucrose (final concentration 0.3 mM) was used as outgrowth 
medium. After 2 h of incubation at 37°C in the outgrowth medium, transformants were selected 
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on yeBHI agar plates with 5 μg ml-1 of chloramphenicol. The selected luminescent S. pyogenes 
clone was named C11
LucFF
. 
 
1.3.5 Antagonistic activity against Streptococcus pyogenes 
FaDu (human pharynx carcinoma cell line; ATCC HTB-43) and HaCat cells (human 
keratinocytes from a spontaneous immortalized, non-tumorigenic cell line) were routinely 
grown in 24-well tissue culture plates in Dulbecco‟s Modified Eagle‟s Medium (DMEM), 
supplemented with 10 % (v/v) heat-inactivated (30 min at 56°C) fetal calf serum, 100 U ml
–1
 
penicillin, 100 mg ml
–1
 streptomycin, 0.1 mM non-essential amino acids, 2 mM L-glutamine, 
and incubated at 37°C in a water-jacketed incubator in an atmosphere of 95 % air and 5 % 
carbon dioxide, until a confluent monolayer was formed. The bacterial cell concentration of an 
overnight culture was determined microscopically with Neubauer Improved counting chamber 
(Marienfeld GmbH, Lauda-Königshofen, Germany). The antagonism was studied through 
exclusion and competition assays. Exclusion consisted of a pre-incubation of the FaDu layer 
with 1 ml of a tester strain suspension (5 x 10
8
 cells ml
-1
), followed by a washing step with 
phosphate-buffered saline (PBS) and the incubation with 1 ml of the indicator strain (S. 
pyogenes C11
LucFF
) suspension (2 x 10
8
 cells ml
-1
). The concentration of 5 x 10
8
 tester cells ml
-1
 
was chosen because corresponded to the plateau of a dose-response curve which was prepared 
during the set-up of the experiment by measuring the antagonistic activity as a function of tester 
cell concentration (Data not shown). 
 Competition consisted of co-incubation of the same number of tester and indicator strains (2 x 
10
8
 cells ml
-1
). After incubation, FaDu layers were quickly washed twice with 1 ml PBS (pH 
7.3) and D-luciferin (Sigma-Aldrich, Steinheim, Germany) was added at the concentration of 
12.5 μM in citrate buffer, pH 5. Immediately, the luminescence signal was measured with a 
Victor 3 luminometer (PerkinElmer, Monza, Italy). Each tester strain was analyzed in triplicate 
in at least two independent experiments. Unpaired Student‟s t-test was run for statistically 
significant differences. 
 
1.3.6 Bacterial adhesion to FaDu cell layer 
FaDu cells were grown in 3-cm Petri plates on microscopy cover glasses as described above. 
Cell monolayers were carefully washed with PBS pH 7.3 before bacterial cells were added. The 
bacterial cell concentration of an overnight culture was determined microscopically with 
Neubauer Improved counting chamber (Marienfeld GmbH). Approximately 2×10
8
 cells of each 
strain resuspended in PBS (pH 7.3) were incubated with a monolayer of FaDu cells. After 1 h at 
37°C, all monolayers were washed 3 times with PBS to release unbound bacteria. Cells were 
then fixed with 3 ml of methanol and incubated for 8 min at room temperature. After methanol 
was removed, cells were stained with 3 ml of Giemsa stain solution (1:20) (Carlo Erba, Milan, 
Italy) and left for 30 min at room temperature. Wells were then washed until no color was 
observed in the washing solution and dried in an incubator for 1 h. Microscopy cover glasses 
were then removed from the Petri plate and examined microscopically (magnification × 100) 
immersed in oil. Adherent bacteria in 20 randomly selected microscopic fields were counted 
and averaged. 
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1.3.7 Antibiotic susceptibility of selected bacteria 
The inhibitory concentrations of the antimicrobial agents were determined by broth 
microdilution in commercial 96-well microtiter plates, for the following concentration ranges: 
ampicillin, chloramphenicol, erythromycin, oxytetracyclin and vancomycin 1-16 μg ml-1; 
gentamicin 8-64 μg ml-1; kanamycin and streptomycin 16-128 μg ml-1. Antibiotics (Sigma-
Aldrich) were serially 1:2 diluted in culture medium starting from a concentrated stock solution 
conserved at –20°C. In brief, bacterial cells from an overnight culture were washed once with 
saline and resuspended in fresh medium at a concentration corresponding to an optical density 
of 1 at 600 nm. Afterward, bacterial suspensions were 1:100 diluted in the liquid medium 
containing the appropriated antibiotic concentration, and loaded in duplicate in microtiter wells 
(200 μl well-1). Three different liquid media were used in this experiment: L-M17, MRS and 
BHI (Table 3). The inoculated plates were subsequently incubated aerobically at 37°C for 48 h, 
after which the inhibitory concentrations of antibiotics were read as the lowest concentration.  
 
1.3.8 Determination of urease activity and PCR detection of ureC gene 
Urease activity was tested by evaluating the release of ammonia by means of the phenol red 
assay (Lanyi, 1987). Specifically, cells from 0.5 ml of an overnight culture were resuspended in 
a solution containing one volume of solution A (urea, 2 g dissolved in 2 ml of ethanol and 4 ml 
of sterilized water) and 19 volumes of solution B (KH2PO4, 1 g l
-1
; K2HPO4, 1 g l
-1
; NaCl, 5 g l
-
1; phenol red, 20 μg ml-1). The suspension was incubated at 37°C for 1-4 h and the development 
of a red-violet colour indicated positive urease activity. The amplification of the gene coding 
for the main subunit of the urease complex (ureC) was carried out as previously described 
(Mora et al., 2004), using primers ureC-F (5‟-CTGTTCATGATCCTATTCAG-3‟) and ureC-R 
(5‟-CGAATACCGAATTCATTCCCATG-3‟). 
 
1.3.9 Stimulation of FaDu monolayers and enzyme-linked immunosorbent assay 
(ELISA) measurement of cytokine production 
Human pharyngeal carcinoma cells (FaDu) were seeded into 24-well plates and grown as 
previously described. Bacterial cells were added to monolayers of FaDu cells in 0.5 ml of fresh 
antibiotic-free Eagle's Minimum Essential Medium (EMEM) containing 25 mM HEPES (pH 
7.4) and incubated overnight at 37°C. Each bacterial strain was used at a multiplicity of 
infection (MOI) of about 1000, while EMEM/HEPES medium without bacterial cells was used 
as control. After overnight incubation, the supernatants were collected by pipetting, centrifuged 
to remove cells, and kept at -80°C. Finally, 17 different cytokines in the supernatants were 
determined on a Bio-plex Array Reader (LUMINEX 100, Bio-RadLaboratories, Hercules, CA) 
using Bio-Plex Human Cytokine 17-plex panel (Bio-Rad), according to the human cytokine 
Bio-Plex panel assay Bio-protocol (Bio-Rad). The list of tested cytokines and the corresponding 
detection limits were as follows: interleukin (IL)-1β, 0,3 pg ml-1; IL-2, 0.2 pg ml-1; IL-4, 0.1 pg 
ml
-1
; IL-5, 0.3 pg ml
-1
; IL-6, 0.2 pg ml
-1
; IL-7, 0.3 pg ml
-1
; IL-8, 0.3 pg ml
-1
; IL-10, 0.2 pg ml
-1
; 
IL-12 (p70), 0.4 pg ml
-1
; IL-13, 0.3 pg ml
-1
; IL-17, 0.5 pg ml
-1
; granulocyte colony-stimulating 
factor (G-CSF), 0.2 pg ml
-1
; granulocyte macrophage colony-stimulating factor (GM-CSF), 1.1 
pg ml
-1
; interferon (IFN)-γ, 2.6 pg ml-1; monocyte chemotactic protein (MCP)-1, 0.8 pg ml-1; 
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macrophage inflammatory protein (MIP)-1β, 0.6 pg ml-1; tumor necrosis factor (TNF)-α, 0.6 pg 
ml
-1
. 
 
1.3.10 Construction of stable NF-κB reporting FaDu cells 
Stable transfectants of FaDu cell line were obtained after transfection with the plasmid pNiFty2 
(InvivoGen, LaboGen, Rho, Italy; Fig. 1.3.1). This plasmid combines five NF-κB sites with the 
insect luciferase reporter gene luc. The presence of active NF-κB molecules in the cell activates 
the promoter, resulting in the expression of the luciferase gene. Transfection was performed by 
means of StoS Transfection Kit (GeneSpin, Milano, Italy) in accordance with the 
manufacturer's protocol. Afterward, cells were resuspended in fresh DMEM medium and 
seeded in 24-well plates for 48 h, in order to obtain the expression of the antibiotic resistance. 
Finally, stable recombinant clones were selected by adding into the culture medium 50 μg ml-1 
of zeocin. 
 
Figure 1.3.1. Genetic map of a plasmid pNiFty2-Luc. 
This plasmid contains promoter combining five NF-
B-binding sites and the firefly luciferase reporter 
gene luc. The presence of NF-B activating molecules 
in the cell activates this transcription factor, which 
binds to the promoter, resulting in the expression of 
the luciferase gene. 
 
 
1.3.11 Study of NF-κB activation 
Recombinant FaDu cells were cultured using the same protocol as for non-transfected FaDu, in 
presence of 50 μg ml-1 of zeocin. After growth, FaDu layer was resuspended in EMEM at a 
concentration of 250.000 cells ml
-1
 in presence of 100 mM HEPES (pH 7.4). After that, 50 μl of 
tester bacterial suspension, containing 2 x 10
9
, 2 x 10
8
 or 2 x 10
7
 cells ml
-1
, were added to 450 
μl of FaDu suspension, resulting in a MOI of about 1000, 100 or 10, respectively. After 
incubation at 37°C for 4 h, samples were kept in ice and sonicated at maximum speed for 5 s 
(Bandelin sonicator, Bandelin electronic GmbH & Co., Berlin, Germany). Bacterial cells and 
insoluble particles were removed by centrifugation and the supernatants were moved into a new 
tube. At this point, 200 μl of supernatants were aliquoted in duplicate into the wells of a 96-
wells white microtiter plate (PerkinElmer); then 12.5 μl of a 10 mM ATP solution and 12.5 μl 
of 0.1 mM D-luciferin were added and the emitted bioluminescence was immediately recorded 
every 90 s with a Victor 3 luminometer (PerkinElmer). The maximum of the light-production 
curve was considered for comparing the results. In a different set of experiments, recombinant 
FaDu cells were simultaneously stimulated with IL-1β (2 ng ml-1). All strains were analyzed in 
duplicate in at least three independent experiments for each MOI considered. Unpaired 
Student‟s t-test was run for statistically significant differences. 
pNiFty2-Luc
4501 bp
Luc
SV40 pAnbetaGlo pAn
NF-kB 5x
ELAM
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1.3.12 Study of the activation of the U937 human macrophage cell line. Cell culture, 
growth conditions, and stimulation protocol.  
The cell line U937 (ATCC CRL-1593.2™) was derived from a human histiocytic lymphoma 
(Sundstrom et al., 1976). These cells are maintained as replicative, non-adherent cells and have 
many of the biochemical and morphological characteristics of blood monocytes (Harris and 
Ralph, 1985). When treated with phorbol myristate acetate (PMA), U937 cells differentiate to 
become adherent, non-replicative cells with characteristics similar to tissue macrophages, 
including similar isoenzyme patterns (Radzun et al., 1983) and other phenotypic markers 
(Harris and Ralph, 1985). The normal growth medium for the U937 cells consisted of RPMI 
1640 medium (Lonza, Basel, Swiss) supplemented with 10 % (v/v) fetal bovine serum (FBS) 
(Gibco-BRL, Life Technologies, Milan. Italy), 2 mM L-glutamine, 100 units ml
-1
 penicillin and 
100 μg ml-1 streptomycin (Sigma-Aldrich). U937 cells were seeded at a density of 5×105 cells 
well
-1
 in 12-well plates and incubated at 37°C in a humidified atmosphere of 95 % air and 5 % 
CO2. Differentiation was induced by the addition of PMA (Sigma-Aldrich) into the cellular 
medium at a final concentration of 100 nM and was allowed to proceed for 48 h. Afterwards, 
cells were washed once with sterile PBS buffer to remove all non-adherent cells. One hour 
before the bacteria were added to the cells, the culture media was replaced with RPMI 1640 
medium supplemented with 1 % (v/v) FBS to allow the cells to adapt. Bacteria were used at 
MOIs of 100 and 1000, and lipopolysaccharide (LPS, final concentration of 1 μg ml-1) from 
Escherichia coli 0127:B8 (Sigma-Aldrich) was used as positive control for pro-inflammatory 
stimulus in U937 cells. An untreated sample, i.e., only RPMI 1640 medium with 1 % (v/v) FBS, 
was used as control.  
 
1.3.13 Inhibition assay with Toll-like Receptor neutralizing antibodies on U937 cells. 
Human anti-Toll-like receptor (TLR) 2 antibody (Invivogen) was added to U937 cells 1 hour 
before the stimulation with bacterial cells. A human immunoglobulin-A (IgA) 2 isotype control 
(Invivogen) was used as control to exclude non-specific binding and blocking activity of the 
antibody. Both the anti-TLR2 and IgA2 isotype control were used at 5 μg ml-1. This 
concentration was determined by examining the neutralizing efficacy of anti-TLR2 with 
zymosan from Saccharomyces cerevisiae (Invivogen) as ligand; we observed that 5 μg ml-1 
resulted in a 5-fold reduction in the expression level of tumor necrosis factor (TNF)-α, a 
cytokine known to be induced in the downstream pathway activated by TLR-2. 
 
1.3.14 Preparation of RNA and reverse transcription.  
After incubating U937 cells at 37 °C four 4 hours, the supernatant was carefully removed from 
each well and the total cellular RNA was isolated from the adhered U937 cells with an RNeasy 
Mini Kit (Qiagen Inc., Valencia, CA). Afterwards, RNA concentration and purity was 
determined with a Nanodrop Spectrophotometer (ND-1000, Thermo Fischer Scientific) and 
reverse transcription to cDNA was performed with the iScript Select cDNA Synthesis Kit 
(Bio-Rad Laboratories, Hercules, CA) using the following thermal cycle: 5 min at 25°C for, 30 
min at 42°C, and 5 min at 85°C. Real-time Quantitative PCR. The mRNA expression levels of 
cytokines were analyzed with SYBR Green technology in real-time quantitative PCR using 
SsoFast EvaGreen Supermix (Bio-Rad) on a Bio-Rad CFX96 system according to the 
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manufacturer's instructions. The primers used are as follow (5‟3‟): 18srRNA forward 
ATCCCTGAAAAGTTCCAGCA; 18srRNA reverse CCCTCTTGGTGAGGTCAATG; IL10 
forward AGCAGAGTGAAGACTTTCTTTC; IL10 reverse CATCTCAGACAAGGCTTGG; 
TNF-α forward TCAGCTCCACGCCATT; TNF-α reverse CCCAGGCAGTCAGATCAT; 
COX2 forward CCCTTGGGTGTCAAAGGTAA; COX2 reverse 
TGAAAAGGCGCAGTTTACG. All primers were selected using the Primer3Plus software 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi), and the specificity of the 
primers was tested with melting curves during amplification and by 1 % agarose gels. 
Quantitative PCR was carried out according to the following cycle: initial hold at 96°C for 30 s 
and then 40 cycles at 96°C for 2 s and 60°C for 5 s. Gene expression was normalized to the 
housekeeping gene 18s rDNA. The amount of template cDNA used for each sample was 12.5 
ng. All results regarding cytokine mRNA expression levels are reported as the fold of induction 
(FOI) respective to the control (namely unstimulated U937), to which we attributed an FOI of 1. 
 
1.3.15 Growth experiments.  
The growth curves of strain ST3 were determined in 384-well microtiter plates using a BioTek 
Synergy HT Multi-Mode Microplate Reader (AHSI S.p.A., Bernareggio Italy) to measure 
growth in M17 broth supplemented with 2 %, 1 %, 5 ‰, 2.5 ‰, 1.25 ‰ or 0.625 ‰ of one of 
the following sugars: fructose, galactose, glucose, inulin, lactose, lactulose, sucrose or 
fructooligosaccharides (FOS). All sugars were purchased from Sigma-Aldrich (Steinheim, 
Germany) with the exception of FOS, which were from Actilight
®
 (Giulio Gross S.p.A., 
Trezzano sul Naviglio, Italy). The preparation of 384-well microtiter plates was conducted with 
an epMotion Automated Pipetting System (Eppendorf, Milan, Italy). Acidification curves were 
determined by inoculating skim milk (Difco) (1 % inoculum) with an overnight culture of 
MIMLh5 and ST3 alone or in co-culture and recording the pH every hour for 24 hours with a 
pH-meter recorder (XS instruments pH 2100, Opto-Lab, Concordia, Italy).  
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1.4 RESULTS AND DISCUSSION 
1.4.1 Identification and molecular characterization of bacterial isolates 
In this study we aimed to select oral bacteria with potential probiotic features for the pharyngeal 
mucosa. We included bacteria newly isolated from the pharynges of healthy donors. Potentially, 
pharyngeal isolates could, in fact, display better performances in the colonization of the oral 
ecosystem than traditional dairy or intestinal probiotic bacteria. A total of 56 isolates were 
obtained from pharyngeal swab samples taken from four healthy donors by using three different 
culture media (Table 1.3.1). After a preliminary grouping of all isolated bacteria through BOX-
PCR fingerprinting (Data not shown) 16S rRNA genes sequence analysis revealed that 39 of the 
isolates belonged to the Streptococcus genus. Streptococcus salivarius was the most represented 
species (28 isolates). We also isolated Streptococcus oralis (6 isolates) and Streptococcus 
infantis (2 isolates), which were distinguished by glucose-6-phosphate dehydrogenase gene 
(gdh) sequence analysis (Bek-Thomsen et al., 2008) and 1 strain of Lactoccus lactis sub. Lactis. 
The only species isolated from all four pharyngeal samples were S. salivarius and Rothia 
mucilaginosa (7 isolates). All the other bacteria are listed in Table 1.3.1. Streptococcus 
salivarius isolates were further characterized at the intraspecies level by means of BOX-PCR 
and RAPD-PCR analyses (Data not shown). A computer evaluation of similarities and 
clustering resulted in a total of 11 unique S. salivarius genotypes out of 28 pharyngeal isolates 
and the K12 commercial probiotic strain (Fig. 1.4.1). The isolates that were included in a single 
genotypic group originated from the same pharyngeal sample, suggesting that they were 
probably multiple isolates. In this research, half of the pharyngeal isolates were ascribed to the 
species Streptococcus salivarius (28 out of 56 isolates), in accordance with previous studies 
showing these bacteria to be the dominant cultivable species in the oro-pharyngeal tract (Kang 
et al., 2006). Nonpathogenic streptococci are the bacteria most largely present at the oro-
pharyngeal level, and they have been proposed to exert a key role in the protection against 
pathogenic agents, which cause inflammation and infections (Tagg & Dierksen, 2003). In 
particular, Streptococcus salivarius already becomes a stable colonizer of the oral microbiota a 
few days after birth and represents, in adults, the major species at the levels of the pharyngeal 
mucosa and dorsal tongue. 
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Figure 1.4.1 Unweighted-pair group method using average linkages (UPGMA) dendrogram 
derived from similarity coefficients calculated by the Jaccard method (simple Jaccard [Sj] 
coefficients; shown on the scale at the bottom), showing the relationship among Streptococcus 
salivarius pharyngeal isolates, analyzed by BOX-PCR and RAPD analysis using primers M13, 
OPI02mod, OPI17mod, and PedAF. Samples with a similarity coefficient higher than 0.9 have 
been included in the same genotype. Selected bacterial isolates included in antagonism 
experiments are indicated in boldface. 
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1.4.2 Oral, dairy and probiotic strains differently adhered to FaDu human pharyngeal 
cell line 
Thirty bacterial strains were studied for their ability to adhere to FaDu epithelial cell layer. 
Along with bacteria isolated from human pharyngeal mucosa we tested bacterial strains of dairy 
and probiotic origin already present on the market. In detail, strains MIMLh5, Viili and DSM 
20617
T
 are used as starters in the production of Grana Padano cheese, Finnish fermented milk 
and yogurt, respectively. The strains Bifidobacterium animalis subsp. lactis Bb12, Lactobacillus 
acidophilus La-5, Lactobacillus rhamnosus GG and Lactobacillus paracasei Shirota are among 
the most widespread probiotic strains in the Western Countries. Certain properties of these 
strains have been compared to Streptococcus salivarius K12, the only probiotic bacterium 
specifically commercialized as probiotic for the pharyngeal mucosa up to date (BLIS K12 
Throat Guard 
TM
, Tagg et al., 2006). The first probiotic property that we considered was the 
adhesion to the host‟s target epithelium. In fact, the ability of commensals and probiotics to 
bind human mucosa has a pivotal importance because it can promote the colonization and 
sustain host epithelium-bacteria cross-talk (Lee et al., 1999). After extensive washings with 
PBS, a significant proportion of cells of most bacterial strains remained attached to the FaDu 
monolayer, providing evidence that the adhesion was not only non-specific physical 
entrapment. In particular, 5 strains displayed a strong adhesive phenotype, coinciding with an 
adhesion index (bacterial cells per 100 FaDu cells) of more than 2500 (Fig. 1.4.2). The 5 most 
adhesive strains included L. helveticus MIMLh5, S. salivarius ST3, S. salivarius K12 and two 
Lactococcus lactis strains (RS5 and Viili). A good adhesion ability was also displayed by 9 
other strains, among which L. rhamnosus GG and 8 S. salivarius strains (Fig.1.4.2). Two strains 
in particular, L. helveticus MIMLh5 and S. salivarius ST3, showed to adhere to FaDu 
pharyngeal epithelial cell line comparably to the oral probiotic bacterium S. salivarius K12 that 
we used as reference (Horz et al., 2007). 
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Figure 1.4.2 Adhesion of bacterial strains to FaDu epithelial cell layer according to their 
adhesion index (AdI, number of bacteria / 100 FaDu cells). (a) Adh = adhesion. +++, strong 
adhesion (AdI > 2500); ++, good adhesion (AdI between 2500 and 500); +, weak adhesion 
(AdI between 500 and 100); -, no adhesion (AdI < 100). (b) Adhesion to FaDu cell monolayers 
as observed with Giemsa staining under a light microscope. Bars, 8 μm. One FaDu nucleus for 
each layer is indicated with the letter N. 
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Figure 1.4.3 Adhesion to FaDu epithelial cells of selected bacterial strains as observed with 
Giemsa staining under a light microscope. Bars, 8 μm. A FaDu nucleus for each layer is 
indicated with the letter N.                                         
 
 
 
 
 
 
 
 
 
 
 
1.4.3 The antagonistic activity against Streptococcus pyogenes on human epithelial cell 
lines is strain-dependent 
Streptococcus pyogenes (group A streptococci, GAS) causes approximately 15 to 30 % of 
pediatric sore throat (Bisno, 1996) and it is the etiological agent of skin and soft tissue 
infections, glomerulonephritis and acute rheumatic fever. The oral administration of probiotic 
bacteria could be a prophylactic strategy effective to reduce the transmission of GAS in the 
community (Wagenvoort et al., 2005). For this reason, we tested the ability of probiotic bacteria 
to antagonize GAS on in vitro epithelial layers. Since the oral cavity contains several types of 
surface, including keratinized and non-keratinized epithelia, besides FaDu, we also included in 
the experimentation the HaCat cell line, which resembles many characteristics of human 
keratinocytes (Boukamp et al., 1998).Twenty-five bacterial strains were tested for their ability 
to adhere to the FaDu epithelial cell layer. We studied 13 S. salivarius strains, including at least 
one representative isolate from each genotypic cluster, and the commercial probiotic strain K12. 
We also tested 5 intestinal probiotic and dairy lactic acid bacteria (Table 1.3.2) and 6 other 
pharyngeal isolates that have been arbitrarily selected. In this experiment we used a three-
component system consisting of the epithelial cell layer, the S. pyogenes C11
LucFF
 indicator 
bioluminescent strain, and the tester bacterium. We measured the reduction of bioluminescence 
produced by S. pyogenes C11
LucFF
 as an indication of the antagonistic activity exerted by the 
tester strains. Antagonism through exclusion was tested on the layers of two different human 
epithelial cell lines, FaDu (Fig. 1.4.4A). and HaCaT (Fig. 1.4.4B). The results showed that 
antagonistic exclusion against S. pyogenes C11
LucFF
 was generally stronger on FaDu 
hypopharyngeal carcinoma cells than HaCaT keratinocytes.  
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Figure 1.4.4 Antagonistic exclusion activity of bacterial pharyngeal isolates and probiotic/food  
strains against bioluminescent Streptococcus pyogenes C11LucFF on FaDu hypopharyngeal 
carcinoma cells (A) and HaCaT keratinocytes (B). Data reported as percent variation of light 
emission, which referred to the cell layer treated with only PBS buffer before incubation with S. 
pyogenes. Numerical results are given as arithmetic means  standard deviations. Each sample 
was processed in triplicate in at least two independent experiments. Strains belonging to 
species S. salivarius are indicated in boldface. Statistically significant differences compared to 
strain K12 were calculated according to an unpaired Student’s t test (**, P< 0.001; *, P<0.05). 
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Adhesion experiments performed on the FaDu cell layer can give a partial explanation of the 
strong antagonizing activity displayed by these strains. (Fig. 1.4.3). In fact, it can be 
hypothesized that the competition for adhesion sites is a major mechanism through which these 
bacteria antagonize S. pyogenes on FaDu cells. 
The results also demonstrated that the exclusion activity is strain specific, since significant 
differences were observed also among strains of the same species. We found a correlation 
between the results obtained with the two cell lines. In fact, with only a few exceptions, those 
strains that significantly reduced the light production in HaCaT cells also did so in the FaDu 
cell layer. Particularly, the following two strains were the most active in both cell lines: L. 
helveticus MIMLh5 (with an average reduction of bioluminescence of -55 % on FaDu and -32 
% on HaCaT) and S. salivarius ST3 (with average reductions of bioluminescence of 40% in 
FaDu and 24% in HaCaT). In addition to MIMLh5 and ST3, the probiotic strains L. 
rhamonosus GG and L. paracasei Shirota and the dairy strain L. lactis subsp. cremoris Viili 
also displayed an antagonistic exclusion significantly stronger than the reference oral probiotic 
strain S. salivarius K12. 
The antagonism by competition was tested only on the FaDu cell layer for the two selected 
strains S. salivarius ST3 and L. helveticus MIMLh5, the reference oral probiotic K12, three oral 
strains (S. salivarius RS13 and RS1, S. oralis ST5p) and the commercial probiotic B. animalis 
lactis Bb12, which were selected in order to have at least one representative strain for each of 
the four typologies of bacterial adhesion on the FaDu layer (Fig. 1.4.2). In this experiment, all 
tested strains markedly inhibited S. pyogenes bioluminescence (> 50 % reduction) and 
particularly L. helveticus MIMLh5 (78 %) and S. salivarius strains (ca. 80 % reduction) We also 
noticed a partial dependence of both exclusion and competition on adhesion ability, since the 
antagonism efficacy was slightly weaker for poorly adhesive strains like ST5p than strongly 
adhesive bacteria (e.g., K12 and ST3; P values of 0.001, according to an unpaired Student‟s t 
test) (Fig. 1.4.2 and Fig. 1.4.5).  
 
Fig. 1.4.5 Antagonistic competition activity of bacterial pharyngeal isolates against 
bioluminescent Streptococcus pyogenes C11lucFF on FaDu hypopharyngeal carcinoma cells. 
Data reported as percentage variation of light emission as referred to the cell layer treated with 
only S. pyogenes cells. Numerical results are given in the arithmetic means  standard 
deviations. All samples resulted significantly different compared to control (P < 0.001, 
according to unpaired Student’s t-test). 
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1.4.4 Inhibition of S. pyogenes and PCR detection of bacteriocin encoding genes 
The potential oral probiotic activity of pharyngeal streptococcal isolates were characterized by 
PCR for known lantibiotic structural genes coding for salivaricin A, salivaricin B, streptin and 
SA-FF22, which are known to be active against S. pyogenes. According to literature, strain K12 
gave an amplicon of the expected length for salivaricin A and B. Among the other isolates, all 
SM S. salivarius isolates and S. salivarius IS7 resulted positive for the only salivaricin A. 
Sequence analyses revelaed that all salivaricin A amplicons, including K12 amplicon, belonged 
to the variant A2 (Wescombe et al., 2006). None of the streptococcal isolates resulted positive 
for streptin and SA-FF22 (Data not shown). When we performed inhibition test of S. pyogenes 
after 24 h incubation at 37°C we observed clear inhibition zones corresponding to the colonies of 
the strains K12 and ST3 (Data not shown). On the contrary, when cell-free neutralized broths were 
used in disk-diffusion tests, inhibition zones were observed only for the reference strain S. 
salivarius K12. Accordingly, PCR experiments suggested that ST3 could not possess bacteriocin 
genes which are known to be encoded in strain K12 on a 190-kilobase transmissible plasmid 
(Hyink et al., 2007). In contrast, ST3 is a plasmid-free strain. Therefore, it appears plausible that 
the pharyngeal isolate ST3 inhibited the growth of S. pyogenes in plate probably partially due to 
its acid production. For what it concerns L. helveticus MIMLh5, this strain was not able to prevent 
S. pyogenes growth. 
1.4.5 Immunomoduatory properties of selected LAB strains 
One mechanism of action of probiotics is suggested to be their modulation of host immune 
responses. In a recent study, Cosseau and collaborators showed that the oral probiotic S. 
salivarius K12 can induce in vitro anti-inflammatory responses in epithelial cells, indicating a 
potential promotion of cellular health and homeostasis (Cosseau et al., 2008). In that study, after 
co-culture of human bronchial epithelial cells (16HBE14O-cells) with strain K12, they observed 
an inhibition of baseline secretion of the chemokine interleukin (IL)-8, in coincidence with the 
inhibition of activation of the NF-κB pathway (Cosseau et al., 2008). In our study, the 
immunomodulatory properties of S. salivarius K12, ST3 and L. helveticus MIMLh5 were tested 
on a FaDu layer by means of ELISA quantification of 17 secreted cytokines. Subsequently, in 
order to elucidate the possible mechanisms involved in the effects on cytokine production, we 
studied the modulation of NF-κB activation. Both experiments were performed in absence and 
presence of IL-1β, a prototypical proinflammatory cytokine that plays a central role in the inflammation 
amplification cascade. 
 
1.4.6 Cytokine induction profile elicited by selected bacterial strains on FaDu cells. 
Overnight incubation of a FaDu monolayer with selected bacteria resulted in a modulation of 
the cytokine production profile, as determined by the Bio-Plex human cytokine 17-plex array 
system. We observed different responses of FaDu cell layer to the three bacterial strains 
included in the experiment (Fig. 1.4.6). Streptococcus salivarius strain ST3 abolished the 
secretion of IL-1β and TNF-α and enhanced the production of IL-8 (from 1721 to 2331 pg ml-1) 
and GM-CSF (from 0.2 to 1.9 pg ml
-1
). The commercial oral probiotic Streptococcus salivarius 
K12 decreased IL-6 and IL-8 (respectively, from 78.1 to 24.2 pg ml
-1 
and from 1721 to 579 pg 
ml
-1
). Furthermore, strain K12 induced a reduction of the secretion of TNF-α (from 1.9 to 0.9 
pg ml
-1
) and G-CSF (from 3.5 to 1.7 pg ml
-1
) and increased GM-CSF (from 0.2 to 1.6 pg ml
-1
). 
Finally, Lactobacillus helveticus MIMLh5 displayed the strongest ability to inhibit the secretion 
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of IL-6 (from 78.1 to 5.5 pg ml
-1
), IL-8 (from 1721 to 111 pg ml
-1
) and G-CSF (from 3.5 to 0.2 
pg ml
-1
). Moreover, strain MIMLh5 decreased TNF-α (from 1.9 to 0.8 pg ml-1) and enhanced 
GM-CSF (from 0.2 to 2.4 pg ml
-1
).  
When FaDu layer was stimulated with 2 ng ml
-1
 of the pro-inflammatory cytokine IL-1 (Fig. 
1.4.6), strains K12 and ST3 reduced IL-6 from 121.5 to 73.7, and 86.7 pg ml
-1
, respectively, and 
IL-8 from 3353 to 2043 and 2261 pg ml
-1
, respectively. For strain MIMLh5, with respect to 
baseline, the presence of IL-1β induced a drastic change of cytokine profile. Several cytokines, 
which were considerably reduced by L. helveticus MIMLh5 at baseline, in fact, resulted in an 
increased secretion when FaDu cells were incubated with MIMLh5 in the presence of IL-1β. 
The modification of MIMLh5‟s effect in the presence of IL-1β was particularly evident for 
cytokines IL-6, IL-8, G-CSF, INF-γ, and TNFα. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.6 Cytokine secretions that 
changed significantly after treatment 
of the FaDu layer with bacterial cells, 
as determined by using the Bio-Plex 
assay. FaDu layers were incubated 
overnight with bacterial cells (2 X 10
8
 
cells ml
-1
) without  and in the presence 
of 2 ng ml
-1
 of IL-1β. The values are 
the means from two experiments 
conducted in duplicate. The vertical 
bars indicate standard deviations. 
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1.4.7 Modulation of NF-κB activation by tested bacteria in transfected FaDu cells. 
To further explore the immunomodulatory properties of selected lactic acid bacteria, we tested 
the effect of the microorganisms on NF-κB activation using a reporter cell line, obtained by 
transfecting FaDu cells with a luciferase reporter vector induced by NF-κB. In FaDu cells, L. 
helveticus MIMLh5 was the only strain that decreased the NF-κB-dependent production of 
bioluminescence (Fig. 1.4.7A). On the contrary, strain ST3 showed a stimulatory effect. NF-κB 
activation was particularly evident for strain ST3, which doubled the bioluminescence produced 
by FaDu cells, when we employed a MOI of about 1000. S. salivarius K12 did not affect 
significantly NF-κB (Fig. 1.4.7A). In a following series of experiments, the effect of bacterial 
strains on NF-κB was assessed during stimulation of FaDu cells with the pro-inflammatory 
cytokine IL-1β (Fig. 1.4.7B). The addition of 2 ng ml-1 of IL-1β to FaDu culture broth caused 
nearly a two-fold increase of NF-κB activity after 4 h incubation. In presence of IL-1, we 
observed that, at a MOI of 1000, strains K12 and ST3 reduced the NF-B activation  in a statistically 
significant manner, while the other conditions tested had no significant effect.  In contrast, strain 
L. helveticus MIMLh5 strongly inhibited NF-κB activation by IL-1β in a concentration 
dependent manner (–84 % at MOI 1000 and –61 %; Fig. 1.4.7B). 
 
Figure 1.4.7 Effects of selected bacterial strains on FaDu cells stably transfected with an NF-
B/luciferase reporter vector, without (A) or with (B) stimulation with IL-1 (2 ng ml-1). 
Luciferase activity is expressed as percent change in relative luminescence units (RLU), 
assuming the control as 100 %. Control, FaDu layers incubated without bacterial cells. The 
values are the means (± standard deviations) of at least three independent experiments 
conducted in duplicate. Asterisks (*) indicate statistically significant differences compared to 
the control. MOI stands for multiplicity of infection (bacterial cells per FaDu cell). 
 
 
1.4.8 The selected LAB strains drive different immune responses in vitro. 
In these experiments, none of the tested strains exhibited a potential pro-inflammatory effect, 
suggesting that they could be well tolerated by human epithelial cells in vivo. This statement is 
consistent with the induced reduction of baseline TNF-α secretion, which was observed with all 
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tested strains. In details, we found different behaviors among selected bacteria tested. While S. 
salivarius strain K12 reduced baseline IL-8 and IL-6 secretion, while ST3 inhibited drastically 
IL-1 . These results have been partially explained by the experiments on NF-B activation. The 
reduced secretion of IL-8 and IL-6 provoked by strain K12 can be attributed to the inhibition of 
NF-B activation, as already proposed by Cosseau et al. (2008). In contrast, S. salivarius ST3 promoted the 
baseline activation of NF-B. Greten with collaborators have recently demonstrated that NF-B activates 
the secretion of a selective inhibitor of caspase-1, a peptidase required for pro-IL-1 maturation (Greten et al., 
2007). Therefore, we can reasonably speculate that the inhibition of IL-1 secretion by strain ST3 could also 
be mediated by a mechanism involving inhibition of the enzyme caspase-1. It is important to stress 
that the stimulatory activity of ST3 bacterial cells on NF-B activation was  eliminated in presence of 
the inflammatory stimulus due to IL-1. Similarly, it is noteworthy that in IL-1-treated FaDu S. salivarius 
strains can considerably reduce IL-6 and IL-8 secretion, suggesting their potential anti-inflammatory activity. 
Finally, Lactobacillus helveticus MIMLh5 at baseline enhanced GM-CSF, decreased TNF-α 
and particularly, displayed the strongest ability to inhibit the secretion of IL-6 (from 78.1 to 5.5 
pg ml
-1
), IL-8 (from 1721 to 111 pg ml
-1
) and G-CSF (from 3.5 to 0.2 pg ml
-1
; Fig. 1.4.6). The 
reduced secretion of these cytokines promoted by strain MIMLh5 in FaDu cells can be 
potentially explained by the concomitant inhibition of NF-κB activation found in our 
experiments (Fig. 1.4.7).  In fact, the transcriptional regulator NF-κB is an inducer of IL-8 and 
several other cytokines, and is a therapeutic target in a wide range of human (auto)-
inflammatory diseases (Yamamoto & Gaynor, 2005). 
It is well known that the mechanism of action of many anti-inflammatory compounds, including 
salicylate and corticosteroids, involves NF-κB inhibition (Auphan et al., 1995; Kopp & Ghosh, 
1994). Furthermore, intestinal and/or probiotic microorganisms have also been proposed to 
exert their immunomodulatory activity through the modulation of the NF-κB signaling and the 
subsequent reduction of IL-8 production (Sokol et al., 2008). 
Interestingly, the cell concentration-dependent ability of L. helveticus MIMLh5 to reduce NF-
κB activation was particularly significant after stimulation by the pro-inflammatory cytokine 
IL-1β. Nevertheless, in this condition, we observed a simultaneous increase of the secretion of 
several cytokines, such as IL-6, G-CSF, INF-γ, and TNF-α. In particular, we found that 
MIMLh5 at baseline can inhibit G-CSF secretion, concomitantly with the stimulation of GM-
CSF. Myeloid dendritic cells (DCs), which drive the T-cell response into a Th1 type, require the 
presence of GM-CSF for survival, in contrast to lymphoid DCs, which induce Th2 response and 
are mobilized by G-CSF (Arpinati et al., 2000; Moser et al., 2005; Rissoan et al., 1999). A 
systemic and local increase of GM-CSF/G-CSF ratio, for instance, has been correlated with a 
Th1-dominating response and good clinical status in cystic fibrosis patients (Moser et al., 2005).  
 
1.4.9 Safety assessment of selected bacteria by antibiotic susceptibility test  
We studied the antibiotic resistance of Lactobacillus helveticus MIMLh5 and Streptococcus 
salivarius K12 and ST3 with reference to the EFSA breakpoints for Lactobacillus helveticus 
and Streptococcus thermophilus (since S. salivarius is phylogenetically close to S. thermophilus) 
respectively (EFSA, 2008). Bacterial strains were found to be sensitive to ampicillin, 
chloramphenicol, erythromycin, oxytetracyclin and vancomycin. A variable resistance was 
observed with the aminoglycoside antibiotics (gentamicin, kanamycin and streptomycin) 
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depending on the strain and the growth medium. All strains were assessed to be resistant to 
kanamycin with the only exception of S. salivarius ST3, when it was grown in LM17 medium 
(Table 1.4.1). Strain K12 was resistant to gentamicin in LM17 medium and to streptomycin in 
BHI medium. Finally, S. salivarius ST3 was resistant to gentamicin in MRS medium and to 
streptomycin in BHI and MRS media (Table 1.4.1). For what it concerns L. helveticus 
MIMLh5, it was found to be sensitive to all tested antibiotics except kanamycin (Table 1.4.1). 
However, it appears reasonable to consider the resistance to kanamycin as intrinsic and not 
related to a specific gene. It is known, in fact, that several lactobacilli have a high natural 
resistance to kanamycin and other aminoglycosidic antibiotics (Bernardeu et al., 2008).  
Table.1.4.1 Antibiotic sensitivities of selected bacterial strains. Minimal inhibitory 
concentrations (MICs). 
 
1 Possible interference of the growth medium is reported (EFSA, 2008). 
2 Microbiological breakpoints categorizing bacteria as resistant (μg ml-1) according to EFSA 
guidelines (EFSA, 2008); S.t. and L.h. stands for Streptococcus thermophilus and Lactobacillus 
helveticus, respectively. 
3 M17 containing 2 % lactose. 
 
 
Recently, the European Food Safety Authority (EFSA) assigned a "Qualified Presumption of 
Safety" (QPS) status (EFSA, 2004) to several lactic acid bacterial species, including 
Lactobacillus helveticus, Streptococcus thermophilus, but not Streptococcus salivarius. In 
Europe, S. salivarius belongs to the risk group 2 (such as S. pyogenes or S. pneumoniae), while 
the very closely related species S. thermophilus, S. uberis and S. vestibularis (Mora et al., 2003) 
belong to risk group 1. Presumably, S. salivarius is considered an opportunistic pathogen 
because, as with many food grade lactobacilli, there have been sporadic reports of infections, 
generally in subjects under adverse medical conditions (Ahmed et al., 2003; Afek et al., 2004; 
Corredoira et al., 2005). Quite the opposite, in other parts of the world, S. salivarius has already 
acquired the status of safe microorganism and has been commercialized for several years as 
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probiotic without any reported adverse consequences (Burton et al., 2006). In the light of the 
above mentioned facts, the optimal strategy to assess the safety of S. salivarius, would be 
considering every specific strain independently, in accordance with FAO/WHO guidelines on 
probiotics (FAO/WHO, 2002), as has been done for the strain S. salivarius K12 (Burton et al., 
2006; Cosseau et al., 2008). From this perspective, the absence of transmissible antibiotic 
resistances is considered a key safety prerequisite for the selection of a probiotic microorganism 
(EFSA, 2004; FAO/WHO, 2002). In this study, S. salivarius strain ST3, according to the EFSA 
breakpoints suggested for S. thermophilus (2008), resulted sensitive to a variety of antibiotics 
that are routinely used for the control of URTIs. Differently, they showed resistance exclusively 
to the aminoglycosidic antibiotics gentamicin, kanamycin and streptomycin, for which an 
intrinsic resistance is known for several lactic acid bacteria (Corredoira et al., 2005; Hummel et 
al., 2007; EFSA, 2008; Maragkoudakis et al., 2009). 
 
1.4.10 ST3 is a natural urease negative S. salivarius strain 
All Streptococcus salivarius isolates obtained from pharyngeal mucosa and the probiotic strain 
K12 were tested for their ability to hydrolyze urea. All tested strains resulted urealytic when 
grown in a medium containing nickel cations, with the only exception of strain ST3. According 
to the phenotypic assay, we failed to amplify by PCR from strain ST3 ureC gene, which 
encodes the alpha subunit protein containing the active site and conserved nickel binding 
ligands of the urease complex. On the contrary, a PCR fragment of the expected length was 
obtained using primers targeting ureC from all the other S. salivarius strains (Data not shown). 
The urease activity is a bacterial feature that exerts an important role in the interaction with the 
human host is. Ammonia production from ureolysis in saliva and crevicular fluids is, in fact, a 
primary source of amino nitrogen and is thought to inhibit the initiation and progression of 
dental caries by reducing acidity (Kleinberg, 1967; Peterson et al., 1985). At the same time, a 
high ammonia concentration can have deleterious effects on host cells (Helgeland, 1985), such 
as fibroblasts and polymorphonuclear leukocytes, and may therefore contribute to tissue 
damage (Helgeland, 1985). Among the species of oral bacteria that have been identified as 
ureolytic, S. salivarius is known to produce high levels of urease (Sissons & Cutress, 1987). 
Unexpectedly, strain S. salivarius ST3, selected in this work for its potential probiotic 
properties, was unable to hydrolyze urea. In the consideration of its use as pharynx's probiotic, 
this bacterium would interact directly with oro-pharyngeal mucosa and tonsil crypts. Therefore, 
the inability to hydrolyze urea could be of potential benefit in preserving the host's mucosal 
cells from ammonia injury.  
 
1.4.11 ST3/MIMLh5 co-suspension did not affect adhesion and antagonistic properties 
of the individual strains on the FaDu cell layer.  
In the following series of experiments, we evaluated in vitro the potential probiotic properties of 
strains ST3 and MIMLh5 used in combination. We first studied the interaction with FaDu 
human pharyngeal cell line in terms of adhesion and ability to antagonize Streptococcus 
pyogenes. We found that the adhesion on pharyngeal epithelium of each strain was not affected 
when the other one was also present, indicating that there is no competition for adhesion sites 
between MIMLh5 and ST3 in our test conditions (MOI of 1000 for each bacterium; Fig. 1.4.8).  
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Afterwards, we measured the bioluminescence produced by S. pyogenes C11
LucFF
 as an 
indication of the exclusion antagonism exerted by strains ST3, MIMLh5 and their mixed 
suspension. L. helveticus MIMLh5 showed a better antagonism against S. pyogenes (72 % 
reduction of luminescence), compared to S. salivarius strain ST3 (53 % luminescence 
reduction). When the tester bacteria were used in combination (MOI 1000 each), the 
antagonistic activity was maintained at the highest level (72 % reduction), indicating that the 
two strains can coexist without reducing their in vitro exclusion ability (Fig. 1.4.9). 
 
 
 
 
 
 
 
 
 
1.4.12 The effect of strain MIMLh5 on NF-κB activation in FaDu epithelial cells is 
predominant over that of strain ST3. 
In this study, we explored the effect of strains ST3 and MIMLh5 in combination on NF-κB 
activation in FaDu cells using the same luciferase reporter system previously described. As 
observed in previous investigations (Guglielmetti et al. 2010a;b), L. helveticus MIMLh5 
decreased the NF-κB-dependent production of bioluminescence, while ST3 showed a 
stimulatory effect (Fig. 1.4.10). When the two bacterial strains were used in combination at the 
same multiplicity of infection (MOI 1000 each), activation of NF-κB was reduced to an extent 
not significantly dissimilar to that determined by MIMLh5 alone (Fig. 1.4.10), indicating that 
the inhibitory effect of this bacterium on NF-κB-mediated responses is predominant over the 
outcome induced by strain ST3. 
Figure 1.4.8 Bacterial adhesion as 
observed with Giemsa staining 
under a light microscope. FaDu 
nuclei appear in red. 
 
Figure 1.4.9 Antagonistic exclusion 
activity against bioluminescent S. 
pyogenes C11lucFF; control is a cell 
layer treated with only PBS before 
incubation with S. pyogenes. 
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1.4.13 Effect of the strains MIMLh5 and ST3 on activation of U937 human 
macrophages.  
Studies on the immunomodulatory effects of probiotics for the oropharyngeal mucosa have thus 
far mainly concentrated on immune responses at the epithelial cell level (Cosseau et al., 2008). 
An evaluation of the responses by cells involved in the immune system is thus required. We 
used PMA-differentiated U937 human macrophages to study the innate immune responses 
induced by L. helveticus MIMLh5 and S. salivarius ST3. In this study, we first treated U937 
cells with PMA for 48 hours to differentiate the cells into macrophages. Subsequently, we 
stimulated the differentiated cells with MIMLh5 and ST3 bacteria. After 4 h of incubation, we 
used RT-qPCR to quantify the gene expression of TNF-α (a cytokine involved in inflammatory 
responses; Belardelli, 1995) and IL-10 (a potent anti-inflammatory interleukin that inhibits the 
production of pro-inflammatory cytokines in several cell types; Fiorentino et al., 1991; 
D‟Andrea, 1993). We tested the strains MIMLh5 and ST3 alone and in combination (co-
incubation) at MOIs of 100 and 1000. In all tested conditions, strains MIMLh5 and ST3 
produced a higher IL-10/TNF-α ratio than lipopolysaccharide (LPS) from Escherichia coli, a 
potent pro-inflammatory stimulus. Unlike LPS, the induction of IL-10 by MIMLh5 or ST3 
alone was never lower than that of TNF-α (Fig. 1.4.11A). Strain ST3, in particular, triggered 
profound IL-10 expression. In co-incubation experiments, we used a total MOI (i.e., the sum of 
the bacterial cell numbers of both strains) corresponding to the MOI of the bacterial strains 
employed individually to see possible synergistic effects. At the lower MOI tested, the mixed 
suspension of MIMLh5 and ST3 resulted in an intermediate cytokine induction compared to 
single strains (Fig. 1.4.11A). On the contrary, synergism was observed at the MOI of 1000; the 
combination of MIMLh5 and ST3 caused a significant increase in the expression of both TNF-α 
and IL-10 (Fig. 1.4.11A). These data show that the bacterial cell concentration affects the 
immune response of U937 cells; a dose-dependent approach should be therefore considered 
when defining a specific immunological effect of a bacterial strain, as demonstrated in previous 
works (Evrard et al., 2011). In this study, the strains MIMLh5 and ST3 significantly induced the 
expression of the pro-inflammatory cytokine TNF-α. Previous studies have shown that different 
Figure 1.4.10. Effect of bacteria on FaDu 
cells stably transfected with an NF-
B/luciferase reporter vector. Control is a 
FaDu layer incubated without bacterial 
cells; MOI stands for multiplicity of 
infection (bacterial cells per FaDu cell); 
interleukin IL-1β was used as positive 
control for NF-B activation. Data in 
histograms are the means (± standard 
deviations) of at least three independent 
experiments conducted in triplicate. 
Bacterial and FaDu luciferase activity is 
expressed as relative luminescence units 
(RLU). Asterisks (**) indicate statistically 
significant differences compared to the 
control (P < 0.001). 
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Lactobacillus species can trigger pronounced pro-inflammatory activity in DCs (Christensen et 
al., 2002; Weiss et al., 2010) and in macrophages (Morita et al., 2002). Macrophages are 
professional phagocytes that reside in the secondary lymphoid organs as well as in almost all 
tissues, including the tonsils (Yamamoto et al., 1988), serving as sentinels to detect microbial 
invaders (Adherem & Underhill, 1999). Upon the recognition of pathogen-associated molecular 
patterns (PAMPs; Janeway & Medzhitov, 2002), macrophages produce inflammatory 
mediators, such as cytokines and chemokines, that alert the immune system to the infection of 
injury. A pro-inflammatory behavior that results in the activation of cell-mediated (Th1 type) 
immunity, like that observed for MIMLh5 and ST3, could thus be crucial in combating 
intracellular pathogen attacks and viral infections and alerting the host‟s immune system. Other 
studies have reported that most lactic acid bacterial strains that have been tested could induce a 
Th1 response, even though this capability is strictly dependent on the specific strain and dose 
used (Perdigòn et al., 2002; Ongol et al., 2008). Notably, in the same studies, some strains of S. 
thermophilus, a species phylogenetically close to S. salivarius, induced a high level of IL-10 
(Ongol et al., 2008). In our experiments, S. salivarius ST3 induced a higher level of IL-10 than 
TNF-α. Furthermore, the increased production of the anti-inflammatory cytokine was more 
pronounced in ST3 than in MIMLh5 at the highest MOI tested (Fig. 1.4.11A). Therefore, we 
speculate that the presence of both bacteria, even at high doses (MOI 1000), might not result in 
detrimental effects. The regulatory effect of the significant IL-10 expression could protect 
against secondary outcomes that can occur after streptococcal infections, namely, reactive 
inflammatory conditions such as rheumatic disease (Puliti et al., 2002). 
 
1.4.14 The strains MIMLh5 and ST3 induce cyclooxygenase (COX)-2 expression in 
U937 cells and in BMDCs.  
Cyclooxygenase (COX), or prostaglandin synthase H (PGH), is a homodimer enzyme involved 
in the synthesis of prostaglandins (PGs) from arachidonic acid (Funk, 2001). PGs are involved 
in several physiological processes and contribute to the protection of the gastrointestinal 
mucosa (Williams et al., 1999; Morteau et al., 2000). Two isoforms of the COX enzyme have 
been identified and described (Kujubu et al., 1991). COX-1 is constitutively expressed in a wide 
range of tissues, whereas COX-2 is constitutively expressed in very few tissues but is induced 
by several stimuli, including bacterial components (Herschmann, 1996). We investigated the 
effect of the strains MIMLh5 and ST3 on COX-2 activation in the U937 cell model. The 
association of the two bacteria resulted in an enhanced transcription of the gene (Fig. 1.4.11B). 
In similar experiments, we also observed a strong increase in COX-2 gene expression in murine 
bone marrow-derived dendritic cells (Data not shown). Although other studies have suggested 
that lactic acid bacteria could affect COX-2 secretion, there is no clear consensus in the 
literature. For instance, several probiotic preparations were found to reduce the amount of 
prostaglandins and levels COX-2 expression at the intestinal level in murine models (Urbanska 
et al., 2010; Amdekar et al., 2011;) and in vitro (Lee et al., 2008). In contrast, other papers 
reported a significant up-regulation of COX-2 expression levels by probiotic bacteria in vitro 
(Otte et al., 2009; Khailova et al., 2010) and in vivo (Khailova et al., 2010; Kwon et al., 2010). 
Lactobacillus acidophilus, a species phylogenetically related to L. helveticus, was reported to 
significantly increase COX-2 expression and PGE2 secretion in the human colon cancer cell line 
Colo320 (Otte et al, 2009). Differences in tested strains and model systems likely explain the 
lack of consensus found in the literature. The ability of the strains MIMLh5 and ST3 to induce 
COX-2 expression suggests that these bacteria could directly affect inflammatory processes not 
only by modulating cytokine secretion but also inducing prostaglandin production.  
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Figure 1.4.11 Transcription analysis of cytokine genes in U937 cells stimulated with 
Lactobacillus helveticus MIMLh5 and Streptococcus salivarius ST3 after 4 h of incubation with 
bacterial strains used alone or in association at two different MOIs. Lipopolysaccharide (LPS) 
was used as positive control at a concentration of 1 μg ml-1. The values are the means (± 
standard deviations) for a result representative of three independent experiments, expressed as 
the fold change in induction respective to the control (U937 unstimulated cells) set at a value of 
1. Asterisks indicate statistically significant differences compared to the corresponding control 
(*, P < 0.05). A, Expression levels of IL-10 and TNF-α. B, Expression levels of COX-2. C, 
Expression levels of IL10 and TNF-α in the presence of a neutralizing antibody against TLR-2 
(anti-TLR2). Anti-TLR2 was added to U937 cells 1 h before stimulation with bacteria. 
Immunoglobulin-A2 isotype (IgA2) was used as control for non-specific blocking activity. 
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COX-2 is involved in the induction of oral tolerance through the action of PGs in guiding T 
cells towards an immunosuppressive phenotype (Newberry et al., 1999) and in resolving 
inflammation (Wallace, 2006). The activity observed for MIMLh5 and ST3 on COX-2 could 
thus be of immediate benefit for host‟s mucosa, and in light of the fact that, rapid COX-2 up-
regulation in response to injury or inflammation has been reported to restore mucosal integrity 
(Tan et al., 2000). 
 
1.4.15 TLR-2 participates in the recognition of the strains MIMLh5 and ST3 by U937 
cells.  
To gain information on possible signaling pathways involved in the immune responses induced 
by L. helveticus MIMLh5 and S. salivarius ST3, we investigated which Toll-like receptor 
(TLR) recognizes these bacteria. TLRs are a class of transmembrane proteins involved in innate 
immunity (Akira and Hemmi, 2003); in mammals, they work as pattern recognition receptors 
(PRRs) and participate in detecting various conserved microbial molecules, such as 
lipopolysaccharide (LPS), lipoteichoic acid (LTA), peptidoglycan (PGN), bacterial lipoproteins, 
lipoarabinomannan, and zymosan (Means et al., 2000). More specifically, TLR-2 forms 
heterodimers with TLR-1 or TLR-6 and primarily interacts with Gram-positive bacteria by 
recognizing PGN, LTA, and lipoproteins (Takeda et al., 2003). 
In this study, we performed experiments in U937 cells with a neutralizing antibody against 
TLR-2 (antiTLR2-Ab) to partially block its ability to bind ligands. An immunoglobulin-A (IgA) 
isotype control was also used to exclude non-specific binding to U937 cell receptors. After 1 
hour pre-incubation with an anti-TLR2 neutralizing Ab (5 μg ml-1), we stimulated the U937 
cells for 4 hours with bacteria. We then evaluated the expression of the genes that encode TNF-
α and IL-10 using RT-qPCR. When TLR-2 was blocked with anti-TLR2, we observed 
significantly less TNF-α mRNA, both when the strains MIMLh5 and ST3 were used 
individually and in combination (Fig. 1.4.11C). These results indicate that TLR-2 is involved in 
mediating the immunostimulatory activity of both strains. These data are consistent with 
previous studies that showed that the immunomodulatory activity elicited by lactobacilli 
involves TLR-2 in macrophages (Shida et al., 2009) and in dendritic cells (Zeuthen et al., 2008; 
Weiss et al., 2010). However, pre-incubation with anti-TLR2 resulted in a reduction of IL-10 
expression only with strain ST3, whereas MIMLh5-mediated expression of IL-10 was not 
affected (Fig. 1.4.11C), indicating that receptors independent from TLR-2 may be involved in 
the induction of this cytokine. The interference of anti-TLR2-Ab with IL-10 induction that we 
observed in our study with strain ST3 is in agreement with the literature. Molecules able to 
induce IL-10 in a TLR2-dependent manner have been already described (Re & Strominger, 
2004; Yamazaki et al., 2011). It is plausible that a similar response mechanism is triggered by S. 
salivarius ST3 in U937 cells. 
When the strains were combined, the reduction of the anti-inflammatory cytokine TNF-α was 
similar to that of ST3 alone (1.43- and 1.34-fold reduction, respectively). Even though anti-
TLR2 generally reduced TNF-α induction, the relative increase of TNF-α gene expression 
caused by the bacteria in combination compared to bacteria employed singularly was markedly 
higher when TLR-2 was blocked with anti-TLR2 than in control conditions (i.e., in presence of 
IgA2, Fig. 1.4.11C). In other words, the synergistic effect of using both strains was intensified 
by the presence of the anti-TLR2 antibody. As a consequence, when TLR-2 was blocked, the 
IL-10/TNF-α ratio increased only slightly (approximately 18 %) with bacteria in combination, 
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whereas the ratio was nearly doubled by the individual strains. We can therefore speculate that 
PRRs other than TLR-2 are involved in the recognition of these bacteria. It might also be 
hypothesized that blocking TLR-2 can impact the formation of heterodimers with other TLRs 
and/or the cooperation of TLR-2 with other types of receptors (such as scavenger receptors), 
therefore causing different cytokine responses.  
 
1.4.16 Strains ST3 and MIMLh5 can be used in combination to ferment bovine milk.  
In light of the in vitro functional properties of L. helveticus MIMLh5 and S. salivarius ST3 in 
combination, we examined the possibility of co-cultivating these bacteria in bovine milk and 
potentially employing MIMLh5 and ST3 in dairy products. L. helveticus MIMLh5 is a natural 
whey starter culture that is well adapted to grow in bovine milk. In contrast, S. salivarius is a 
human oral commensal isolate that cannot proliferate when cultivated in milk due to its limited 
ability to use lactose as the sole carbon and energy source. We determined the growth curve of 
ST3 with eight different carbohydrates at six concentrations in M17 medium (Data not shown). 
Strain ST3 displayed optimal growth in the presence of glucose, sucrose, fructose and 
fructooligosaccharides (FOS); its growth was significantly reduced with inulin and lactose but 
was not detectable with galactose and lactitol (Fig. 1.4.12A). Interestingly, strain ST3 
metabolized Actilight
®
 (Fig. 1.4.12B), a commercial product consisting of a mixture of short-
chain FOS (1-kestose, nystose, and fructosylnystose) that is frequently used as a prebiotic 
supplement. When we added one of the four sugars that are efficiently metabolized by ST3 to 
skim milk, ST3 growth became similar to that in M17 supplemented with the same sugar. 
Subsequently, we performed acidification curves by monitoring the pH in skim milk 
supplemented with 2 % glucose after 1 % inoculum of the overnight cultures of strains ST3 and 
MIMLh5 alone and in co-culture. The association of the two strains resulted in a faster 
acidification of the medium (Fig. 1.4.13). In fact, after 6 hours of incubation at 42 °C, ST3 and 
MIMLh5 monocultures reached pH 5.2 and 5.5, respectively, whereas their co-culture reduced 
the pH to 4.9 in skim milk supplemented with 2 % glucose or FOS (Fig. 1.4.13). After 6 hours 
of co-incubation in skim milk supplemented with glucose at 42°C, ST3 and MIMLh5 reached a 
number of viable cells of 9.5  108 and 8.9  107 CFU ml-1, respectively (Fig. 1.4.13), indicating 
that both strains contributed to the milk acidification. These data support the potential of using a 
combination of strains ST3 and MIMLh5 to ferment milk for the production of a novel food 
product. 
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Figure 1.4.12. Growth curves of Streptococcus salivarius ST3. A, Growth in M17 supplemented 
with 2 % of 8 different carbon sources. B, Growth in M17 supplemented with 6 different 
concentrations of Actilight
®
 fructooligosaccharides (FOS). The curves are representatives of 
two experiments carried out in sextuplicate. 
    
 
 
Figure 1.4.13 Growth of Lactobacillus helveticus MIMLh5 and Streprococcus salivarius ST3 
(single culture and co-culture) at 42°C in skim milk supplemented with 2 % glucose or FOS. A, 
bacterial plate counts of co-culture; T0, immediately after 1 % inoculum; T3 and T6, after 3 
and 6 h, respectively. B, acidification curves. 
 
 
 
1.5 Conclusions 
57 
 
1.5 CONCLUSIONS 
There is an increasing interest in prophylactic strategies effective for upper respiratory tract 
infections, that represent a major cause of medical prescription for antibiotics, especially in 
children. The identification of bacterial strains that could be used as probiotics for the 
pharyngeal mucosa is one potential strategy. 
During this first part of the research, an in vitro rational process led us to select two potential 
probiotic bacterial strains for the pharyngeal mucosa, the commensal S. salivarius ST3 and the 
dairy bacterium L. helveticus MIMLh5. These bacteria efficiently adhered to human epithelial 
pharyngeal cell lines, antagonizing the adhesion of Streptococcus pyogenes. Furthermore, 
immunological tests suggested a good degree of adaptation of these selected strains to the host 
and potential immunomodulatory and anti-inflammatory abilities. 
Therefore we further characterized the two selected strains, and as first we demonstrated that 
strains MIMLh5 and ST3, when used together, maintain their in vitro probiotic abilities. 
Subsequently, we gave particular attention to bacterial immunomodulatory properties because 
modulation of the host‟s immunity is one of the most commonly purported benefits of the 
consumption of probiotics and is supported by an increasing number of in vitro and in vivo 
studies (Corthesy et al., 2007). We found that the combination of MIMLh5 and ST3 resulted in 
a synergistic effect, according to cytokine induction, that might help the host immune system to 
react to potential pathogens while maintaining a balance between pro- and anti-inflammatory 
cytokines, thus preventing possible exaggerated responses. Finally, we observed that these 
microorganisms grow efficiently when co-cultured in milk, suggesting that the preparation of a 
milk-based fermented product containing both MIMLh5 and ST3 can be a practicable solution 
for the administration of these bacteria. 
In conclusion, we propose the combined use of Lactobacillus helveticus MIMLh5 and 
Streptococcus salivarius ST3 for the preparation of novel products that can display probiotic 
properties for the pharyngeal mucosa (Taverniti et al., 2012). 
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2.1 STATE OF THE ART 
2.1.1 Beneficial effects reported for L. helveticus strains 
Lactobacillus helveticus is a non-spore forming Gram positive thermophilic homofermentative 
lactic acid bacterium, which has a long history of use in the production of cheese types where 
high cooking temperatures are required. Besides its well-known technological importance in 
cheese making, a growing number of studies is demonstrating that L. helveticus strains can also 
exhibit significant health-promoting properties. There are, in fact, more than 50 scientific 
publications on the probiotic properties of L. helveticus, including in vitro characterizations, in 
vivo animal studies and interventional/clinical trials. These studies demonstrate that members of 
the species L. helveticus can potentially affect human health through direct or indirect 
mechanisms, such as the inhibition of pathogens, modification of gut microbiota and modulation 
of the host immune system. It has been shown the ability of strains belonging to the L. helveticus 
species to exert immunostimulatory effects, both when used alone or in combination with other 
bacterial strains, and at local and systemic level (Taverniti & Guglielmetti, 2012). 
It is important to note that within the L. delbrueckii group, the species L. acidophilus and L. 
helveticus are phylogenetically very closely related (the 16S rDNA sequences of these bacteria 
differ by just 1.6%; Callanan et al., 2008); however, while L. helveticus is a specialist dairy 
culture, L. acidophilus is a natural inhabitant of the human gut. L. acidophilus strains, moreover, 
are commonly used as probiotics. If we compare these two species, more than 250 scientific 
studies have been published concerning the probiotic potential of L. acidophilus in less than 3 
years (from January 2010 to August 2012, according to a PubMed search), whereas L. helveticus 
has been included in less than 20 studies on probiotics in the same period. Although limited 
respect to L. acidophilus, the literature on the potential beneficial effects of L. helveticus includes 
significant scientific facts that highlight the ability of L. helveticus strains to interact with the host 
and influence health. Thus, all these studies reporting that L. helveticus cells and cell 
components, or the enzymatic activities of this bacterium, are linked to specific effects on host 
physiology, support that the species L. helveticus includes strains that can be properly considered 
to be probiotic.  
 
2.1.2 The impact of bacterial cell viability and the role of bacterial cell molecules: the 
paraprobiotic approach  
The mechanisms underlying probiotic effects are generally attributed to the interaction of 
probiotics with other microorganisms (members of the microbiota or pathogens) or to the cross-
talk of probiotics with host cells. The former type of interaction is typically (though not 
exclusively) dependent on the viability of probiotic cells, since it is exerted by competitive 
exclusion (competition for nutrients or adhesion sites), direct inhibition of certain 
microorganisms (production of antimicrobial molecules) or increased growth of healthy 
components of the microbiota (nutritional or environmental proto-cooperation). In contrast, direct 
interaction with the host can be mediated by bacterial cells independently from their viability and 
is based on the capacity of human cells to recognize specific bacterial components or products, 
giving rise to responses that commonly involve the mucosa associated lymphoid tissue (MALT) 
and, therefore, the immune system (Adams, 2010). 
The FAO/WHO official definition of probiotics specifies that probiotic microorganisms must be 
“live”, and this stipulation is supported by an extensive number of studies suggesting that to 
2.1 State of the art 
71 
 
provide health benefits, probiotic microorganisms must be viable (Gobbetti et al. 2010). 
However, the administration of viable bacterial cells to certain categories, like individuals with 
weaker immune systems, enhanced inflammatory responses and/or compromised mucosal barrier 
functions, could turn “generally recognised as safe” harmless probiotic bacteria into detrimental 
microorganisms (Besselink et al., 2008). The emerging concern regarding safety problems arising 
from the extensive use of live microbial cells is enhancing the interest in non-viable 
microorganisms or microbial cell extracts and single bacterial components, as they could 
eliminate shelf-life problems and reduce the risks of microbial translocation and infection. There 
exist and expanding scientific literature concerning studies in which non-viable microbial cells or 
crude microbial cell fractions have been investigated as health-promoting agents (Kataria et al. 
2009; Taverniti & Guglielmetti, 2011). The scientific literature suggests that loss of viability of 
probiotic microorganisms can induce complex effects in terms of immunomodulation.  
Products intentionally containing non-viable microbial cells are already present on the market 
(e.g., Lactéol Fort from PUMC Pharmaceutical Co., Ltd and Fermenti Lattici Tindalizzati from 
Frau, AF United S.p.a.). Therefore, the use of killed/inactivated bacteria and/or bacterial 
components, as long as the beneficial effects are retained, would represent an advantage because 
it is possible to make these bacteria potentially harmless through a tailored inactivation treatment, 
or through the employment of a specific and characterized compound extracted from bacterial 
cell.  
In the last fifteen years several definitions of probiotic have been proposed, some of them even 
comprising non-viable microbial cells. For instance, Prof. S. Salminen (1999) spoke about 
probiotics as “microbial cell preparations or components of microbial cells that have a beneficial 
effect on the health and well-being of the host”. Therefore, since the FAO/WHO official 
definition of probiotics might results, in some cases, restrictive, a new terminology which could 
unambiguously define the use of nonviable microorganisms or microbial fractions to positively 
affect health would be required. To this aim, has also been recently proposed the term 
“paraprobiotic” (or “ghost probiotics”), to be defined as “nonviable microbial cells (intact or 
broken) or crude cell extracts (i.e., with complex chemical composition), which, when 
administered (orally or topically) in adequate amounts, confer a benefit on the human or animal 
consumer” (Taverniti & Guglielmetti, 2011). Purified molecules of microbial origin or pure 
microbial cell products are omitted from the concept of paraprobiotic, since their use should be 
included in conventional pharmaceutical methodologies. However, this new approach and all the 
emerging studies regarding the bioactive properties of bacterial components open the way to new 
perspectives and possible use of probiotic and their single molecules. 
 
2.1.3 Immunomodulatory properties of bacterial cell components  
Several mechanistic studies have demonstrated that specific chemical compounds isolated from 
bacteria can induce specific immune responses. These investigations provide the scientific basis 
for a molecular explanation of the immunological effects observed in vivo after administration of 
inactivated probiotic bacteria or probiotic cell extracts. Excluding extracellular bacterial 
products, a major role in immunomodulatory activity should be mediated by the structural 
components of the cell, particularly the cell envelope, the outermost structure that immune 
system cells come into contact with first, which includes cell wall constituents or, if they are 
present, S-layer proteins, capsule and pellicle (Chapot-Chartier et al., 2009). 
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The immunological effects of bacterial cell envelope components are not surprising, considering 
data present in literature and the immunomodulatory properties attributed to specific molecular 
cell wall components.  
Peptidoglycan (PGN) and lipopolysaccharide (LPS, also known as bacterial endotoxin) for 
instance, are well-known potent activators of immune responses. PGN is the main constituent of 
Gram-positive bacterial cell walls, accounting for up to 90% of their weight, whereas it 
constitutes only 15-20% of the cell wall in Gram-negative bacteria (Warshakoon, 2009). A thick 
PGN layer is generally the outermost structure covering Gram-positive cells, whereas in Gram-
negative bacteria, there is an outer biological membrane that contains around 13% LPS and 
exposes the LPS-core polysaccharides and LPS-O-antigens to the external environment. PGN 
and LPS have traditionally been considered molecules that promote adverse events, such as 
fever, arthritis and auto-immune diseases (Marteau &Shanahan, 2003; Nahra &Dellinger, 2008; 
Opal, 2010). Nonetheless, the composition of PGN and LPS differs largely from one bacterium 
to another, and even small chemical modifications can yield significantly different 
immunological consequences (Lebeer et al., 2010).  
In Gram-positive bacterial cell walls, there are molecules protruding from the external surface of 
the PGN layer known as teichoic acids (TAs). TAs are phosphodiester polymers of glycerol or 
ribitol, and they can be covalently linked to either peptidoglycan (wall teichoic acids, WTAs) or 
the cytoplasmic membrane (lipoteichoic acids, LTAs). Several studies have demonstrated the 
involvement of TAs in immune responses. With respect to microorganisms of probiotic interest, 
TAs from lactobacilli have been proposed to elicit proinflammatory responses through Toll-like 
receptor (TLR)-2 (Matsuguchi et al. 2003; Vidal et al., 2003). 
Proteins associated with probiotic bacteria have been shown to elicit immune responses. For 
example, the heat shock protein GroEL (Hsp60 class), of L. johnsonii La1 (NCC 533), which is 
also present at the cell surface, was expressed in E. coli, and its purified recombinant form 
(rGroEL) was shown to bind to mucins and epithelial cells, stimulating IL-8 secretion in 
macrophages and HT29 cells in a CD14-dependent manner (Bergonzelli et al. 2006). Another 
example is BopA, a cell surface-associated lipoprotein of Bifidobacterium bifidum MIMBb75 
that mediates adhesion to human Caco-2 intestinal epithelial cells. Upon purification from strain 
MIMBb75, BopA has been demonstrated to induce the production of IL-8 by Caco-2 cells in a 
dose-dependent manner (Guglielmetti et al., 2008). 
 
2.1.4 Surface layer proteins  
Some microorganisms may also engage in cross-talk with the host immune system by means of 
their surface layer (S-layer) proteins. Surface (S-) layers are crystalline arrays of proteinaceous 
subunits present as the outermost component of cell wall in several species of the genus 
Lactobacillus, as well as in many other bacteria and Archaea (Sára & Sleytr, 2000). The presence 
of S-layer has been described in many species of lactobacilli such as Lactobacillus acidophilus, 
L. helveticus, L. casei, L. brevis, L. buchneri, L. fermentum, L. bulgaricus, L. plantarum , L. 
crispatus, and more recently in L. kefir and L. parakefir isolated from kefir grains (Mobili et al., 
2010). S-layer is composed from one single protein or glycoprotein, forming crystalline structure 
of 5–15 nm with identical pores, which have diameter of 2–8 nm (Sleytr, 1997). The pores 
comprise up to 70 % of the lattice surface area (Sleytr & Beveridge, 1999). S-layer proteins have 
the ability to self-assemble into monomolecular crystalline arrays. The S-layer lattice can exhibit 
oblique, square, or hexagonal symmetry. From the Lactobacillus S-layer proteins, only oblique 
and hexagonal lattice types have been characterised (Figure 2.1.1), but in most cases, only a 
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periodic structure, without further characterisation, has been observed using electron microscopy 
analysis. Problems related to electron microscopy of Lactobacillus S-layers have been reported, 
and these problems may be one of the reasons why the lattice type and lattice constants have not 
been determined for most of the S-layer proteins of these bacteria (Åvall-Jääskeläinen & Palva, 
2005). 
 
Figure 2.1.1. Scanning electron micrograph of a freeze-etched preparation of a bacterial cell 
with an Slayer with oblique (p2; A) and hexagonal (p6; B) lattice symmetry. Scale bar = 100 nm. 
Adapted from Sleytr & Beveridge (1999). 
 
 
 
S-layer proteins are normally the most abundant bacterial proteins, constituting even up to 15 % 
of total bacterial protein content (Åvall-Jääskeläinen & Palva, 2005). In the case of L. helveticus, 
it forms around 45 % of cell wall dry weight (Messner et al., 1997). Most of the S-layer proteins 
of the genus Lactobacillus appear to be non-glycosylated, and up to date all known L. helveticus 
S-layer proteins are known not to have this modification. The Slayer monomers are non-
covalently linked to each other as well as to the supporting cell wall. The overall lack of identity 
between the S-layer proteins of different species is a common characteristic of all bacterial S-
layer proteins. Lactobacilli make no exception in this respect (Åvall-Jääskeläinen & Palva, 2005; 
Gatti et al., 2005). The highest similarity can be found in the C-terminal region. The N-terminal 
regions are more variable except the signal peptides (Nterminal secretion signals) that share a 
high level of sequence similarity. Typical characteristics of Lactobacillus spp. S-layer proteins, 
distinguishing them from other Slayer proteins, is small size, ranging from 25 to 71 kDa and thus 
being among the smallest known for the S-layer proteins, which can be up to 200 kDa (Åvall-
Jääskeläinen & Palva, 2005). S-layer proteins of lactobacilli have high content of positively 
charged residues, which makes them highly basic proteins: predicted isoelectric point (pI) values 
range from 9.35 to 10.4 (Mobili et al., 2010). A characteristic feature of Lactobacillus spp. S-
layer proteins is a high percentage (23–33 %) of amino acid residues with hydroxyl groups and a 
high content of hydrophobic amino acid residues, ranging from 31.9 % to 38.7 %, which is a 
typical feature for all S-layer proteins (Åvall-Jääskeläinen & Palva, 2005).  
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2.1.5 Functional roles of Surface layer proteins 
Even though S-layer protein is so abundant in carrying bacteria, its general role still remains 
elusive. Several specific functions have been assigned to the S-layer from different 
microorganisms (protective coats, molecular sieves, molecule and ion traps, cell adhesion and 
surface recognition, virulence factors). A protection role against hostile factors has been 
proposed for these superficial structures, considering that purified S-layers are stable toward non-
physiological pH, radiation, temperature, some kind of proteolysis, high pressures and detergent 
treatments (Mobili et al., 2010). Moreover, when the S-layer is extracted with chaotropic agents 
such as 5M lithium chloride, microorganisms become more sensitive toward aggressive 
environments such as the gastro intestinal juices (Frece et al., 2005). 
Several studies demonstrated participation of lactobacilli S-layer protein in mechanisms of 
aggregation (Kos et al., 2003; Chen et al., 2007), adhesion to epithelial cells (Åvall-Jääskeläinen 
et al., 2003; Tallon et al., 2007), activity against pathogens (Horie et al., 2002; Golowczyc et al., 
2007), adhesion to mucus and extracellular matrix (ECM) protein (Antikainen et al., 2002; De 
Leeuw et al., 2006), development of complex microbial communities (Angulo et al., 1993; 
Garrote et al., 2004).  
S-layer protein has also been proposed to play a role in the interaction with host immune system. 
The commercial probiotic Lactobacillus acidophilus NCFM strain possesses an S-layer primarily 
composed of a 45 kDa protein named SlpA. Konstantinov and collaborators (2008) demonstrated 
that NCFM SlpA was recognized and bound by DC-SIGN (Dendritic Cell-Specific Intercellular 
adhesion molecule-3-Grabbing Nonintegrin, also known as CD209), a C-type lectin receptor 
present on both macrophages and dendritic cells. Notably, they found that NCFM-expressing 
SlpA was captured by DC-SIGN on DCs, resulting in an interaction that appeared to be crucial 
for the activation of IL-4-producing T cells; in contrast, a knockout mutant of L. acidophilus 
NCFM lacking SlpA demonstrated significantly impaired binding to DC-SIGN (Konstantinov et 
al., 2008). These data were confirmed by experiments performed with purified SlpA protein, 
which ligated to DC-SIGN and induced IL-10 expression by DCs in the presence of LPS 
(Konstantinov et al., 2008). 
In particular for lactobacilli, different approaches have been used to study and comprehend the 
role of S-layer protein. Indirect approaches were targeted to test the impact of S-layer protein on 
specific properties of bacteria (like aggregation, adhesion, haemagglutination) before and after S-
layer removal. Direct approaches mainly focused on the study of the isolated protein in its 
interaction with other bacteria, eukaryotic cells or different kind of matrices and inert surfaces. 
Both approaches seem to suggest that the role of S-layer is not only species-specific, but also 
strain-dependent. Thus, a general prediction of its role in carrying lactobacilli is not possible, and 
should be evaluated case by case for each specific strain (Mobili et al., 2010). Even small 
differences in the aminoacidic sequences and, consequentially, in the structural characteristic of 
S-layer proteins can result in diverse surface and/or probiotic properties of whole bacteria 
(Mobili et al., 2009). In this perspective we wanted to characterize S-layer protein of our strain 
MIMLh5. 
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2.2 AIMS OF THE STUDY 
Considered the L. helveticus ability to support the cross-talk with host‟s immune system, and on 
the basis of our results obtained for strain MIMLh5 as potential probiotic for the oro-pharyngeal 
mucosa, we decided to deeper characterize its immunomodulatory potential. To this aim we 
tested MIMLh5 effects on different cell lines, including intestinal epithelial cells and different 
type of macrophages, by means of both in vitro and ex vivo experiments. Moreover, we tried to 
identify the bacterial cell components that could mediate the bacterial interaction with host‟s 
cells. Thus, using the same models above mentioned, we compared the immunomodulatory 
properties of the whole bacterium with the ones of its purified Surface-layer protein, which has 
been already demonstrated to play a role in the interaction with host immune system in other 
bacterial strains belonging, or closely related to L. helveticus species. We, moreover, tried to 
identify which host cell receptors can be involved in the recognition of both the whole bacterium 
and the protein, in order to possibly define which kind of signaling pathways could be activated. 
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2.3 MATERIALS AND METHODS 
2.3.1 Bacterial strains, isolation, and growth conditions  
L. helveticus MIMLh5 was grown in de Man-Rogosa-Sharpe (MRS) broth (Difco Laboratories 
Inc., Detroit, MI, USA) at 42°C, whereas L. acidophilus NCFM was grown in the same medium 
at 37°C. Lactobacillus strains were inoculated from frozen glycerol stocks and sub-cultured twice 
in MRS using 1:100 inoculum. For immunological experiments, bacterial cells from an overnight 
culture were collected, washed twice with sterile phosphate-buffered saline (PBS) and then 
resuspended in the same medium used to culture human or murine cells. Bacteria were tested at a 
multiplicity of infection (MOI) of 100 and 1000. 
 
2.3.2 Extraction, purification and chemical characterization of the S-layer protein from 
L. helveticus MIMLh5  
Extraction of the S-layer protein from L. helveticus MIMLh5 was performed with LiCl as 
described previously (Lortal et al., 1992; Smit et al., 2001; Johnson-Henry et al., 2007; Agave 
Biosystems, 2012). Briefly, 500 ml of an overnight culture of MIMLh5 was harvested by 
centrifugation at 10000 g for 20 min at 4°C and washed with 1 volume of cold sterile MilliQ 
water. The cell pellet was extracted with 0.1 volume of 1 M LiCl solution for 30 min at room 
temperature in the presence of Protease Inhibitor Cocktail (Sigma-Aldrich, St. Louis, MO, USA) 
with slight agitation and centrifuged. The cell pellet was then extracted with 0.1 volumes of 5 M 
LiCl solution for 1 h at room temperature in the presence of Protease Inhibitor Cocktail and 
centrifuged. The supernatant was filtered through a 0.2 μm filter and exhaustively dialyzed for 36 
h at 4°C against distilled water using 12000 kDa cut-off membranes (Sigma-Aldrich), which 
were prepared for dialysis by boiling in 2% of NaHCO3 and 1 mM EDTA solution. At each water 
change, 0.001% of Protease Inhibitor Cocktail was added. The dialysate was collected and 
centrifuged at 20000 g for 20 min at 4°C. The supernatant was removed, and the pellet 
resuspended in sterile MilliQ water and freeze dried. We calculated an approximately 4-fold 
underestimation in the quantification of S-layer protein with Bradford microassay method using 
bovine serum albumin (BSA) as a standard (probably due to the difference in aminoacidic 
residue composition between S-layer and BSA proteins). For this reason, for all the experiments 
in this study, the amount of S-layer was determined by measuring the weight of freeze dried 
dialyzed protein on an electronic analytical balance. Protein purity was determined by sodium 
dodecylsulphate–polyacrylamide gel electrophoresis (SDS–PAGE) and RP–HPLC analysis. 
SDS–PAGE. S-layer protein and total bacterial lysates were resuspended in SDS–PAGE 
(Laemmli) sample buffer, boiled for 5 min, and separated on 10% polyacrylamide gel in TRIS–
glycine–SDS buffer on Mini-PROTEAN 3 system (Bio-Rad Italia, Milan, Italy). Gels were 
stained with Coomassie brilliant blue G-250 (Sigma-Aldrich) or silver staining. RP–HPLC/ESI–
MS analysis of the S-layer protein. RP–HPLC/ESI–MS analysis was performed on Waters 
Alliance 2695 instrument (Waters, Vimodrone, Italy) connected to a Q-Tof micro mass 
spectrometer (Micromass/Waters) equipped with an orthogonal electrospray source (Z-spray). S-
layer protein was dissolved in 8 M urea and separated at 40 C on PLRP-S column (2.1 mm i.d., 
5 m, 300 Å, Polymer Laboratories Ltd, Church Stretton, UK). The eluents used for the 
separation were: solvent A, 0.1 % TFA in MilliQ-treated water, and solvent B, 0.1 % TFA in 
acetonitrile. The linear elution gradient expressed as the solvent B proportion was as follows: 0 
min, 25 %; 0 to 5 min, 25 %; 5 to 35 min, 25 to 55 %; 35 to 36 min, 55 to 95 %; 36 to 38 min, 95 
%; 38 to 39 min, 95 to 25 % (run–to–run time, 40 min). Protein was eluted at a flow rate of 0.2 
ml min
-1
 and monitored at 210 nm with Waters 2996 Photodiode Array Detector (Waters). Mass 
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spectra acquisition was performed in positive ion mode. The optimized mass spectrometry 
conditions were: capillary voltage 3200 V, source temperature 100 C, and cone voltage 45 V. 
The electrospray ionization (ESI) gas was nitrogen. The Tof analyzer collected data between m/z 
650 and 2000. The acquired MS spectrum was analyzed with the MassLynx 4.1 software 
(Waters). MS data were processed using MaxEnt 1 algorithm. 
 
2.3.3 Experiments with Caco-2 cell layers  
 In vitro cultivation. Caco-2 cells (human epithelial colorectal adenocarcinoma cell line; ATCC 
HTB-37) were routinely grown in Eagle‟s minimum essential medium (EMEM) supplemented 
with 10% (v/v) heat-inactivated (30 min at 56°C) fetal calf serum (FCS), 100 U/ml penicillin, 
100 mg ml
-1
 streptomycin, 0.1 mM nonessential amino acids (NEAA), and 2 mM L-glutamine 
and were incubated at 37°C in a water-jacketed incubator in an atmosphere of 95% air and 5% 
carbon dioxide. Study of NF-κB activation. Stable recombinant Caco-2 cell line was generated by 
transfecting cells with the plasmid pNiFty2-Luc (Invivogen, Labogen, Rho, Italy) as described by 
Guglielmetti et al. (2010). This plasmid contains a promoter with five NF-B-binding sites 
followed by the firefly luciferase reporter gene luc. Stimuli that activate NF-B promote its 
binding to the vector promoter, resulting in the expression of the luciferase gene. After growth in 
the presence of 50 g ml-1 zeocin, cell monolayers (approximately 3×105 cells well-1) were 
carefully washed with 0.1 M Tris-HCl buffer (pH 8.0). Subsequently, 50 µl of a tester bacterial 
suspension containing 2.5 × 10
8
 cells (or the purified S-layer protein) were added to 0.45 ml of 
fresh EMEM medium, containing 100 mM HEPES (pH 7.4). The resulting 0.5 ml were finally 
pipetted in the microtiter well containing Caco-2 layer, resulting in a MOI of approximately 
1000. Stimulation was conducted both in presence and absence of 2 ng ml
-1
 of interleukin (IL)-
1β. After incubation at 37°C for 4 h, the samples were treated and the bioluminescence was 
measured as described by Stuknyte et al. (2011). All conditions were analyzed in triplicate in at 
least two independent experiments. 
 
2.3.4 Study of the activation of U937 human macrophage cell line  
Cell culture, growth conditions, and stimulation protocol. The cell line U937 (ATCC CRL-
1593.2) was derived from a human histiocytic lymphoma (Sundstrom & Nilsson, 1976). These 
cells are maintained as replicative, non-adherent cells and have many of the biochemical and 
morphological characteristics of blood monocytes (Harris & Ralph, 1985). When treated with 
phorbol myristate acetate (PMA), U937 cells differentiate to become adherent, non-replicative 
cells with characteristics similar to tissue macrophages, including similar isoenzyme patterns 
(Radzun et al., 1983) and other phenotypic markers (Harris & Ralph, 1985). The normal growth 
medium for the U937 cells consisted of RPMI 1640 medium (Lonza, Basel, Lonza, Basel, 
Switzerland) supplemented with 10% (v/v) fetal bovine serum (FBS) (Gibco-BRL, Life 
Technologies, Milan. Italy), 2 mM L-glutamine, 100 U ml
-1
 penicillin and 100 μg ml-1  
streptomycin (Sigma-Aldrich). U937 cells were seeded at a density of 5×10
5
 cells well
-1
  in 12-
well plates and incubated at 37°C in a humidified atmosphere of 95% air and 5% CO2. 
Differentiation was induced by the addition of PMA (Sigma-Aldrich) into the cellular medium at 
a final concentration of 100 nM and was allowed to proceed for 48 h. Afterwards, cells were 
washed once with sterile PBS buffer to remove all non-adherent cells. One h before the bacteria 
were added to the cells, the culture medium was replaced with RPMI 1640 supplemented with 
1% (v/v) FBS to allow the cells to adapt. Bacteria were used at MOIs of 100 and 1000. 
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Lipopolysaccharide (LPS, final concentration of 1 μg ml-1) from Escherichia coli 0127:B8 
(Sigma-Aldrich) was used as a positive control for pro-inflammatory stimulus in U937 cells. An 
untreated sample, i.e. only RPMI 1640 medium with 1% (v/v) FBS, was used as control. 
Inhibition assay with TLR neutralizing antibodies. Human anti-TLR4 and anti-TLR2 antibodies 
(Invivogen) were added to U937 cells 1 h before the stimulation with bacterial cells. A human 
immunoglobulin-A (IgA) 2 isotype (Invivogen) was used as control to exclude non-specific 
binding and blocking activity of the antibody. Anti-TLR4, anti-TLR2 and IgA2 isotype were all 
used at 5 μg ml-1. This concentration was determined by examining the neutralizing efficacy with 
zymosan from Saccharomyces cerevisiae (Invivogen) as ligand for anti-TLR2, and LPS from E. 
coli 0127:B8 (Sigma-Aldrich); we observed that 5 μg ml-1 resulted in a 5-fold and 2-fold 
reduction when, respectively, anti-TLR2 and anti-TLR4 were used to partially block the action of 
their corresponding ligand in triggering the expression level of TNF-α, a cytokine known to be 
induced in the downstream pathway activated by TLR2 and TLR4 (Jones et al., 2001; Flo et al., 
2002). 
 
2.3.5 Isolation and differentiation of mouse bone marrow-derived macrophages 
(BMDMs)  
 Bone marrow cells from C57BL/6 mice were collected by flushing the femurs and tibias from 6- 
to 8-week-old mice with sterile PBS. Erythrocyte-depleted bone marrow cells were resuspended, 
counted and seeded in six-well plates at a density of 5×10
6
 cells ml
-1
 in RPMI medium (2 ml 
well
-1
) supplemented with 10% (v/v) heat-inactivated FBS (Gibco), penicillin (100 U ml
-1
), 
streptomycin (100 μg ml-1), glutamine (2 mM), 50 μM 2-mercaptoethanol, 15 mM HEPES 
(Sigma–Aldrich) and 30 ng ml-1 murine macrophage colony-stimulating factor (M-CSF) 
(Peprotech, Rocky Hill, NJ, USA). Cells were incubated at 37°C in 5% CO2 humidified 
atmosphere. After 24 h, non-adherent cells were transferred to new six-well plates with complete 
RPMI medium supplemented with 30 ng ml
-1
  murine M-CSF. On days 3 and 5, the cultures were 
fed by adding 1 ml well
-1
  of RPMI complete medium supplemented with 30 ng ml
-1
  murine M-
CSF, and the cells were allowed to grow and differentiate for 7–8 days. Purity of BMDM cell 
populations (>90%) was acquired by flow cytometry (BD FACSCanto II, San Jose, CA, USA) 
and analyzed by FlowJo software. APC-labeled anti-CD11c (N418) (eBioscience, San Diego, 
CA, USA) and PerCP-Cy5.5-labeled anti-F4/80 (BM8) (eBioscience) were used as antibody 
mixtures. Prior to stimulation, non-adherent cells were discarded by aspirating the medium and 
washing once with sterile PBS. Fresh RPMI media supplemented with 1% FBS was added to 
adherent cells and was kept at 37°C in a 5% CO2 humidified atmosphere for one h. Subsequently, 
macrophages were stimulated for 4 h. After stimulation, the cells were scraped and collected for 
RNA extraction. 
 
2.3.6 Isolation of mouse peritoneal cavity macrophages (PCMs)  
C57BL/6 mice were euthanized by CO2 inhalation. Cells were elicited from the peritoneal cavity 
by injecting 5 ml of cold, sterile PBS supplemented with 3% FBS (Gibco) and 2 mM EDTA. A 
gentle massage of the peritoneum was performed to dislodge any attached cells into the PBS 
solution. The fluid was then aspirated through a syringe and immediately transferred to 50 ml 
polypropylene tubes kept on ice. This procedure was repeated twice. Peritoneal cells were then 
centrifuged and resuspended in RPMI supplemented with 10% (v/v) heat-inactivated FBS, 
penicillin (100 U ml
-1
), streptomycin (100 μg ml-1), glutamine (2 mM), 50 μM 2-
mercaptoethanol, and 10 mM HEPES (Sigma-Aldrich). The cells were counted, seeded on 6 
2.3 Materials and Methods 
79 
 
well-plates at a density of 1×10
6
 cells ml
-1
, and cultured for 24 h at 37°C in a 5% CO2 humidified 
atmosphere. After 24 h, cells were washed three times with PBS to remove non-adherent cells, 
and fresh RPMI media supplemented with 1% FBS was added to adherent cells. After 1 h 
incubation at 37°C in a 5% CO2 humidified atmosphere, the macrophages were stimulated for 4 
h. Subsequently, the cells were scraped and collected for RNA extraction. 
 
2.3.7 Ethics statement  
All experimental methods have been accepted by the National Animal Experiment Board 
(Finland). 
 
2.3.8 Preparation of RNA and reverse transcription  
For both in vitro and ex vivo experiments, after incubating macrophages at 37°C for 4 h, the 
supernatant was carefully removed from each well and the total cellular RNA was isolated from 
the adhered cells with an RNeasy Mini Kit (Qiagen Inc., Valencia, CA, USA). Afterwards, RNA 
concentration and purity was determined with a Nanodrop Spectrophotometer (ND-1000, 
Thermo Fischer Scientific, Middletown, VA, USA) and reverse transcription to cDNA was 
performed with the iScript Select cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA) 
using the following thermal cycle: 5 min at 25°C, 30 min at 42°C, and 5 min at 85°C. Reverse 
transcription quantitative PCR (RT-qPCR). The mRNA expression levels of cytokines were 
analyzed with SYBR Green technology in RT-qPCR using SsoFast EvaGreen Supermix (Bio-
Rad Italia, Segrate, Italy) on a Bio-Rad CFX96 system according to the manufacturer's 
instructions. The primers used are as follow (5‟3‟): for human macrophages, 18S rRNA 
forward ATCCCTGAAAAGTTCCAGCA; 18S rRNA reverse CCCTCTTGGTGAGGTCAATG; 
IL10 forward AGCAGAGTGAAGACTTTCTTTC; IL10 reverse 
CATCTCAGACAAGGCTTGG; TNF-α forward TCAGCTCCACGCCATT; TNF-α reverse 
CCCAGGCAGTCAGATCAT; COX2 forward CCCTTGGGTGTCAAAGGTAA; COX2 reverse 
TGAAAAGGCGCAGTTTACG. For murine macrophages, 18S rRNA forward 
GTGATCCCTGAGAAGTTCCAG; 18S rRNA reverse TCGATGTCTGCTTTCCTCAAC; IL10 
forward GCCCAGAAATCAAGGAGCAT; IL10 reverse TGTAGACACCTTGGTCTTGGAG; 
TNF-α forward CTTCTGTCTACTGAACTTCGGG; TNF-α reverse 
CAGGCTTGTCACTCGAATTTTG; COX-2 forward TGTGCTGACATCCAGATCAT; COX-2 
reverse GGCAAAGAATGCAAACATCA. All primers were designed using the Primer3Plus 
software (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi), and the specificity 
of the primers was tested with melting curves during amplification and by 1% TAE agarose gel 
electrophoresis. Quantitative PCR was carried out according to the following cycle: initial hold at 
96°C for 30 s and then 40 cycles at 96°C for 2 s and 60°C for 5 s. Gene expression was 
normalized to the housekeeping gene coding for the18S rRNA. The amount of template cDNA 
used for each sample was 12.5 ng. All results regarding cytokine mRNA expression levels are 
reported as the fold of induction (FOI) in comparison to the control (namely unstimulated 
macrophages), to which we attributed a FOI of 1. 
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2.3.9 Statistical analysis  
The significance of the results was analyzed by unpaired heteroscedastic Student‟s t test with 
two-tailed distribution. Differences of P < 0.05 were considered to be significant. 
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2.4 RESULTS AND DISCUSSION 
2.4.1 Extraction, purification and analysis of MIMLh5 S-layer protein  
The S-layer protein (SlpA) of L. helveticus MIMLh5 was extracted with LiCl and purified as 
described in the methods section. We verified that the protocol based on LiCl-washes efficiently 
removed most of the S-layer protein from the surface of L. helveticus cells. In fact, when we 
loaded the LiCl-treated and LiCl-untreated bacterial cells resuspended in SDS-PAGE loading 
buffer on a polyacrylamide gel, the electrophoretic profiles displayed a nearly complete 
disappearance of the band corresponding to SlpA (Fig.2.4.1A). SDS-PAGE and RP-HPLC 
analyses revealed that the protein was purified to apparent homogeneity (Fig. 2.4.1B, C and D). 
Furthermore, we did not consider as possible the contamination of the S-layer preparation with 
lipoteichoic acids (LTA), because it was previously demonstrate that LiCl treatments do not 
remove LTA from L. helveticus cells (Mozes & Lortal, 1995). Mass spectrometry indicated a 
molecular mass of 43853 Da, which is consistent with the average molecular mass calculated 
from the amino acid sequence deduced from the slpA gene sequence (Fig. 2.4.1E). 
 
 
Figure 2.4.1 Biochemical characterization of L. helveticus 
MIMLh5 S-layer protein. A, SDS-PAGE profile of MIMLh5 
cells before (lanes 1-3) and after (3-6) treatment with LiCl 
solutions. B (Coomassie-blue staining) and C (silver 
staining), SDS-PAGE profile of purified S-layer protein; 50 
ng to 3 µg of protein have been loaded per well on the gel. 
D, HPLC profile of purified S-layer protein. E, ESI-MS 
spectrum of the S-layer protein and reconstructed mass 
spectrum, indicating an average mass value of 43853 Da. 
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2.4.2 L. helveticus MIMLh5 reduces NF-κB activation in transfected Caco-2 cells  
In this study, we investigated L. helveticus, a bacterium specialized for colonizing dairy 
environments and traditionally used in the manufacture of Swiss-type and long-ripened Italian 
cheeses. Phylogenetically, L. helveticus is closely related to L. acidophilus (the 16S rDNA 
sequences of these bacteria differ by just 1.6%; Callanan et al., 2008), an intestinal bacterium 
regularly used as a probiotic and thoroughly investigated for its ability to modulate host immune 
responses (Konstantinov et al., 2008; Weiss et al., 2010; Maroof et al., 2012; Taverniti & 
Guglielmetti, 2012). Studying the interaction of the dairy bacterium L. helveticus with the host 
immune system could provide important insights into the health-modulating potential of a 
bacterium that, in contrast to the intestinal/probiotic L. acidophilus, had its adaptive evolution in 
dairy environments and, therefore, outside of a human/animal host. We performed a preliminary 
immunological characterization of L. helveticus MIMLh5 using a reporter cell line obtained by 
transfecting Caco-2 cells with a luciferase reporter vector induced by active NF-κB. Therefore, 
we compared MIMLh5 with the well-described commercial probiotic strain, L. acidophilus 
NCFM, which we included as a reference. In these experiments, L. helveticus MIMLh5 and L. 
acidophilus NCFM cells from an overnight culture were incubated with the transfected Caco-2 
layer for 4 h at 37°C at an MOI of 1000. Similar to what we observed in our previous studies on 
the pharyngeal epithelial FaDu cell-line, L. helveticus MIMLh5 significantly reduced NF-κB 
activation both at baseline and in the presence of IL-1β (Fig. 2.4.2); bioluminescence was, in fact, 
always significantly lower when bacterial cells were added to the Caco-2 layer compared to the 
unstimulated control. In both tested conditions, strain MIMLh5 was significantly more effective 
in the immunomodulatory activity than L. acidophilus NCFM (Fig. 2.4.2). 
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Figure 2.4.2 Effect of Lactobacillus acidophilus NCFM, Lactobacillus helveticus MIMLh5 and 
its purified S-layer protein on human epithelial colorectal Caco-2 cells stably transfected with an 
NF-κB/luciferase reporter vector at baseline (A) or stimulated with 2 ng ml-1 of IL-1β (B). A 
recombinant Caco-2 layer was incubated with EMEM medium only (A) or with the addition of 
IL-1β (B). Bacterial strains were used at a multiplicity of infection (MOI) of 1000 (bacterial cells 
per Caco-2 cell). S-layer protein was tested at two different concentrations (100 and 10 μg ml-1). 
Data in histograms are the means (+ standard deviations) from at least three independent 
experiments conducted in triplicate. Data are reported as percentage variation of light emission 
(relative luminescence units, RLU), assuming that the corresponding control was 100%. 
Asterisks indicate statistically significant differences: ***, P < 0.001; **, P < 0.01; *, P < 0.05. 
 
      
 
2.4.3 S-layer protein from L. helveticus MIMLh5 reduces the activation of NF-κB in 
recombinant Caco-2 cells  
In the following part of the study we proceeded with the characterization of strain MIMLh5 by 
studying the possible involvement of the S-layer protein (SlpA) in mediating bacterial effects on 
the host immune system. SlpA protein is an abundant molecule present on the outer surface of all 
L. helveticus strains, constituting up to 15% of total Lactobacillus protein content (Åvall-
Jääskeläinen & Palva, 2005). For L. helveticus, SlpA forms approximately 45% of the cell 
wall dry weight (Messner et al., 1997). Even if many functions have been 
suggested/hypothesized (Beveridge et al., 1997; Horie et al., 2002; Smit et al., 2002), the actual 
role of the S-layer protein remains elusive. We isolated the S-layer protein from strain MIMLh5 
to employ in experiments on recombinant Caco-2 cells. We found that similar to whole bacterial 
cells, purified S-layer protein was able to significantly reduce the activation of NF-κB at both 
concentrations tested (Fig. 2.4.2). Studies concerning the effects of Lactobacillus S-layer proteins 
on intestinal epithelial cells have already been performed (Frece et al., 2005; Johnson-Henry et 
al., 2007). Specifically, the properties described to date refer mainly to the role of S-layer 
proteins in mediating the bacterium‟s ability to antagonize pathogens due to the capability of the 
protein to efficiently adhere to the intestinal epithelium. This effect has been demonstrated for the 
L. helveticus (Kos et al., 2003; Frece et al., 2005) and L. acidophilus strains (Smit et al., 2002; 
Buck et al., 2005). Nonetheless, the S-layer protein was also demonstrated to exert direct effects 
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on the immune responses of intestinal epithelial cells. For instance, it was shown that the S-layer 
protein from L. acidophilus ATCC 4356
T
 reduced Salmonella Typhimurium FP1-induced 
apoptosis in Caco-2 cells, and this effect was dependent on the inhibition of caspase-3 activation 
(Li et al., 2011). In another study, the oral immunization of mice with the purified SlpA from L. 
helveticus M92 induced an increase in total levels of serum IgG, IgM and IgA (Beganović et al., 
2011). 
 
2.4.4 MIMLh5 strain and its S-layer protein elicit pro-inflammatory responses in human 
U937 macrophages  
After a preliminary immunological investigation performed on epithelial cells, we employed cells 
belonging to the innate immune system to study the host‟s immune responses triggered by L. 
helveticus MIMLh5 and its S-layer protein. We used macrophages, which are professional 
phagocytes serving as sentinels to detect microbial host invaders (Benoit et al., 2008). 
Macrophages undergo activation upon environmental signals, including microbial products and 
cytokines (Aderem & Underhill, 1999). We quantified via RT-qPCR the gene expression of 
TNF-α (a cytokine involved in inflammatory responses; Belardelli, 1995), IL-10 (a 
multifunctional cytokine whose principal routine function appears to be to limit and ultimately 
terminate inflammatory responses; Fiorentino et al., 1991; D‟Andrea, 1993) and COX-2. COX-2 
is a homodimeric enzyme involved in the synthesis of prostaglandins (PGs), which are hormones 
that participate in physiological processes such as inflammation, as well as in protecting the 
gastrointestinal mucosa (Williams et al., 1999; Morteau et al., 2000). After 4 h of stimulation of 
the U937 cells, MIMLh5 induced a pronounced pro-inflammatory profile at MOI 100 and 1000, 
as evidenced by an enhanced induction of COX-2 and TNF-α compared to IL-10 (Fig. 2.4.5A). 
The cytokine-expression profile of the purified S-layer protein was similar to that induced by the 
MIMLh5 strain itself. The involvement of the S-layer protein in the immunostimulating effects of 
MIMLh5 was also confirmed in experiments involving bacterial cells without the S-layer (i.e., 
after LiCl-extraction of the protein). In fact, we observed that at MOI 1000, the removal of the S-
layer resulted in a decrease in COX-2 and TNF-α induction levels, whereas IL-10 levels did not 
change (Fig. 2.4.5A). A similar trend was observed at MOI 100, even if the data are not 
statistically significant (Fig. 2.4.5A). Furthermore, the addition of the purified S-layer protein to 
MIMLh5 cells without S-layer proteins resulted in a significant increase of COX-2 and TNF-α 
gene expression, while IL-10 remained unaffected (Fig. 2.4.5A). These results indicate that the S-
layer protein from strain MIMLh5 could be primarily involved in inducing the expression of the 
pro-inflammatory factors COX-2 and TNF-α in human U937 macrophages. 
 
2.4.5 Bone marrow-derived macrophages (BMDMs) display a pro-inflammatory profile 
upon stimulation with MIMLh5 and its S-layer protein  
After the in vitro evaluation of the immunological activity of L. helveticus MIMLh5 and the 
purified S-layer protein on human U937 macrophages, we used the same approach to study their 
effects in ex vivo experiments by isolating and differentiating macrophages from mouse bone 
marrow. Similar to our previous results with human macrophages, we found that L. helveticus 
MIMLh5 induced, at both MOIs tested, a clear pro-inflammatory profile, as evidenced by a 
strong induction of COX-2 and TNF-α but not IL-10 (Fig. 2.4.3). The results obtained by 
incubating BMDMs with S-layer protein confirmed the pro-inflammatory properties of the 
protein on murine macrophages (Fig. 2.4.3). Furthermore, when we exposed BMDMs to the 
bacterium after the elimination of the S-layer, we observed a trend of reduction (although this 
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result was not statistically significant) of TNF-α levels for MIMLh5 (particularly at the highest 
MOI tested), whereas the absence of the protein led to a slight increase of IL-10 levels (Fig. 
2.4.3).  
Thus, both in experiments on human U937 macrophages and on murine BMDMs, MIMLh5 
exerted pro-inflammatory effects by inducing high levels of TNF-α and COX-2 and lower levels 
of IL-10. Interestingly, the purified SlpA extracted from L. helveticus MIMLh5, according to the 
expression levels of TNF-a and COX2, seems to be responsible for the pro-inflammatory 
behavior of the whole bacterium, as also confirmed by the experiments performed with SlpA-
depleted MIMLh5 cells (Fig. 2.4.3 and Fig. 2.4.5A). 
The ability to induce pro-inflammatory cytokines has already been shown in lactic acid bacteria 
(LAB) (Christensen et al., 2002; Morita et al., 2002; Peridigón et al., 2002; Ongol et al., 2008). 
Nonetheless, such ability of LAB should not be considered detrimental. In fact, even though 
cytokines belonging to the TNF-α superfamily are connected to the occurrence of inflammatory 
diseases (Kwon et al., 2010), they have also been shown to participate in the rejection of tumors 
and infections (Yasutake et al., 1999; Dinarello, 2003; Wajant et al., 2003). Furthermore, the 
induction of TNF-α could be important for the initiation of cross-talk among immune cells 
without causing any inflammation or detrimental effects (Galdeano et al., 2007). In addition, a 
transient inflammatory state could aid host defense. As recently suggested, differences among 
pathogenic, probiotic and commensal microorganisms lie in the magnitude of the immune 
response evoked, which can be defined as strong, intermediate or homeostatic (Lebeer et al., 
2010). 
Similarly, the up-regulation of COX-2 induced by LAB has been demonstrated both in vitro 
(Otte et al., 2009; Khailova et al., 2010) and in vivo (Khailova et al., 2010; Kwon et al., 2010). 
The pro-inflammatory role of COX-2, however, has recently been questioned. In fact, it has been 
proposed that COX-2 can induce the resolution of inflammation (Wallace, 2006) and an 
immunosuppressive phenotype in T-cells (Newberry et al., 1999) through the activity of PGs. In 
addition, it has also been shown that a rapid COX-2 up-regulation in response to injury or 
inflammation helps to restore mucosal integrity (Tan et al., 2000). In this context, the effects of 
MIMLh5 and SlpA on COX-2 expression could potentially be beneficial for the host‟s mucosa. 
The ability of specific cell wall components to drive the immune response elicited by LAB has 
been rarely described (de Ambrosini et al., 1996; Tejada-Simon & Pestka, 1999). Concerning S-
layer proteins, Konstantinov and colleagues (2008) demonstrated that SlpA from L. acidophilus 
NCFM mediates the interaction of the bacterium with human monocyte-derived dendritic cells 
(DCs) by specifically binding to the ligand of the dendritic cell-specific intercellular adhesion 
molecule (ICAM)-3-grabbing non-integrin (DC-SIGN). Even if the purified SlpA protein of 
NCFM did not affect DCs maturation, it was responsible for the anti-inflammatory cytokine 
profile observed for L. acidophilus NCFM because the protein induced higher levels of IL-10 in 
the presence of LPS when compared to SlpA or LPS alone.  
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Figure 2.4.3 Quantitative analysis of cytokine gene expression in murine bone marrow-derived 
macrophages (BMDMs) after 4 h stimulation with L. helveticus MIMLh5 and its S-layer protein. 
Expression levels of TNF-α, IL-10 and COX-2 are indicated as the fold change of induction 
(FOI) relative to the control (unstimulated BMDMs), which was set at a value of 1. LPS was used 
as a positive control at a concentration of 1 μg ml-1. S-layer protein was tested at a concentration 
of 10 μg ml-1. MIMLh5 was used at MOIs 1000 and 100. MIMLh5 w/o Slay: MIMLh5 cells after 
removal of the S-layer protein by LiCl-extraction. Presented data are the means of measurements 
(+ standard deviations) for a result representative of three independent experiments. Asterisks 
indicate statistically significant differences compared to results for the corresponding control (*: 
P < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
In comparison to the SlpA of L. acidophilus NCFM, our data suggest that the S-layer protein 
isolated from L. helveticus MIMLh5 exhibits a more pronounced pro-inflammatory behavior. 
Although the S-layer proteins of L. acidophilus NCFM and L. helveticus MIMLh5 are highly 
similar (73% identity, 83% positivity; Data not shown), it has been suggested that even small 
differences in surface proteins could alter the type of immune responses elicited by LAB 
(Vinderola et al., 2004; Lebeer et al., 2010). Nonetheless, the most plausible explanation for the 
different immunological behavior observed between MIMLh5 and NCFM SlpAs (Konstantinov 
et al., 2008) could reside in the different cell models utilized. 
When we tested strain L. helveticus MIMLh5 and its SlpA on macrophages, we observed an 
immunological effect (stimulation of the pro-inflammatory factors) that was substantially 
different from what was noted for epithelial cells (i.e., inhibition of NF-κB activation). These 
results are not surprising, considering that macrophages are immune cells that can express class 
and number of receptors on their cell surface considerably different from epithelial cells. This 
fact might result in recognition through diverse mechanisms and activation of alternative 
signaling pathways. Moreover, it is plausible (and desirable) that a potential probiotic candidate 
and its cell components do not trigger any inflammatory response at the host epithelium. This 
type of non-inflammatory interaction can be assimilated to a mechanism of oral tolerance, which, 
in vivo, is due to the natural cohabitation of epithelial cells with commensal and/or food-
associated bacteria. In contrast, when bacteria come in direct contact with immune cells, for 
instance, when they cross the epithelial barrier following loss of epithelial integrity, the immune 
system is typically alerted through pro-inflammatory signaling. 
2.4 Results and Discussion 
87 
 
2.4.6 The S-layer protein from the strain MIMLh5 induces pro-inflammatory activity in 
murine peritoneal cavity macrophages (PCMs)  
 Once we defined the immune profile induced by MIMLh5 and its S-layer protein in vitro on 
human U937 cells and ex vivo on BMDMs, we verified whether the same pro-inflammatory 
response could be confirmed in tissue-specialized macrophages. To this aim, we employed 
macrophages isolated from the mouse peritoneal cavity. Unlike the previous results, when we 
used the whole bacterium, we observed a balanced profile between pro- and anti-inflammatory 
cytokines in PCMs because the induction of IL-10 was not lower than the induction of TNF-α 
(Fig. 2.4.4). However, consistent with our findings in U937 cells and BMDMs, the S-layer 
protein triggered higher levels of COX-2 and TNF-α compared to IL-10 in peritoneal 
macrophages (Fig. 2.4.4). Furthermore, in contrast to U937 cells and BMDMs, the pro-
inflammatory factor levels induced in PCMs by the S-layer protein were almost equal to the 
levels induced by LPS. This pronounced pro-inflammatory activity was shown to be dose-
dependent because when we tested a lower concentration of the protein, 0.1 μg ml-1, TNF-α and 
COX-2 levels were lower compared to LPS, although the pro-inflammatory factor profile was 
qualitatively the same. The results obtained by employing PCMs, therefore, confirm the 
involvement of S-layer protein principally in promoting pro-inflammatory immune responses. 
 
Fig. 2.4.4 Quantitative analysis of cytokine gene expression in murine macrophages isolated 
from peritoneal cavity after 4 h stimulation with L. helveticus MIMLh5 and its S-layer protein. 
Expression levels of TNF-α, IL-10 and COX-2 are shown as the fold change of induction (FOI) 
relative to the control (unstimulated peritoneal macrophages), which was set at a value of 1. LPS 
was used as a positive control at a concentration of 1 μg ml-1. S-layer protein was tested at 
concentrations of 10 and 0.1 μg ml-1. MIMLh5 was used at MOIs 1000 and 100. Presented data 
are the means of measurements (+ standard deviations) for a result representative of three 
independent experiments. 
 
 
This finding suggests that MIMLh5 bacterial cells could be more prone to induce an anti-
inflammatory response in this cellular system compared to U937 cells and BMDMs. Such 
different behavior can be explained by considering that different immune responses can be 
induced by the same stimulus depending on the cell type, origin and polarization (Habil et al., 
2.4 Results and Discussion 
88 
 
2011). Moreover, because BMDMs and U937 cells have been maturated in vitro, it is plausible 
that they are less physiological than PCMs, and that they could not possess all the features of 
matured macrophages. It could also be speculated that macrophages from the peritoneal cavity 
can present different phenotypes compared to other macrophage populations due to the activity 
exerted on PCMs by the intestinal microbiota, which can promote a more tolerogenic activity 
based on differential expression of  pattern-recognition receptors (PRRs). Accordingly, the 
induction of an anti-inflammatory cytokine profile by lactobacilli has been observed in murine 
PCMs (Marcinkiewicz et al., 2007). Nonetheless, in comparison to whole bacterial cells, the pro-
inflammatory effect of S-layer protein was particularly evident in PCMs. In fact, for MIMLh5 
cells, the TNF-α/IL-10 ratios were 0.84 at MOI 100, 0.35 at MOI 1000, and approximately 3.7 
when purified SlpA protein was used as a stimulus. 
 
2.4.7 Toll-like receptor (TLR)-2 is involved in the recognition of the S-layer protein from 
strain MIMLh5 in human U937 cells  
To gain information about the possible signaling pathways underlying the immune response 
activated by the S-layer protein isolated from L. helveticus MIMLh5, we evaluated whether 
TLR2 and TLR4 could be involved in the recognition of this protein. To this aim, we used 
neutralizing antibodies (Abs) on U937 cells to partially block the ability of TLR2 and TLR4 to 
bind ligands prior to the addition of the S-layer protein. We found that TLR2 and, to a lesser 
extent, TLR4 are involved in mediating the pro-inflammatory response elicited by S-layer protein 
because the treatments with Abs significantly reduced the S-layer-induced activation of TNF-α 
and COX-2, but not IL-10 (Fig. 2.4.5B). TLR2 is a receptor that was previously shown to be 
involved in mediating the immunological effects of LAB (Konstantivov et al., 2008; Zeuthen et 
al., 2008; Vizoso et al., 2009; Weiss et al., 2010). The observed differences when anti-TLR2 was 
used, either alone or in combination with anti-TLR4, were statistically significant compared to 
U937 cells stimulated with S-layer protein in the presence of Immunoglobulin-A2 isotype 
(IgA2), which was used as a control for nonspecific blocking activity. From these data, we can 
hypothesize that the S-layer, which is the outermost part of the bacterial cell wall, might come in 
contact first with host cells, mediate bacterial recognition, and therefore play a key role in 
triggering the immune response. 
 
2.4.8 S-layer protein modulates the pro-inflammatory response triggered by LPS in 
human U937 macrophages  
In a final set of experiments, we tested the effects of the S-layer protein on U937 cells in 
presence of LPS. Interestingly, we observed that the presence of the S-layer protein induced a 
clear reduction in the pro-inflammatory cytokine TNF-α, compared with the levels induced by 
LPS alone (Fig. 2.4.5C). These results suggest that although the S-layer protein and LPS 
presented similar pro-inflammatory effects, the simultaneous presence of both stimuli did not 
result in an additive or synergistic effect on the pro-inflammatory response. Rather, the addition 
of the S-layer protein induced a reduction of the stimulating activity of LPS. In our experiments 
on macrophages, the SlpA of MIMLh5 induced a cytokine profile qualitatively similar to that 
evoked by LPS; nonetheless, the cytokine induction levels on human U937 cells and murine 
BMDMs were lower for the S-layer protein than for LPS. In peritoneal macrophages, the S-layer 
protein triggered a cytokine induction similar to LPS only when ten-times more S-layer protein 
(10 µg) was present compared to LPS (1 µg).  
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Figure 2.4.5. Quantitative analysis of cytokine gene expression in U937 human macrophages 
after 4 h of stimulation. Expression profiles of TNF-α, IL-10 and COX-2 are indicated as the fold 
change of induction (FOI) relative to the control, which was set at a value of 1. Presented data 
are the means (+ standard deviations) for a result representative of three independent 
experiments. Asterisks indicate statistically significant differences: **, P < 0.01; *, P < 0.05. A, 
U937 cells stimulated with L. helveticus MIMLh5 (MOIs 1000 and 100) and its S-layer protein 
(10 μg ml-1); control: unstimulated U937 cells; MIMLh5 w/o Slay: MIMLh5 cells after LiCl-
extraction of the S-layer protein; MIMLh5 w/o Slay + Slay: S-layer-depleted MIMLh5 cells 
supplemented with 10 μg ml-1 of the purified S-layer protein; lipopolysaccharide (LPS) was used 
as a positive control at a concentration of 1 μg ml-1. B, Cytokine expression profiles in the 
presence of neutralizing antibodies against TLR2 (a-TLR2) and TLR4 (a-TLR4); 
immunoglobulin-A2 isotype (IgA2) was used as a control for nonspecific blocking activity; IgA2 
and anti-TLRs were added at a concentration of 5 μg ml-1  on U937 cells 1 h before stimulation 
with the S-layer protein; anti-TLR2/4: anti-TLR2 and anti-TLR4 simultaneously added at a 
concentration of 2.5 μg ml-1  each; control: U937 cells incubated with IgA2). C, Cytokine 
expression profiles in U937 cells stimulated with L. helveticus MIMLh5 S-layer protein and LPS; 
LPS and S-layer were added at a concentration of 1 μg ml-1  and 10 μg ml-1, respectively, both 
when used alone and in association; control: unstimulated U937 cells. 
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These data indicate that the SlpA of MIMLh5 is not a pro-inflammatory stimulus as potent as 
LPS. We could hypothesize that the S-layer alone, in basal conditions, may exert a mild 
stimulatory effect on the immune system. However, in the presence of an inflammatory stimulus, 
such as LPS, the MIMLh5 S-layer could act as an immune modulator, representing a potential 
protective element against the septic shock caused by LPS, as already observed in murine models 
for certain probiotic bacteria (Arribas et al., 2009a;b). 
Since S-layer protein and LPS interact with different TLRs, the observed modulatory effect of 
the S-layer protein should not be attributed to a competition for the same host cells‟ receptors 
but, more likely, to an activation of different immune response pathways. 
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2.5 CONCLUSIONS 
The cross-talk between host and intestinal/probiotic bacteria principally relies on the capacity of 
host cells to recognize specific bacterial components or products, thus giving rise to responses 
that most frequently involve the mucosa-associated lymphoid tissue (MALT) and, therefore, the 
immune system (Adams, 2010; Taverniti & Guglielmetti, 2011). Specifically, cell surface 
components of commensal or food/probiotic bacteria, known as microbe-associated molecular 
patterns (MAMPs), can be identified by pattern recognition receptors (PRRs) on host‟s cells 
constituting the innate immune system, resulting in the activation of immune responses. The 
molecular mechanisms of such immune modulations are largely unknown. Therefore, the 
immunological characterization of single bacterial components, according to the strategy 
undertaken during this study, represents a reductionist approach of key importance for the 
elucidation of host–microbial interplays and bacterial modes of action that result in the immune 
modulation. In this study, we characterized the dairy strain Lactobacillus helveticus MIMLh5 and 
its surface layer protein (SlpA) using in vitro and ex vivo analyses. We found that MIMLh5 and 
SlpA exert anti-inflammatory effects by reducing the activation of NF-κB on the intestinal 
epithelial Caco-2 cell line. On the contrary, MIMLh5 and SlpA act as stimulators of the innate 
immune system by triggering the expression of pro-inflammatory factors (Taverniti et al., 2012). 
These results must not be surprising, since several studies reveal that probiotics exert stimulatory 
effects rather than suppressory effects on innate immunity. This mechanism is similar to a 
“physiologic inflammation”, like the one induced by the commensal flora, that can be useful for 
immune system development and for combating pathogens (Pagnini et al., 2010). 
Furthermore, our study supports the concept that the viability of bacterial cells is not always 
essential to exert immunomodulatory effects (Adams, 2010). In fact, dead or inactivated bacterial 
cells, or even their single molecular components, might also be effective in exerting beneficial 
immunostimulating properties, thus permitting the development of safer therapies for the 
treatment of specific diseases. This approach has recently been defined as paraprobiotic 
intervention (Taverniti & Guglielmetti, 2011). In addition, a deeper understanding of the 
molecular mechanisms of cross-talk between bacteria and the host organism‟s system is of great 
importance to better define the benefits and potential risks associated with the administration of 
probiotic therapies (Besselink et al., 2008). 
Moreover, the possible medical and clinical uses of the S-layer protein are particularly intriguing, 
especially in light of the physicochemical properties of this molecule. The S-layer proteins are 
crystalline arrays of subunits forming a highly regular crystalline structure that has the capacity 
to reassemble spontaneously in suspension at the liquid-air interface, at solid surfaces, at floating 
lipid monolayers, on liposomes, and on nanocapsules (Sleytr et al., 2003; Sleytr et al., 2007). 
These features could support the use of the S-layer protein as a bioactive coating material, as a 
matrix for the immobilization and delivery of different molecules, and as a template for the 
formation of regularly arranged bioactive nanoparticles (Pum & Sleytr, 1999). Future efforts will 
explore the feasibility of such applications. 
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3.1 STATE OF THE ART 
3.1.1 Anthocyanins: chemical structure, sources and bioavailability 
Berries such as cranberries, blueberries, strawberries, blackcurrant and raspberries contain 
significant amounts of non-nutritive phytochemicals including polyphenols and other 
antioxidants. Polyphenols are defined chemically as substances that have an aromatic ring with 
an hydroxyl substituents, including esters and glycosides. Polyphenols are grouped in different 
classes (Fig. 3.1.1) on the basis of the number of phenolic rings and of the type and number of 
elements bound to the rings (Manach et al., 2004).  The classes include: simple phenolic acids; 
stilbenes; more complex chalcones; flavonoids, divided into seven subclasses that include 
flavonols, flavanols, flavones, flavanones, flavanonols, isoflavones and anthocyanins (Nicholson 
et al., 2008).  
 
 
Figure 3.1.1. Polyphenol classes in fruit and vegetables. 
 
 
 
Anthocyanins (ACNs) compounds, of the flavonoid class, are natural pigments that provide 
colours ranging from dark blue to purple to fruits and vegetables, including edible berries. They 
can be found in nature in different structural arrangements (Fig. 3.1.2) depending on the number 
of glycosilating sugars, their position in the aglycone (anthocyanidin) and the degree and nature 
of esterification of the sugar with aliphatic or aromatic acids (Giordano et al., 2007). 
Flavonoids in general exist in plant predominantly as glycoside conjugates. The absorption of 
some (but not all) components into the circulatory system occurs in the small intestine 
(Silberberg et al., 2006). Flavonoids and their metabolites which have not been absorbed in the 
small intestine can be absorbed in the large intestine, upon colonic microflora action, which will 
lead to the production of phenolic acids and hydroxycinnamates. These molecules can also be 
absorbed and ultimately excreted in urine system (Manach et al., 2005).  
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Fig. 3.1.2 Chemical structures of selected anthocyanidins (Adapeted from Nicholson et al., 
2008.) 
 
 
 
 
Wild blueberry (WB, Vaccinium augustifolium) is one of the richest sources in ACNs and is 
composed of different anthocyanidins such as delphinidin, malvidin, petunidin, cyanidin and 
peonidin. (Bushway et al., 1983). 
 
In a recent study it was found  that following the intake of a blueberry product, ACNs were 
rapidly absorbed, and their plasma concentration increased 1 h after consumption, achieving their 
maximum concentration at 1.5 h. In particular, the main compounds found at plasma levels were 
Cyanidin-3-glc, Malvidin-3-glc, and Delphinidin-3-glc (Del Bo‟ et al., 2012).  
Moreover the excretion of hippuric acid increased  within 24−48 h demonstrating that ACNs and 
other phenolic compounds were absorbed and metabolized.  
Interestingly metabolites of ACNs in the plasma, urine, feces, and tissues were also found  in an 
animal model, the Sprague-Dawley (SD) rats fed with a wild blueberry-enriched diet (8%) for 4 
and 8 weeks (Del Bo‟ et al., 2010). However it was not possible to detect their native forms in 
liver, brain tissues or in the plasma since ACN metabolites are rapidly metabolized and the 
animals were sacrificed 3-4 h after the last meal, as also confirmed in previous studies (Felgines 
et al., 2002). ACNs content in the urine significantly increased at 8 weeks compared to that at 4 
weeks. The percentage of intake that is absorbed can varys with structure and the food matrix. 
The exact yields and proportions of metabolites from any substrate can be also dependent on the 
individual's genetic profile and on the composition and competence of the individual's intestinal 
microbiota. In fact since most of the ACNs introduced with foods reach the colon, they can be 
extensively metabolized by intestinal microbiota, which contribute to the bioavailability and 
bioefficacy of ACNs and phenolic compounds in the systemic circulation. Moreover, it has been 
recently documented that ACNs and phenolic compounds from wild blueberry can positively 
modulate the composition of intestinal microbiota and promote the colonization of the 
gastrointestinal tract by beneficial bacteria (i.e., Bifidobacterium spp. and Lactobacillus spp.) at 
the expense of unhealthy bacteria (Vendrame et al., 2011). 
 
 
 
 
3.1 State of the art 
102 
 
Figure 3.1.3 Absortption and excretion of ACNs and metabolites. (A) Total plasma ACN, (B) Mv-
3-glc, and (C) Cy-3-glc concentrations after the consumption of 300 g of unblanched (NB-P) and 
blanched (BL-P) blueberry pur es. Data are mean   SD. (A) BL-P was significantly different 
with respect to NB-P at 1.5 and 2 h; p ≤ 0.05. (B) BL-P at 2 h was significantly different with 
respect to BL-P at 1 h; p ≤ 0.05. D) Total hippuric acid concentration in urine before and 24 and 
48 h after the consumption of the unblanched (NB-P) and blanched (BL-P) blueberry pur es. 
Data are mean ± SD. Data with different letters are significantly different at p ≤ 0.05. 
 
 
 
 
3.1.2 Biological activities of ACNs 
Different health-promoting properties have been attributed to anthocyanins. 
The most documented and important property is the antioxidant activity (capacity to scavenge 
free-radicals) since it is involved in the development of several chronic degenerative diseases 
(Espin et al., 2007). Several studies, moreover, have shown that ACNs can play a critical role in 
promoting host health through diverse mechanisms: amelioration of lipid profile and vasomotor 
tone, modulation of detoxifying enzyme, reduction of blood pressure (Mazza et al., 2002; Norton 
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et al., 2005; Del Bo‟ et al., 2010), and by exerting anti-inflammatory and antitumoral properties 
(Bagchi et al., 2004).  
Particularly, anti-inflammatory abilities have been demonstrated to be partially due to a direct 
action on host immune system (Karlsen et al., 2007). Many phenolic compounds have been 
shown to exert their effects through the modulation of pro-inflammatory cytokines, which are the 
chemical mediators of the immune system, involved in the cross-talk and priming.of the immune 
cells. Phenolic compounds in fact can be recognized by specific receptors of the intestinal 
mucosa triggering specific immune responses. Consequently, it has been proposed that they may 
decrease the risk of individuals to develop pathologies related to chronic exposures to pro-
inflammatory cytokines (Clarke & Mullin, 2008). As an example, in fact, some pure polyphenols, 
such as quercetin, have been demonstrated to inhibit nuclear factor κB (NF-κB) activation in 
intestinal models of inflammation (Romier et al., 2008). The transcriptional regulator NF-κB is a 
transcriptional inducer of several inflammatory cytokines and is a therapeutic target in a wide 
range of human (auto)inflammatory diseases (Yamamoto & Gaynor, 2001).  
In particular the effects described for ACNs seem to be dependent on the inhibition of NF-kB 
activation and down-stream signals, and possibly on modulating effects on other pro-
inflammatory pathways (Calixto et al., 2004). Nevertheless, no single or definitive mechanism 
can explain all the effects of polyphenol compounds that appear to be signal specific and cell 
type dependent, with no general rule governing structure/activity relationships.  
Further investigations are therefore necessary to validate a potential beneficial role of singles or 
mixtures of polyphenols contained in foods. 
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3.2 AIMS OF THE STUDY 
Wild blueberry has been hypothesized to exert immunomodulatory potential due to its high 
content of ACNs and other bioactives. Considered the abilities, already reported in literature, of 
bioactive molecules of food-origins to exert anti-inflammatory effects on the host (like ACNs 
and other polyphenols), we wanted  to better investigate the single contribution of different  
fractions isolated from wild blueberries. To this aim we extracted and characterized three 
fractions from WB and tested their immunomodulatory potential both on intestinal epithelial cells 
and on cells properly belonging to the innate immune system. 
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3.3 MATERIALS AND METHODS 
3.3.1 Extraction and characterization of different fractions from Wild Blueberry 
(Vaccinium angustifolium) Powder  
Extraction of bioactives from WB. Soluble (sugars and organic acids), phenolic (Phe) and 
anthocyanin (ACN) fractions were obtained from a freeze-dried Wild Blueberry (WB) powder 
provided by Future-Ceuticals Company (Momence, IL, USA). Extraction was performed 
following a method described by Wrolstad (2005) with few modifications. Briefly, the powder 
was suspended in a 1% TFA aqueous solution, sonicated for 10 min, and centrifuged at 3000 × g 
for 10 min. Fractions separation from the supernatant was obtained through solid-phase 
extraction (SPE)-cartridge (Strata-X  3 ml, Phenomenex, Torrence, CA) preactivated with 
methanol (5 ml) and then washed with water (5 ml). The elution of soluble, Phe and ACN 
fractions were carried out respectively with HCl 0.01 N (5 ml), ethyl acetate (10 ml) and 
methanol (5 ml) containing 0.1% HCl,. The fractions were dried under vacuum with rotavapor 
(RC Jouan 10, Jouan,  Winchester, VA) at 20°C for ACN, 40°C for Phe and up to 60°C for the 
soluble fraction. The residues were dissolved in methanol acidified with HCl (0.05 mM) for the 
ACNs, methanol for the Phe, and water for the soluble fractions. The solutions were analyzed for 
the content of ACNs, Phe, sugars and organic acids, and stored at -20°C until use. 
 
Analysis of Anthocyanin and phenol fractions. The analysis was performed with a liquid 
chromatographic system, which consisted of an Alliance mod. 2695 (Water, Milford, MA) 
equipped with a mod. 2998 photodiode array detector (Waters). The separation was carried out 
through a C18 Kinetex column (150 x 4.6 mm, 2.6 µm, Phenomenex, Torrence, CA) at 45°C and 
1.7 ml/min as flow rate. The eluents were (A) 1% H3PO4 and (B) acetonitrile/water (35:65, v/v). 
The elution gradient was linear as indicated: 0-15 min 14% B; 15-25 min from 14 to 20% B; 25-
35 min from 20 to 32% B; 35-45 min from 32 to 50% B; 45-48 min from 50 to 90% B; 90 % for 
3 minutes. Chromatographic data were acquired from 200 to 700 nm and integrated at 520 
(anthocyanins) and 320 nm (phenolic acids). Calibration curves ranged from 2 to 50 mg l
-1
 were 
obtained for cyanidin (Cy-), delphinidin (Dp-), petunidin (Pt-), peonidin (Pe-) and malvidin (Mv-
) 3-O-glc, Cy- and Pt-3-O-gal and Pt-3-O-ara and chlorogenic acid. For the anthocyanins, the 
working solution was diluted from the stock solution with methanol acidified with 0.1% TFA. 
Each analysis, was carried out in duplicate. The identification of single ACNs was confirmed by 
LC coupled to ESI-MS (electro spray ionization - mass spectrometry) as already described by 
Del Bo‟ et al. (2010). Briefly, the mass spectrometer operated in positive full-scan mode in the 
range 200-800 Da. The capillary voltage was set to 3.5 kV, the cone voltage to 20 V, the source 
temperature to 130 °C, and the desolvating temperature to 350°C. Data were acquired by 
Masslinx 4.0 software (Micromass, Beverly, MA). 
 
Analysis of sugars. Glucose and fructose were quantified in WB powder and fractions by UPLC 
(Acquity, Waters) coupled with a triple quadrupole mass spectrometer mod. Quattro micro 
(Micromass, Beverly, MA). 
The separation was carried out on BEH (Ethylene Bridged Hybrid) Amide column (150 x 2.1 
mm, 1.7 µm, Waters) at 35°C. Solvents were (A) triethylamine 0.2% and (B) triethylamine 0.2% 
in acetonitrile. Flow-rate was 0.40 ml min
-1
. The calibration curve was obtained from 1 to 50 mg 
l
-1
 for both sugars. The mass spectrometer operated in ESI negative mode monitoring the ions 
with m/z 179 (glucose, fructose). The capillary voltage was set to 3.0 kV, the cone voltage to 20 
V, the source temperature to 120 °C, and the desolvating temperature to 250°C.   
 
Analysis of organic acids. Malic and citric acid were analyzed by UPLC (Acquity, Waters) 
coupled to a triple quadrupole mass spectrometer mod. Quattro micro (Micromass, Beverly, 
MA). The separation was performed on C18 Atlantis T3 column (150 x 2.1 mm, 1.7 µm, Waters) 
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at 45°C and the flow rate was 0.5 ml min
-1
. The eluent was formic acid 0.05%. The calibration 
curves were obtained at concentration ranged from 2 to 25 mg l
-1
 for both malic and citric acid.  
The capillary voltage was set to 3.5 kV, the cone voltage and the collision energy was specific 
for each compound. The source temperature was 120°C, the desolvating temperature was 300°C 
and argon was used at 1.3x10
-3
 mbar to improve fragmentation in the collision cell. Masslinx 4.0 
acquired data with Quan-Optimize option for fragmentation study. The fragmentation transitions 
for the multiple reaction monitoring (MRM) were (m/z)
-
 133115, 13371 for malic and (m/z)
-
 
191111, 19187 for citric acid, with a dwell time of 0.2 s per transition.  
 
 
3.3.2 Experiments with Caco-2 cell layers 
In vitro cultivation. Caco-2 cells (human epithelial colorectal adenocarcinoma cell line; ATCC 
HTB-37) were routinely grown in Eagle‟s minimum essential medium (EMEM) supplemented 
with 10% (v/v) heat-inactivated (30 min at 56°c) fetal calf serum (FCS), 100 U/ml penicillin, 100 
mg/ml streptomycin, 0.1 mM nonessential amino acids (NEAA), and 2 mM L-glutamine and 
were incubated at 37°c in a water-jacketed incubator in an atmosphere of 95% air and 5% carbon 
dioxide. Study of NF-κB activation. Stable recombinant Caco-2 cell line was generated by 
transfecting cells with the plasmid pNiFty2-Luc (Invivogen, Labogen, Rho, Italy) as described by 
Guglielmetti et al. (2010). This plasmid contains a promoter with five NF-B-binding sites 
followed by the firefly luciferase reporter gene luc. Stimuli that activate NF-B promote its 
binding to the vector promoter, resulting in the expression of the luciferase gene. Briefly, Caco-2 
were transfected by means of the StoS transfection kit (GeneSpin, Milan, Italy), in accordance 
with the manufacturer‟s protocol. Afterwards, cells were resuspended in fresh EMEM, seeded in 
24-well plates, and incubated for 48 h, in order to obtain the expression of the antibiotic 
resistance. Finally, stable recombinant clones were selected by adding into the culture medium 
50 μg ml-1 of zeocin (InvivoGen). 
 
3.3.3 Study of the immunomodulatory activity of WB ACNs 
After growth in the presence of 50 g/ml zeocin, cell monolayers (approximately 3×105 cells 
well
-1
) were carefully washed with 0.1 M Tris-HCl buffer (pH 8.0). Subsequently, fresh EMEM 
medium, containing 100 mM HEPES (pH 7.4) was added to Caco-2 cells. The soluble, Phe and 
ACNs fractions obtained by WB powder have been tested. Concentrations used were 25, 50 and 
100 μg ml-1 for the water soluble fraction (calculated considering the sugars and organic acid 
concentration), and 5, 25, 50 and 100 μg ml-1 for the phenolic (calculated considering the 
chlorogenic acid concentration) and the anthocyanin fractions (calculated considering the total 
ACNs concentration). Recombinant Caco-2 cells were simultaneously stimulated with IL-1β (2 
ng ml
-1
), used as pro-inflammatory stimulus. After incubation at 37°C for 4 h, 24-well plates 
were put on ice for 15 min; recombinant Caco-2 cells were detached mechanically from the 
bottom of a well, samples were transferred into an eppendorf tube and subjected to sonication at 
maximum power for 5 s using a Bandelin SONOPLUS Ultrasonic Homogenizer (Bandelin 
electronic GmbH & Co., Berlin, Germany). Insoluble particles were removed by centrifugation 
and the supernatants were transferred into a new tube. One hundred μl of supernatants were 
aliquoted in duplicate into the wells of a 96-well white microtiter plate (PerkinElmer, Monza, 
Italy) by means of epMotion Automated Pipetting System (Eppendorf, Milan, Italy). Then 12.5 μl 
of a 10 mM ATP solution (i.e. up to the final concentration of 1 mM) and 12.5 μl of 0.1 mM D-
luciferin were added and the emitted bioluminescence was immediately measured every 120 s 
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with a VICTOR3 1420 Multilabel Counter (PerkinElmer). The maximum of light production 
curve was considered for comparison of results. All conditions were analyzed in duplicate in 
eight independent experiments. 
 
3.3.4 Study of the WB ACNs effect on U937 human macrophage cell line  
Cell culture, growth conditions, and stimulation protocol. The cell line U937 (ATCC CRL-
1593.2) was derived from a human histiocytic lymphoma (Sundstrom and Nilsson, 1976). These 
cells are maintained as replicative, non-adherent cells and have many of the biochemical and 
morphological characteristics of blood monocytes (Harris  and Ralph, 1985). When treated with 
phorbol myristate acetate (PMA), U937 cells differentiate to become adherent, non-replicative 
cells with characteristics similar to tissue macrophages, including similar isoenzyme patterns 
(Radzun et al., 1983) and other phenotypic markers (Harris  and Ralph, 1985). The normal 
growth medium for the U937 cells consisted of RPMI 1640 medium (Lonza, Basel, Lonza, Basel, 
Switzerland) supplemented with 10% (v/v) fetal bovine serum (FBS) (Gibco-BRL, Life 
Technologies, Milan. Italy), 2 mM L-glutamine, 100 U ml
-1
 penicillin and 100 μg ml-1 
streptomycin (Sigma-Aldrich). U937 cells were seeded at a density of 5×10
5
 cells well
-1
 in 12-
well plates and incubated at 37°C in a humidified atmosphere of 95% air and 5% CO2. 
Differentiation was induced by the addition of PMA (Sigma-Aldrich) into the cellular medium at 
a final concentration of 100 nM and was allowed to proceed for 48 h. Afterwards, cells were 
washed once with sterile PBS buffer to remove all non-adherent cells. One h before the bacteria 
were added to the cells, the culture medium was replaced with RPMI 1640 supplemented with 
1% (v/v) FBS to allow the cells to adapt. After adaptation U937 cells were stimulated for 4h at 
37°C with three different concentration of the WB ACNs fraction. ACNs fraction were tested at 
final concentrations of  25, 10 and 1 μg ml-1. Lipopolysaccharide (LPS, final concentration of 1 
μg ml-1) from Escherichia coli 0127:B8 (Sigma-Aldrich) was used as pro-inflammatory stimulus 
in U937 cells. We also added MetOH + 0.05 mM HCl to RPMI 1640 medium 1% (v/v) FBS 
(Data not shown) and to LPS in contact with U937 cells to evaluate any possible interference on 
macrophages responses from the solvent. In all these experiments, however, the final 
concentration of MetOH + 0.05 mM HCl in contact with U937 cells was always lower than the 
0.1% of the final volume in the well. We performed two type of stimulations: 1 h of 
preincubation with LPS which followed the addition of ANCs for 3 h, and 1 h of preincubation 
with ACNs and subsequent addition of LPS for 3 h.  
 
3.3.5 Preparation of RNA and reverse transcription  
For both in vitro and ex vivo experiments, after incubating macrophages at 37°c for 4 h, the 
supernatant was carefully removed from each well and the total cellular RNA was isolated from 
the adhered cells with an RNeasy Mini Kit (Qiagen Inc., Valencia, CA, USA). Afterwards, RNA 
concentration and purity was determined with a Nanodrop Spectrophotometer (ND-1000, 
Thermo Fischer Scientific, Middletown, VA, USA) and reverse transcription to cDNA was 
performed with the iScript Select cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA) 
using the following thermal cycle: 5 min at 25°C, 30 min at 42°C, and 5 min at 85°C. Reverse 
transcription quantitative PCR (RT-qPCR). The mRNA expression levels of cytokines were 
analyzed with SYBR Green technology in RT-qPCR using SsoFast EvaGreen Supermix (Bio-
Rad Italia, Segrate, Italy) on a Bio-Rad CFX96 system according to the manufacturer's 
instructions. The primers used are as follow (5‟3‟): 18S rRNA forward 
ATCCCTGAAAAGTTCCAGCA; 18S rRNA reverse CCCTCTTGGTGAGGTCAATG; TNF-α 
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forward TCAGCTCCACGCCATT; TNF-α reverse CCCAGGCAGTCAGATCAT. Primers were 
designed using the Primer3Plus software (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi), and the specificity of the primers was tested with melting 
curves during amplification and by 1% TAE agarose gel electrophoresis. Quantitative PCR was 
carried out according to the following cycle: initial hold at 96°C for 30 s and then 40 cycles at 
96°C for 2 s and 70°C for 5 s. Gene expression was normalized to the housekeeping gene coding 
for the18S rRNA. The amount of template cDNA used for each sample was 50 ng. All results 
regarding cytokine mRNA expression levels are reported as the fold of induction (FOI) in 
comparison to the control (namely unstimulated U937 macrophages), to which we attributed a 
FOI of 1. 
 
3.3.6 Statistical analysis  
The statistical analysis was performed by means of STATISTICA software (Statsoft Inc., Tulsa, 
OK, US). Analysis of variance (ANOVA) with type of treatment as the dependent factor was 
used to evaluate the immunomodulatory activity. Post-hoc analysis of differences between 
treatments was assessed by the Least Significant Difference (LSD) test with p ≤ 0.05 as level of 
statistical significance. 
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3.4 RESULTS AND DISCUSSION 
3.4.1 Modulation of NF-κB activation by WB soluble, phenolic and anthocyanin 
fractions in Caco-2 cells 
To evaluate the presence of potential bioactive molecules in our WB powder preparation, as 
preliminary immunological investigation, we tested the effects of the three different fractions 
isolated from WB on NF-κB, a transcriptional factor responsible for the induction of pro-
inflammatory cytokines in immune responses. To this aim we used a reporter cell line obtained 
by transfecting Caco-2 cells with a luciferase reporter vector induced by NF-κB. In Table 3.4.1 
the chemical composition of the different WB fractions is reported. 
 
Table 3.4.1 Different WB fractions characterization and concentration tested in in vitro 
immunological assay on NF-κB-transfected Caco-2 cells. A: water soluble fraction; B: phenolic 
fraction; C: anthocyanin (ACN) fraction. 
A 
Compound 
Extracted 
 
CaCo cell addition 
 
μg/ml 
 
25 μg/ml 50 μg/ml 100 μg/ml 
Glucose  2284,4 
 
13,97 27,9 55,9 
Fructose 1836,4 
 
11,3 22,6 45,2 
Malic acid 19,9 
 
0,12 0,24 0,48 
Citric acid 47,2 
 
0,29 0,58 1,16 
 
 
B 
Compound 
Extracted 
 
CaCo cell addition 
 
μg/ml 
 
μg/ml μg/ml μg/ml μg/ml 
Chlorogenic acid 719,2 
 
5 25 50 100 
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C 
Compound 
Extracted 
 
CaCo cell addition 
 
μg/ml % 
 
μg/ml μg/ml μg/ml μg/ml 
Delphinidin 3-gal 166 10,6 
 
0,53 2,7 5,4 10,8 
Delphinidin 3-glc 224 14,3 
 
0,72 3,6 7,2 14,4 
Cyanidin 3-gal 69 4,4 
 
0,22 1,1 2,2 4,4 
Delphinidin 3-ara 102 6,5 
 
0,33 1,7 3,4 6,8 
Cyanidin 3-glc 99 6,3 
 
0,32 1,6 3,2 6,4 
Petunidin 3-gal  107 6,8 
 
0,35 1,8 3,6 7,2 
Cyanidin 3-ara + 
Petunidin 3-glc 
167 10,7 
 
0,54 2,7 5,4 10,8 
Peonidin 3-gal 38 2,4 
 
0,12 0,6 1,2 2,4 
Petunidin 3-ara + 
Malvidin 3-gal 
247 15,8 
 
0,96 3,8 7,6 15,2 
Peonidin 3-glc + 
Malvidin 3-glc 
279 17,9 
 
0,89 4,4 8,8 17,6 
Malvidin 3-ara 65 4,2 
 
0,20 1,0 2,0 4,0 
Total 1563 100  
 
5 25 50 100 
 
These experiments were performed in the presence of the pro-inflammatory stimulus IL-1β. All 
WB fractions, namely ACNs, Phe and water soluble, were tested at different concentrations (Fig 
3.4.1). We found no effects for the Phe and the water soluble fractions on Caco-2 cells, while the 
ACNs fraction had a significant effect in reducing the activation of NF-κB, and in a dose-
dependent manner. In fact, the addition of ACNs at the concentration of 50 and 100 μg/ml 
reduced the bioluminescence, and therefore the NF-κB activation, up to 70% and 85% (p≤0.05), 
respectively.  
Roles of ACNs in modulating the activation of NF-κB, and the down-stream signals, have been 
already reported in literature (Epinat  & Gilmore, 1999; Karlsen et al., 2007). Interestingly, 
ACNs isolated from bilberries and blackcurrant have been demonstrated to modulate LPS-
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induced activation of NF-κB in monocytes, and supplementation with ACNs in a parallel-
designed, controlled clinical trial reduced the levels of circulating NF-κB-dependent 
inflammatory mediators (Karlsen et al., 2007). 
 
Figure 3.4.1 Modulation of light emission expressed by Caco-2 cells stably transfected with a 
NF-κB/luciferase reporter vector and incubated in presence of Interleukin-1β with different 
fractions extracted from wild blueberry powder. Data are reported as percent variation of light 
emission, referred to the control. Control: Caco-2 cell layers incubated only with media 
supplemented with MetOH + 0.05 mM HCl at a concentration correspondent to the one present 
in highest concentration of fractions tested. ACN: anthocyanin fraction; PHE: phenolic fraction; 
S.F.: soluble fraction. Fraction concentrations reported (5-25-50-100) are referred to μg ml-1. 
The values are the means (± standard deviations) for eight independent experiments conducted in 
duplicate. Asterisks indicate statistically significant differences compared to results for the 
control (*, P<0.05.) 
 
 
 
The transcription factor NF-kB is essential in orchestrating the inflammatory responses to a wide 
range of insults, by leading to the induction of  genes involved in innate immune response and in 
the  secretion of inflammatory responses mediators, like chemokines and cytokines (Pahl, 1999). 
High levels and/or prolonged presence of pro-inflammatory mediators is connected to increased 
risks of chronic-degenerative diseases onset (Libby, 2002; Boos and Lip, 2006). Therefore, the 
use of natural bioactive molecules, like WB ACNs which possess the ability to modulate NF-κB 
activation as we also tested and described in our study, might represent a mild an effective 
strategy in dampening inflammatory processes. 
However, when the same ACNs fraction was tested on bone marrow-derived dendritic cells 
(BMDCs; Data not shown) we found  no effect in inducing Th1-related nor Treg cytokines. Our 
results suggest that food molecules, like ACNs extracted from WB, may not have an effect on 
immune system per se, but rather they modulate the immune responses in presence of other 
stimuli, as demonstrated in our experiments on epithelial Caco-2 cells in presence of IL-1β, and 
as also confirmed in the experiments on U937 macrophages in presence of LPS. 
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3.4.2 WB ACNs fraction displays in vitro protective effects towards LPS-dependent 
inflammatory response on human U937 macrophages 
In the subsequent immunological experiments we moved from epithelial cells to cells properly 
belonging to the immune system, and we decided to focus on ACNs, since it was the only 
fraction which showed immunomodulatory properties in our first characterization on Caco-2 
cells. To study the host‟s responses elicited by ACN at level of innate immunity, we employed 
macrophages cells, which are professional phagocytes which undergo activation upon 
environmental signals (Benoit et al., 2008). We used PMA-differentiated U937 human 
macrophages, and we first treated U937 cells with PMA for 48 hours to differentiate the cells 
into macrophages. Subsequently, we stimulated the differentiated cells with WB ACNs at three 
different concentrations, namely 25, 10 and 1 μg ml-1.  We decided to use concentrations lower 
than the ones tested on Caco-2 cells, since it is plausible that in vivo epithelial cells are exposed 
to higher amounts of dietary molecules with respect to immune cells. After 4 h of incubation, we 
used RT-qPCR to quantify the gene expression of TNF-α, a cytokine involved in inflammatory 
responses (Belardelli, 1995). In these experiments we used LPS to induce a pro-inflammatory 
response on U937 macrophages. 
Since ACNs fraction has been resuspended in MetOH + 0.05 mM HCl, as first we wanted to 
verify any possible interference of the solvent on cell permeability and/or on cell responses. 
When we incubated U937 cells with RPMI 1% (v/v) FBS media supplemented with MetOH + 
0.05 mM HCl (at a concentration correspondent to that present in the highest concentration of 
ACNs used), we found that TNF-α expression levels were similar to the control (U937 cells 
incubated only with RPMI media 1% (v/v) FBS; Data not shown); moreover, the presence of 
MetOH + 0.05 mM HCl had only a slight impact on TNF-α expression level induced by LPS 
(Fig. 3.4.2). 
When we stimulated U937 cells only with the ACNs extracts we found no difference in the 
induction of TNF-α compared to control, thus confirming the lack of immune response towards 
these molecules, as previously observed on BMDCs (Data not shown). Consequently, we tested 
the ACNs fraction on U937 cells together with LPS, by using two different experiment settings: 1 
h of preincubation of U937 cells with LPS and then addition of ACNs, and 1h of preincubation of 
macrophages with ACNs and subsequent addition of LPS for 3 h. The aims were to mimic and 
evaluate, respectively, a possible anti-inflammatory activity of the ACNs in presence of an 
ongoing inflammatory status, or a protective role towards an incoming inflammatory agent. For 
the first hypothesis we found that only the highest concentration tested of ACNs had a significant 
effect in decreasing the induction of TNF-α with respect to U937 cells stimulated only with LPS. 
In the other experiment we observed, instead, a clear dose-response in the anti-inflammatory 
activity of ACNs. Moreover, two ACNs concentrations (25 and 10 μg ml-1) resulted significantly 
effective in reducing the inflammatory response induced by LPS on U937 cells. 
Summarizing our immunological experiments, we observed that ACNs fraction extracted from 
WB powder displayed anti-inflammatory properties, both on epithelial cells by decreasing the 
activation NF-κB in presence of IL-1β, and by exerting a protective role towards LPS-induced 
TNF-α in immune cells. These abilities might be particularly useful in several inflammatory 
disorders. Obesity, for instance, is a low-grade chronic inflammatory disease, characterized by 
macrophages infiltration in the white adipose tissue (WAT) (Trayhurn & Wood, 2004). The 
production of pro-inflammatory factors by activated macrophages can result in further 
inflammation of  the WAT, contributing to the pathogenesis of obesity-related diseases, like 
hypertension, type 2 diabetes and atherosclerosis (Laine et al., 2007). It has been reported that 
obese subjects present high serum levels of pro-inflammatory factors, like TNF-α (Fantuzzi, 
2004; Wellen and Hotamisligil, 2005). Diet-derived obesity has been also shown to lead to high 
level of serum LPS; moreover, endotoxemia and the presence of activated macrophages have 
been demonstrated to be connected with high plasma levels of LPS (Cani et al., 2008).  
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Fig. 3.4.2 Quantitative analysis of TNF-α gene expression in U937 macrophages after total 4 h 
stimulation. Expression levels of TNF-α is indicated as the fold change of induction (FOI) 
relative to the control (unstimulated U937 cells), which was set at a value of 1. LPS was used  at 
a concentration of 1 μg ml-1. LPS+Met: U937 cells stimulated with LPS supplemented with 
MetOH + 0.05 mM HCl at a concentration correspondent to the one present in highest 
concentration of fractions tested. ACNs fractions were tested at concentrations of 25, 10 and 1 
μg ml-1. MetOH + 0.05 mM HCl was added in all samples in order to reach the same 
concentration present in the highest quantity of ACNs used. LPS+ACNs: U937 prestimulated for 
1 h with LPS and afterwards for 3h also with ACNs; ACNs+LPS: U937prestimulated  with ACNs 
for 1 h and then also with LPS for 3h. The values are the means (± standard deviations) for at 
least three independent experiments. Asterisks indicate statistically significant differences 
compared to results for U937 stimulated with LPS+MetOH + 0.05 mM HCl (*, P<0.05). 
 
 
 
 
 
As a matter of fact LPS may induce in macrophages, through the activation of NF-κB, the 
production of pro-inflammatory cytokines like TNF-α, which are detrimental for WTA by 
causing inflammation and insulin-resistance (Overman et al., 2010).  
The use of compounds like WB ACNs, that have been shown to possess anti-inflammatory 
properties by acting on NF-κB and LPS responses, could be of help in the treatment or better in 
the prevention of pathological consequences associated to specific inflammatory disorders. Anti-
inflammatory features have been already demonstrated for different categories of polyphenols, 
and isolated from diverse origins. For instance, a grape-powder extract used in in vitro 
experiments on U937 macrophages reduced the LPS-induced production of inflammatory 
cytokines (Overman et al., 2010). A proanthocyanidin-rich cranberry fraction has been reported 
to decrease the LPS-induced cytoxicity in macrophages and oral epithelial cells (La et at., 2009). 
In a recent study, protocatechuic acid (PCA), which is a major metabolite of anthocyanins, 
determined an attenuation of LPS-induced lung injury; moreover, the pretreatment of mice with 
PCA protected by LPS-caused histiologic alterations in lungs and inhibited the induction of pro-
inflammatory cytokines like TNF-α (Wei et al., 2012). 
Therefore, the intake of fruit and vegetables containing bioactive molecules like ACNs, might 
represent a natural and safe strategy in the prevention and management of chronic-degenerative 
diseases caused by inflammatory status.  
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3.5 CONCLUSIONS 
Inflammation consists of a complex series of  reactions and processes activated by the host in 
order to prevent ongoing tissue damage, and to repair processes and defense mechanisms against 
infectious diseases. However, if prolonged, inflammation may contribute to the pathogenesis of 
chronic diseases such as diabetes, neurodegenerative diseases, cancers, and cardiovascular 
disease (Nathan, 2002; Blomhoff , 2005; Karlsen et al., 2007). Thus, an attenuation of such 
processes might potentially help in retarding or preventing detrimental consequences.  
Several studies report that anthocyanins display anti-inflammatory features. The  anti-
inflammatory activity of anthocyanins have mainly been attributed to a direct antioxidant action, 
since ACNs are well-known anti-oxidant factors able to control lipid peroxidation and to dampen 
detrimental effects of reactive-oxygen species. 
However, more recently it has been proposed, and also demonstrated, that the anti-inflammatory 
attitude of such molecules is also mediated by a direct regulatory effects on the expression of  
genes involved in the inflammatory and immune responses. Several studied have shown ACNs 
immunomodulatory activity in cell cultures and animal models (Wang & Mazza, 2002; Herath et 
al., 2003; Cimino et al., 2006).  
Accordingly, in our experiments on ACNs isolated from WB we demonstrated that these 
molecules can have immunomodulatory properties, both on epithelial cells and on immune cells, 
in particular in presence of pro-inflammatory stimuli.  
In conclusion, exploring the role of food and, more specifically, the effect of bioactive 
compounds such as ACNs on the metabolic processes involved in diseases is crucial, also for 
designing public health directives for population approaches to prevention, and the results 
obtained in the present study add important knowledge and insights on the properties of ACN- 
rich foods and their exploitation for the prevention and treatment of chronic inflammatory 
diseases. 
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15
th
 Workshop on the Development in the Italian PhD Research on Food Science 
Technology and Biotechnology, 15-17 September, 2010 (Portici, Italy) 
 
The role of probiotic microorganisms and dietary compounds in the modulation of 
immune response: a mechanistic approach 
 
Valentina Taverniti 
 
The research project of this PhD thesis deals with probiotic bacteria and dietary components 
and their role in immune responses, especially at intestinal level. The main goal of the project is 
the identification of bacterial and dietary molecules determining the immunomodulating 
activity. To this aim, we will employ in vitro experimental approaches such as luciferase 
reporter gene systems, real time quantitative PCR and ELISA tests, to evaluate the expression of 
immunologic key mediators on different cell lines. 
. 
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10
th
 Symposium on Lactic Acid Bacteria, 28 August – 1 September, 2011 (Egmond aan 
Zee, The Netherlands) 
 
Lactic acid bacteria as potential probiotics for the pharyngeal mucosa 
 
Guglielmetti S, Taverniti V, Minuzzo M, Arioli S, Stuknyte M, Zanoni I, Granucci F, Karp M, 
Mora D 
 
The probiotic approach represents an alternative strategy in the prevention and treatment of 
infections in those body sites where the microbiota plays a role in the maintenance of 
physiological homeostasis. In this context, we evaluated in vitro the potential abilities of oral, 
probiotic and dairy bacteria in controlling Streptococcus pyogenes infections at the pharyngeal 
level. Initially, we analysed the bacterial adhesion on FaDu hypopharyngeal carcinoma cells 
and the ability to antagonize S. pyogenes on FaDu layer and HaCat keratinocytes. Due to their 
promising adhesive and antagonistic features, we studied the oral isolate Streptococcus 
salivarius ST3 and the dairy strain Lactobacillus helveticus MIMLh5 also through 
immunological in vitro experiments. We performed the quantification of several cytokines and 
the measurement of NF-κB activation in FaDu cells. Strain ST3 significantly increased NF-κB 
activation at baseline, while it had an opposite effect when FaDu cells were co-stimulated with 
IL-1β. In addition, ST3 biased cytokines production at baseline (reduction of IL-1β and TNFα, 
increase of MIP-1β and GM-CSF) and after IL-1β-induction (reduction on IL-6 and IL-8). 
MIMLh5 efficiently reduced the induction of IL-6, IL-8 and TNF in a dose-dependent 
manner. After stimulating with IL-1β, active NF-κB was still markedly lowered. Nevertheless, 
we observed an increased secretion of IL-6, IFN-γ and GM-CSF under these conditions. In 
addition, MIMLh5 increased the GM-CSF/G-CSF ratio. This is compatible with a switch of the 
immune response towards a TH1 pathway, as supported by our observation that MIMLh5, once 
in contact with bone marrow derived dendritic cells, triggered the secretion of TNFα and IL-2. 
In conclusion, we propose ST3 and MIMLh5 as a potential probiotic bacteria for the human 
pharynx, with promising antagonistic and immunomodulatory properties. 
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16
th
 Workshop on the Developments in the Italian PhD Research on Food Science 
Technology and Biotechnology, 21-23 September, 2011 (Lodi, Italy) 
 
The role of probiotic microorganisms and dietary compounds in the modulation of 
immune response: a mechanistic approach 
 
Valentina Taverniti 
 
To investigate the immunomodulatory properties of probiotic bacteria, two strains of 
Lactobacillus helveticus have been selected through a screening assay based on a NF-
κB/luciferase reporter gene system in Caco-2 human intestinal epithelial cell line. The setup of 
a purification protocol of their Surface (S)-layer proteins allowed testing the role of these 
molecules in the immune response. In vitro and ex vivo experiments, respectively performed on 
U937cell line and murine bone marrow-derived macrophages, demonstrated the involvement of 
S-layer protein in a transient activation of the immune system. 
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The 4
th
 Interdepartmental Twinning Symposium, 28 September- 2 October, 2011 
(Tammela, Finland) 
 
Immunomodulatory characterization of S-layer protein from the dairy probiotic 
strain Lactobacillus helveticus MIMLh5 
 
Taverniti V, Stuknyte M, Minuzzo M, Arioli S, Mora D, Karp M, Pesu M, Guglielmetti S 
This work is targeted to a mechanistic investigation on the immunomodulatory properties of the 
dairy bacterium Lactobacillus helveticus MIMLh5, a strain isolated from Grana Padano cheese 
natural whey starter culture, that already showed to possess probiotic abilities and to modulate 
the immune response at pharyngeal level. Thus we decided to test the activity of this strain at 
gut level, using as proper model the intestinal epithelial Caco-2 cell line, and we observed that 
MIMLh5 was able to efficiently decrease the activation of the transcriptional factor NF-κB. To 
individuate which bacterial components could be responsible for the immunological activity, 
attention was given to Surface (S)-layer protein, which represents up to 14% of total protein 
content in L. helveticus. We improved an extraction protocol that allowed us to obtain the 
protein with a high level of purity, and thus suitable for immunological experiments. When we 
tested in Caco-2 model the purified protein isolated from L. helveticus MIMLh5, we saw that it 
was able to decrease the activation of NF-κB, similarly to the whole bacterium, both at baseline 
and in presence of IL-1β. We decided to study the effects on cells of the immune system; in in 
vitro experiments on U937 cell line, we observed  by quantitative Real Time-PCR (RT-qPCR) 
that both the bacterium and the purified protein were more prone to induce the activation of pro-
inflammatory cytokines such as COX2 and TNF-α, respect to the anti-inflammatory/regulatory 
IL10. These results were even confirmed when we performed ex vivo experiments by isolating 
macrophages from mouse peritoneal cavity and bone marrow (BMDMs), and moreover in bone 
marrow-derived dendritic cells. We found confirmation of the involvement of S-layer protein in 
the activation of the immune system elicited by the bacterium since, when we tested the 
bacterial cells without S-layer (after LiCl treatment for the removal of the protein), the 
propensity to induce pro-inflammatory cytokines decreased, while the level of IL10 did not 
change significantly. Moreover, when the protein was added to LiCl-washed bacterial cells the 
pro-inflammatory attitude raised again. We performed also preliminary in vivo experiments by 
injecting S-layer protein in Zebrafish embryos; even in this case we observed an increased level 
of some pro-inflammatory cytokines (like IFN-γ) respect to control embryos. As first step to 
individuate the signal pathways involved in the immune response elicited by MIMLh5 and its 
protein, we found that Toll-like Receptor (TLR)2 is involved in the recognition of both the 
whole bacterium and the purified protein. Its block resulted in a less production of TNF-α and 
COX2. Indeed the blocking effect was more efficient in LiCl-treated cells, probably due to the 
absence of the protein.  In conclusion from all these data it seems that S-layer protein is a key 
molecular determinant for the immunomodulatory properties observed in L. helveticus 
MIMLh5. The pro-inflammatory activity elicited by the whole bacterium and the purified 
protein, as already demonstrated for other probiotics , could be transient and thus resulting in a 
“positive” activation of immune system that can support human-host defence and homeostasis. 
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The Oxygen Club Of California - Oxidants And Antioxidants In Biology - Cell Signaling 
And Nutrient-Gene Interaction, 20-23 june, 2012 (Alba, Italy) 
 
Immunomodulatory properties of Wild Blueberries (Vaccinium Angustifolium) in human 
intestinal epithelial Caco-2 Cells: preliminary data 
 
Fracasetti D, Del Bo‟C, Guglielmetti S, Riso P, Taverniti V, Klimis-Zacas D, Porrini M 
 
Wild blueberries (WB) are a rich source of polyphenols, particularly anthocyanins, which may 
be beneficial for human health because of their antioxidant, antiinflammatory and 
immunomodulatory potential. This study aims to investigate the immunomodulatory potential 
of three WB fractions (anthocyanin, phenolic and soluble fraction) in an inflammatory state 
model, based on human intestinal Caco-2 cells. A reporter gene system was prepared by 
transfecting Caco-2 cells with the pNiFty-SEAP reporter- construct containing an engineered 
ELAM promoter with 5 NF-kB binding sites and an insect luciferase reporter gene. The 
transfected Caco-2 cells were stimulated with interleukin (IL)-1β to mimic an inflammatory 
state and then supplemented with 5 mg/L, 25 mg/L, 50 mg/L and 100 mg/L of the anthocyanin, 
phenolic and soluble fractions. Immunomodulatory activity for each fraction was monitored in 
real time by quantification of bioluminescence with a luminometer. The addition of 
anthocyanins at the concentration of 50 and 100 mg/L reduced the bioluminescence, and 
therefore NF-κB activation, up to 70% and 85% (p≤0.05), respectively. No dose-response was 
observed after supplementing Caco-2 cells with both phenolic and soluble fractions. These data 
suggest that only the anthocyanin fraction can modulate Caco-2 cells inflammatory state in the 
experimental conditions adopted. Future experiments will address supplementation of Caco-2 
cells with anthocyanin standards to elucidate the compound(s) responsible for the observed 
immunomodulatory effect.   
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17
th
 Workshop on the Developments in the Italian PhD Research on Food Science 
Technology and Biotechnology, 19-21 September, 2012 (Cesena, Italy) 
 
The role of food and probiotic microorganisms, and dietary compounds in the modulation 
of the immune response 
 
Valentina Taverniti 
 
The aim of this PhD research project was to investigate the interaction between the immune 
system and (i) bacterial cells and (ii) their components, and (iii) food molecules. Specifically, 
our experiments were designed to study by means of in vitro and ex vivo analyses the possible 
signalling pathways involved in the cross-talk between epithelial and immune cells, and a dairy 
bacterium, its purified Surface (S)-layer protein and an anthocyanin fraction extracted from 
wild blueberry (Vaccinium Angustifolium). 
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Itaca 
 
Sempre devi avere in mente Itaca -  
raggiungerla sia il pensiero costante.  
Soprattutto, non affrettare il viaggio;  
fa che duri a lungo, per anni, e che da vecchio  
metta piede sull’isola, tu, ricco  
dei tesori accumulati per strada  
senza aspettarti ricchezze da Itaca.  
Itaca ti ha dato il bel viaggio,  
senza di lei mai ti saresti messo  
sulla strada: che cos’altro ti aspetti? 
 
 
E se la trovi povera, non per questo Itaca ti avrà deluso.  
Fatto ormai savio, con tutta la tua esperienza addosso  
già tu avrai capito ciò che Itaca vuole significare. 
 
 
 
 
Ithaka 
 
Keep Ithaka always in your mind. 
Arriving there is what you are destined for. 
But do not hurry the journey at all. 
Better if it lasts for years, 
so you are old by the time you reach the island, 
wealthy with all you have gained on the way, 
not expecting Ithaka to make you rich. 
 Ithaka gave you the marvelous journey. 
Without her you would not have set out. 
She has nothing left to give you now. 
  
And if you find her poor, Ithaka won’t have deceived you. 
Wise as you will have become, so full of experience, 
you will have understood by then what Ithaka means. 
 
 
 
(1911 - Konstantinos P. Kavafis) 
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